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ABSTRACT 
The cyclodextrins and their derivatives have been utilised as complexing agents for 
a wide range of pharmaceutical compounds, through their ability to include small 
molecular weight molecules inside an annular cavity formed by linked glucose 
residues of varying number. The non-steroidal anti-inflammatory drugs (NSAIDs), a 
group of agents that share a similar therapeutic effect in the management of 
inflammatory processes in the body, have been studied as guest molecules for 
inclusion in cyclodextrins, due to a number of potential advantages that are 
conferred by complexation, such as improved bioavailability, modified side-effect 
profiles and the control of drug release from novel formulations. 
This study has tested a number of commonly used NSAIDs belonging to certain 
structural groups, together with a number of cyclodextrins and their derivatives, and 
attempts have been made to prepare complexes in the solid state and characterise 
them using physicochemical methods. The cyclodextrins used were native seven-
and eight-membered J3- and y-cyclodextrin and two methylated derivatives of 
J3-cyclodextrin, namely heptakis(2,6-di-O-methyl)-J3-cyclodextrin and heptakis(2,3,6-
tri-O-methyl)-J3-cyclodextrin, abbreviated as DIMES and TRIMEB respectively. 
NSAIDs belonging to the salicylate, fenamate, profen, oxicam and indene structural 
groups were used. These included diflunisal, mefenamic acid, niflumic acid, 
tolfenamic acid, flufenamic acid, ibuprofen, ketoprofen, piroxicam, tenoxicam, 
indomethacin and sulindac. 
All complexes were prepared in aqueous solution and characterised using methods 
such as thermal analysis (hot stage microscopy, thermogravimetric analysis, 
differential scanning calorimetry), X-ray powder diffraction (XRD), UV 
spectrophotometry, microanalysis and single crystal X-ray photography. Properties 
such as thermal behaviour and X-ray diffraction were used as evidence that 
complexation had occurred, by observing any modification in these properties of the 
host and guest. 
A number of complexes were obtained for which thermal analysis and XRD gave 
confirmation of the formation of a complex, and unit cell data could be obtained for 
seven complexes for which single crystals of suitable size were obtained. Two 
crystal structures~ for the complexes of p-cyclodextrin and TRIMEB with ibuprofen, 
one of the profen group of NSAIDs, were solved using X-ray analysis. The guest 
molecule in the p-cyclodextrin complex is disordered and could not be modelled, but 
was located and refined in the TRIMEB complex. 
Ibuprofen is a chiral molecule and the crystal used for analysis of the complex with 
TRIMEB was obtained from a vial containing racemic drug. Only the (S)-isomer was 
found to be present in the crystal. Based on these results, the possibility of racemic 
resolution of ibuprofen by TRIMEB was investigated and it was concluded that 
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1. INTRODUCTION TO CYCLODEXTRINS 
The cyclodextrins, also less commonly known as Schardinger's dextrins, 
cycloamyloses and cycloglucans, are naturally occurring cyclic oligosaccharides 
composed of six or more 1,4-linked a.-0-glucopyranose units. Initially reported in 
1891 by Villiers as degradation products of starch 1, their structure was investigated 
more fully by Schardinger2·3, and their use as complexing agents for small molecular 
weight compounds that can insert into the central cavity formed by the macrocycle, 
and as catalysts in certain chemical reactions, as well as for racemic resolution, 
came to be recognised through the work of Freudenberg and French among 
others4•5•6•7•8•9. Studies in recent years have placed their focus on their application in 
pharmaceutical and other industries through their ability to modify the 
physicochemical characteristics and reactivity of substances, and a large number of 
review articles and books devoted to the subject are currently available 10•11 •12·13. 
1.1 ISOLATION AND CHARACTERISATION 
Cyclodextrins are included in a mixture of end-products formed by the action of 
Bacillus macerans amylase (cyclodextrin-transglycolase or CGT) on helical starch 
molecules and related compounds2•3•9. The enzyme does not cleave fragments of 
any particular size, and cyclodextrins of between six and twelve glucose units have 
been identified using chromatography and other separation techniques 14 , with those 
of six, seven and eight units being the most common products. These have been 
designated by Greek lettering according to the number of units, namely a.- (6), p- (7) 
and y-cyclodextrin (8) (Fig.1.1 a), having a cavity size ranging from 5-8A into which 
small molecules may be inserted (Fig.1.1 b). The higher-chain cyclodextrins (o,c and 
longer) have been isolated and identified in chromatography columns 14'15 , though 
their potential use as complexing agents is seen as limited, due to a large cavity 
that is energetically similar to the aqueous environment and unable to effectively 
complex small molecules, a high water solubility and a relatively flexible structure. 
Cyclodextrins of four or less units are not known to exist, possibly due to steric 
hindrance 16. 
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Fig 1.1: Structure of a.-, J3- and y-cyclodextrin. (a) macrocyclic conformation 
and (b) dimensions of cavities 
(a) 
(b) 
1,37nm 1,53nm 1,69 nm 
0,57 
Their applications in the pharmaceutical and food industries necessitate a high 
degree of purity, and the isolation of cyclodextrins from the end-products of the 
amylase activity of Bacillus macerans, and other bacterial strains known to produce 
CGT, has been extensively investigated, both to improve yields and to isolate 
cyclodextrins of specific size from acyclic dextrins and other cyclodextrins contained 
in the starch digests 17'18'19. Organic compounds of a certain size may preferentially 
insert into a cavity of particular radius, with the resulting precipitation of an insoluble 
complex, though traces of potentially hazardous chemicals in the final product are a 
disadvantage of this method20·21 , and the use of efficient bacterial CGT is 
preferred21 . Separation of cyclodextrins for analytical purposes may be effected 
using chromatographic and other methods, such as selective dissolution and 
electrophoresis22 •23·24 . 
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1.2 MACROCYCLIC STRUCTURE AND PROPERTIES 
1.2.1 Structure and conformation 
The repeating a-0-glucopyranose units that make up a-, p-, and y-cyclodextrin are 
all present in the largely undistorted 4C1 - chair conformation, joined via a-1,4 
linkages to form the macrocycle (Fig. 1.2a). The spatial configuration of functional 
groups conferred by this conformation imparts certain features to the cyclodextrins 
which contribute to the mode by which guest molecules are accommodated within 
the cavity (Fig. 1.2b). 
Fig. 1.2: (a) Conformation of glucose subunit and (b) arrangement of 
primary and secondary rims 
(a) (b) 
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The two rims of the cyclodextrin ring are composed of glucose hydroxyl groups and 
are thus hydrophilic. The primary (1 °) rim, formed of relatively free-moving C(6)-0H 
groups, is narrower than the secondary (2°) rim of more rigidly placed C(2)- and 
C(3)-0H groups, giving the macrocycle the shape of a truncated cone. Rotation of 
the primary hydroxyl groups can partially close off one end of the cavity. The shape 
adopted by the cavity is shown in Fig. 1.1. The interior of the cavity consists of 
glucopyranose methylene and methine groups and the 0(4)-glycoside linkages, 
arranged as layers of C-H bonds, then glycoside oxygens, then another layer of C-H 
bonds, making the cavity relatively apolar. 
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An asymmetry in charge distribution, caused by the presence of half as many OH 
groups on the primary than on the secondary rim, leads to a strong dipole moment 
running parallel to the axis of the macrocycle, and this could be expected to affect 
the mode of complexation with guest molecules that contain charged species. The 
non-bonding electron pairs on the glycoside oxygens are inwardly directed and give 
the cavity a high electron-density, lending it some Lewis base character13. Overall, 
however, the cavity has a positive charge and would be expected to preferentially 
include neutral and anionic molecules. Studies on complexes with ionic species 
have shown this to be the case25 '26 '27 ·28 '29 . 
X-ray crystallographic studies have been used to characterise the conformations of 
a-, p- and y-cyclodextrins in the solid state. They are non-hygroscopic and 
crystallise from aqueous solution as stable hydrates that can be stored without 
decomposition for many years. A number of crystal structures of parent 
cyclodextrins have been reported stating varying degrees of hydration and 
differences in positioning of water molecules within the crystal, depending on the 
conditions of crystallisation, such that a-cyclodextrin can have three forms (I and II, 
both hexahydrates30·31 , and 111, with 7. 57 waters32), p-cyclodextrin may form an 
undecahydrate33 or dodecahydrate34·35 dependent on the relative humidity of the 
crystal environment such that a low humidity may cause loss of water without crystal 
structure being destroyed36 , and y-cyclodextrin has been reported with 11, 14 and 
17 waters of crystallisation37 '38 '39 . These waters are distributed within the empty 
cavity and in the interstitial spaces between adjacent cyclodextrin molecules. 
The water molecules that are enclosed within the cavity possess a high thermal 
motion and tend to exhibit a degree of disorder. The displacement of these waters 
from this relatively apolar environment by more hydrophobic guest molecules, and 
the subsequent gain in energy by redistribution into the solvent bulk, is seen as part 
of the driving force behind complexation. This is discussed in Section 1.3.2. 
A complex network of hydrogen-bonding stabilises the structure and confers certain 
chemical properties on the cyclodextrin molecule. lntramolecular hydrogen bonds 
between secondary rim C(2)- and C(3)-0H groups on adjacent residues, and 
intermolecular hydrogen bonds between OH groups and waters of crystallisation, 
both contribute to the conformation of the cyclodextrin within the crystal. The 
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presence of waters of crystallisation is important in determining the structure in the 
solid state, due to special arrangements of the atoms and the formation of a 
hydrogen bonding network that includes the cyclodextrin, guest and water 
molecules40'41 '42 . 
lntramolecular hydrogen bonds on the secondary face are observable in a 
broadening of the voH bands in the infrared spectrum, and have been characterised 
in neutron diffraction studies43'44 . The degree of distortion of the units from the 
coplanar model determines the degree to which these hydrogen bonds are formed 
and maintained. This in turn has an effect on a number of other characteristics, in 
particular the solubilities of the individual cyclodextrins (Section 1.3.1), and they 
lower the overall energy of the molecule45•46 . 
1.2.2 Substituted cyclodextrins 
The presence of a large number of terminal OH groups lends the cyclodextrins to 
substitution. Those of particular interest have been the derivatives of 
j3-cyclodextrin, due mainly to the favourable cavity volume and low aqueous 
solubility of the native compound. A large number of other derivatives have been 
prepared and are commercially available, for use as complexing agents and as 
enzymes, and recent studies have placed their focus on preparing cyclodextrin 
derivatives that may specifically interact with certain guests47 . The difference in 
reactivity of the C(2), C(3) and C(6) hydroxyl groups is not great, making 
substitution a sometimes difficult process as yet unsuitable for the large-scale 
industrial production of derivatives, except in a few instances48•49·50 . 
Solubility may be improved by substitution on the j3-cyclodextrin macrocycle, even 
with hydrophobic substituents. This is notable with the most commonly studied 
derivatives, namely the methylated and hydroxypropylated cyclodextrins. Two 
methylated derivatives of p-cyclodextrin, heptakis(2,6-di-0-methyl)-j3-cyclodextrin 
and heptakis(2,3,6-tri-O-methyl)-j3-cyclodextrin, commonly abbreviated as DIMES 
and TRIMEB51 , have been proposed as drug carriers in the pharmaceutical industry, 
and have formed part of this study. The structure of these compounds is given in 
Fig.1.3. However, there are limitations to their use, especially in parenteral dosage 
forms, due to their potential toxicity. This is discussed further in section 1.5.2. 
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Fig. 1.3: Structure of DIMES and TRIMEB subunits 
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The aqueous and other solubilities of the cyclodextrins are given in Fig.1.4. A 
number of chemical factors contribute to the differing solubilities, based on the 
conformations of the individual cyclodextrins in solution and the nature of the 
substituents on the derivatised cyclodextrins: 
1. Hydrogen bonding. In a-cyclodextrin, one residue is distorted from the plane 
of the macrocycle and only four of a possible six hydrogen bonds may be 
formed between 0(2) and 0(3) groups located on the secondary rim52 . In 
p-cyclodextrin, a complete belt of hydrogen bonds is formed as all the units 
are in an essentially undistorted conformation. The aqueous solubility of 
p-cyclodextrin is the lowest of the cyclodextrins, possibly because of this 
complete layer of hydrogen bonds. In y-cyclodextrin, the molecule is larger 
and relatively more flexible, exhibiting a significant degree of non-coplanarity, 
such that the extent of hydrogen-bonding is less than with the other 
cyclodextrins and it is highly water-soluble. This increase in solubility is seen 
with the higher-chain cyclodextrins, which behave in a similar manner to 
straight-chain oligosaccharides and are extremely water-soluble. 
2. Substituted cyclodextrins, particularly the methylated and hydroxypropyl 
derivatives, are highly water soluble, despite a predicted increase in 
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hydrophobic character on formation of ether groups. This may again be due 
to the relatively more flexible conformation of the macrocycle, and the 
decrease in the number of hydrogen-bonding connections between C(2)- and 
C(3)-0H groups. 
3. Temperature can have a significant effect on solubility (Fig. 1.4a). For the 
native cyclodextrins, solubility increases with an increase in temperature, the 
degree varying with each individual cyclodextrin. However, on decreasing 
the temperature, a hysteresis profile is followed and a supersaturated 
solution is obtained. This can be seen most prominently with j3-cyclodextrin. 
4. Cosolvents. Studies on the polarity of j3-cyclodextrin, using fluorescence and 
other techniques, have shown that the value is similar to that of a 40% 
ethanol/water mixture. The solubility of j3-cyclodextrin in alcohol/water 
mixtures is given in Fig. 1.4b and can be seen to show a maximum at 
approximately that percentage. Thus, a higher concentration of cyclodextrin 
may be brought into solution by the use of cosolvents, though the 
advantages of this may be limited, due to possible solvent/guest competition 
for the host cavity and the formation of ternary complexes53 . 
Fig. 1.4: Solubilities of a.-, 13- and y-cyclodextrin. (a) Aqueous solubility with 
temperature change and (b) solubility of ~-cyclodextrin in ethanol/water mixture 
(reproduced from 13). 
(a) (b) 
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1.3.2 Solid-state structure 
Cyclisation should introduce a geometrical strain into the cyclodextrin, and this 
would be imposed on the glycoside bridge that links the residues. Thus, the 
glycoside C-0-C angle in a-cyclodextrin would be expected to be smaller than in the 
higher cyclodextrins, but conformational changes that occur in the macrocycle and 
induce the distortion seen in a-cyclodextrin release some of that strain, and a 
comparison of angles shows an agreement among the three52 ·54 . 
A number of other geometrical parameters are used to define the conformations of 
cyclodextrins and their complexes, based on results obtained from X-ray analyses. 
These are outlined in detail below and values for a-, p- and y-cyclodextrin are given 
in Table 1.1: 
1. Torsion angle indext - this defines the differences in conformation of individual 
glucopyranose units and the small changes that occur on complexation. 
2. The 0(4)···0(4') distance is another indication of the conformation of the 
glucose units, and is related to the torsion angles. An increase in distance is 
seen from a- to y-cyclodextrin, indicating a release in bond strain by the 
introduction of more units. 
3. Tilt angle - the primary rim is narrower than the secondary rim, such that the 
glucose units are positioned at an angle to the plane of the macrocycle, as 
measured by a polygon described through the 0(4) atoms. Specifically, the tilt 
angle is defined as the angle made by the plane through 0(4'), C(1), C(4) and 
0(4) to the plane of the macrocycle. An inclination of the primary (0(6)) end of 
the residue toward the centre of the cavity is denoted by a positive angle. 
Differences in tilt angle are a measure of the degree of change in conformation 
to accommodate a guest molecule on complexation. Parameters for the 
methylated cyclodextrins differ significantly in their values, as will be discussed 
further on. 
4. A measure of the roundness and symmetry of the cyclodextrin ring is obtained 
by calculating the distance of each 0(4) atom from the centre of gravity of all 
the 0(4) atoms. 
t The torsion-angle index is defined as I 1J1(C1-C2) I + I 1j!(C2-C3) I - I 1J1(C3-C4) I - I 1j!(C4-C5) I 
+ I lj/(C5-05) I + I lj/(05-C1) I. where 1v(C1-C2) is the torsion angle 0(5)-C(1 )-C(2)-C(3). 
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Table 1.1: Crystallographic parameters for a.-,P- and y-cyclodextrin 13 
a. p y 
0(4)--·0(4') distance (A)* 4.31 4.36 4.50 
Radius of the 0(4) polygon (A) * 4.30 5.04 5.88 
Tilt angle (0 ) * 19 13 14 
C(1 ')-0(4)-C(4) angle (0 ) * 119.0 117.7 112.6 
0(2)···0(3') distance (A) * 3.00 2.86 2.81 
Crystal form hexagonal plates monoclinic quadratic 
parallelepipeds prisms 
* These are average values for all glucose residues in the asymmetric unit. 
1.3.3 Structure in solution 
Techniques such as nuclear magnetic resonance (NMR), infrared spectroscopy (IR) 
and dialysis methods have been used to determine the conformation of 
cyclodextrins in solution. Results have shown that each glucose unit is present in 
the same 4C1 conformation and that the macrocyclic structure is almost identical to 
that in the solid state, even for the relatively more flexible y-cyclodextrin. The 
intramolecular hydrogen bonding network would also be identical, and this would 
explain the solubility properties of the cyclodextrins. It would thus be possible to 
state that complexes in solution are in many respects similar in structure to those 
determined from crystallographic studies 13. 
However, there are possible differences in stoichiometry that should be noted. 
Whereas complexation in solution is typically characterised by insertion of the 
guest, or part of the guest, into the cavity, and the formation of a stoichiometric 
complex, the value being dependent on a number of factors such as concentration 
and pH, guest molecules may be located between cyclodextrin molecules in the 
crystalline complex, and these solid-state complexes may not be absolutely 
stoichiometric in composition. Furthermore, the crystal may contain "empty" cavities 
of cyclodextrin hydrate, with no guest present. 
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1.3.4 Substituted cyclodextrins 
Both DIMES and TRIMEB are highly water-soluble, though solubility does decrease 
with increased methylation. One unusual feature of the methylated derivatives is 
that solubility decreases with increasing temperature, such that crystallisation will 
occur rapidly at higher temperatures, dependent on concentration and within a 
narrow temperature range. Redissolution is just as rapid, though at a lower 
temperature, and the profile is characterised by a hysteresis loop. This is shown as 
a graph, with comparison to p-cyclodextrin, in Fig.1.555 . 













1.4 CYCLODEXTRIN COMPLEXES 
1.4.1 Uses of cyclodextrin complexes 
flCO .,.. ------ solubility 
60 °C 
The cyclodextrins and their polymers have found applications in a number of 
industries through their ability to complex molecules and modify their 
physicochemical characteristics. A molecule within a cyclodextrin is encapsulated 
and isolated from its environment, which may be advantageous in conferring 
stability to otherwise labile compounds56 . This may be applied to a number of 
commercially useful substances such as pharmaceuticals, agrochemicals and 
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foodstuffs, as well as dyes, flavourants and fragrances used in a number of 
industries. Some of the advantages of complexation can be summarised: 
1. Stabilisation of light- and oxygen-sensitive compounds and modification of 
chemical reactivity, thus allowing for more manageable formulation. A few 
examples include the pyrethrin insecticides, which are sensitive to light57, 
vitamin 0 3 (cholecalciferol/
8
, certain prostaglandins59·60·61 , and nitroglycerin, 
which may be complexed with j3-cyclodextrin to reduce its explosive 
properties and allow formulation in tablets62 . 
2. Fixation of volatile substances, especially aromatic oils used as flavourants in 
toiletries and foodstuffs, with retention of essential properties such as taste 
and smell. An oil may then also be easier to manipulate as a powder or 
emulsion in complexes with cyclodextrin e.g. chamomile, garlic and rosemary 
oils, and certain toothpaste, chewing gum and bath additives21 ·63 ·64·65·66·67 . 
The flavour will be released through dissociation of the complex once it 
comes into contact with water or saliva. 
3. Modification of physicochemical characteristics, especially the aqueous 
solubility of poorly soluble or insoluble substances, thus allowing easier 
dissolution or dispersion in the aqueous medium, which is important in 
biological applications e.g. dispersal of tablets in the stomach upon oral 
administration and improvement in bioavailability68·69·70 . 
4. The masking of pigments and unpleasant odour and taste may also be 
achieved by complexation with cyclodextrins 71 ·72 ·73·74•75·76 . Many drug 
substances are astringent or bitter-tasting and complexation may be 
especially useful in paediatric drug formulations as the cyclodextrins are 
relatively sweet and have a taste threshold similar to sucrose 13 . 
5. Improved compatibilty within multicomponent systems by the isolation of 
incompatible substances from each other77 ·78 , though care needs to be taken 
to avoid exposure to moisture which may partially disintegrate the complex 
and bring these substances into contact with each other13. 
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Other uses of the cyclodextrins, as enzymes and in racemic resolution, are beyond 
A 
the scope of this study as they are utilised primarily outside of the pharmaceutical 
industry56 . As catalysts, the ability to form covalent and non-covalent bonds with a 
number of substrates makes the cyclodextrins capable of improving rates of 
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reaction under specified conditions. Examples include ester and amide hydrolysis, 
decarboxylation and oxidation 10. 
Being chiral molecules, the cyclodextrins, and especially cyclodextrin polymers, may 
be used to resolve racemic mixtures of substances by formation of diastereomeric 
pairs79•80•81 ·82•83•84 . This may be applied with drugs where one isomer has a 
considerably greater potency than another, and where isolation may allow for a 
reduction in the dose required to effect a therapeutic response, with a possible 
reduction in side-effects and other adverse reactions that may be associated with 
that drug. Generally, however, the cyclodextrins have been found to be weakly 
selective and their usefulness in this area is still limited85 '86 . The behaviour of 
cyclodextrins towards the chiral non-steroidal anti-inflammatory drugs (NSAIDs), 
specifically the profen analogues, will be discussed further in Section 5.5. 
1.4.2 Mode of complexation 
A guest molecule will insert into the cavity of cyclodextrin or interact with the 
macrocycle and, through hydrogen bonding and other forces, an inclusion complex 
will be formed. The preparation and characterisation of these complexes involves 
an understanding of the possible mechanisms underlying the "driving force" behind 
complexation and how the physicochemical characteristics of the cyclodextrin and 
guest molecule may be modified through interaction. 
The formation of an inclusion complex involves the replacement of water molecules 
located within the "empty" cavity of cyclodextrin by a guest molecule of suitable size 
and shape, thereby reducing the free energy of the system. A number of factors 
may be identified as contributing to the driving force that enacts this substitution in 
solution, and these can be summarised as follows87: 
1. The size and shape of the guest molecule, as well as the properties of 
functional groups and the relative polarity, are seen as possibly the most 
important factors in determining whether complexation will proceed. A guest, 
or portion of a guest, must be able to insert into the cavity with minimal steric 
effects to hinder progress, though a tight fit in the cavity is considered 
important, to effect favourable distances for intermolecular interaction. 
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2. The energy of interaction between water and the hydrophobic cavity of 
cyclodextrin, and between a relatively apolar guest and solvent water, is 
reduced by insertion of the guest into the cavity and release of cavity-bound 
water into the solvent bulk. The unfavourable environment within the cavity 
means that water molecules are unable to satisfy hydrogen bonding 
potential, and their expulsion from the cavity increases their degrees of 
freedom, as well as decreasing the potential energy of the system, and these 
changes all favour complexation. 
3. A number of interactions between cyclodextrin and guest, such as van der 
Waals forces, hydrophobic interactions within the cavity, and hydrogen 
bonding, impart a greater stability and lower energy to the complex88·89. 
These interactions may dominate in the formation of complexes, as well as 
the increased hydrogen bonding potential of waters released into the 
medium. 
4. A decrease in ring strain, most notable in a-cyclodextrin, where conformation 
is more distorted and the macrocycle becomes more symmetrical on 
complexation than in 13- and y-cyclodextrin. This may contribute to overall 
complexation, but is not considered as important as other factors52 . 
All of these factors may act simultaneously to effect complexation, with that 
contributing most being the nature of the guest, most particularly size, shape and 
distribution of functional groups. The chemical nature of the guest appears 
relatively unimportant, except where moieties are able to interact strongly with the 
cyclodextrin and drive the equilibrium toward complexation. 
A scheme showing the steps involved in complexation is given in Fig.1.6. Expelled 
water molecules show an increase in energy associated with transition to the 
gaseous phase, as well as an increase in rotational degrees of freedom resulting 
from release into a more favourable environment. They condense back into the 
liquid phase as they are drawn into the solvent bulk. The guest molecule, shedding 
its hydrate coating, also assumes the properties of an ideal gas and inserts into the 
cavity, with a corresponding increase in host-guest interactions. Finally, water is 
restored around the cyclodextrin and any exposed parts of the guest. 
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Fig. 1.6: Scheme showing the mode of complexation of cyclodextrin with 
guest molecules in solution (reproduced from 13). The guest molecule is 
p-xylene, and water molecules are shown as circles. 
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1.4.3 Equilibrium of complexation 
0 0 0 
0 0 
0 0 
An equilibrium is established in solution between complexation and dissociation, 
which may be represented as: 
kc 
CD+ G ~CD·G 
kd 
The rate of formation of the complex is determined by the constant kc, and that of 
dissociation by kct, and the equilibrium obtained gives a measure of the stability of 
the complex. The overall equilibrium constant K (= kclkct) is determined by a number 
of factors, and these in turn determine the conditions under which a stable complex 
may be formed in solution: 
1. Size of guest molecule - the rate of complexation and decomposition is 
slower with larger guests, due to a possibly stronger interaction with the 
cyclodextrin cavity. This may also be dependent on the type and size of 
substituents. 
2. Ionisation of the guest molecule impedes complexation, due to an increase 
in possible interactions with solvent water molecules. Altering the pH of the 
medium may thus affect the equilibrium90. 
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3. Relative concentration of guest and cyclodextrin in solution. An excess of 
one or the other may promote complexation. The stoichiometry of the 
complex may also be affected, though this could depend in part on the 
nature of the guest molecule and whether a 1: 1 or higher complex is formed 
in equimolar solution. 
4. Interaction between host and guest, through hydrogen bonding, van der 
Waals forces and hydrophobic interactions, related to the structure of the 
guest and the presence of certain functional groups. A QOFRbina~ign of 
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1.4.4 Solubility of the complex 
Attempts to crystallise a complex from solution must take its solubility characteristics 
into account. Studies have shown that the stability of a complex and its solubility 
are independent of each other, though enhancement of the poor solubility of a 
guest is directly related to the ability of a complex to form in solution. 
Measurements of the equilibrium constant will therefore not ensure that a complex 
can be readily crystallised, despite high stability. 
The solubility isotherm for a guest, however, gives an important indication of the 
possibility of precipitating a complex. A scheme, Fig.1. 7, illustrates how solubility 
may be affected by the concentration of cyclodextrin. Complexation in solution will 
follow profile A. A further increase in cyclodextrin concentration can improve 
solubility up to a point limited by its own solubility. Where this is linear, it follows the 
type AL solubility curves proposed by Higuchi and Connors91 . 
If the complex is more soluble than the cyclodextrin, no precipitation will occur. 
Where complex solubility is limited, the isotherm will follow profile B i.e. a saturation 
point of guest and cyclodextrin has been reached. A greater concentration of 
cyclodextrin, either by addition to the medium or reduction in solvent volume, may 
then result in a decrease in guest solubility, indicating precipitation of the complex. 
Where no improvement is seen in solubility, the complex formed is insoluble and will 
precipitate (Br). 
SECTION 1 1-16 












So= saturation solubility of the guest in aqueous solution. Sc= solubility limit of complex. 
Si= concentration of dissolved guest in the free and complexed state. 
(adapted from Higuchi and Connors91 ) 
1.4.5 Complex characterisation 
The solubility profile of a guest in the presence of cyclodextrin, as well as the mode 
of complexation, may be measured using a number of techniques that record 
modifications in certain physicochemical characteristics of the guest or cyclodextrin. 
UV spectrophotometry may be used as the cyclodextrins do not absorb in the UV 
wavelength range, but will cause changes in the spectra of guests where a 
chromophore is shielded by the cyclodextrin cavity92•93 . This may be used to obtain 
a solubility profile as shown in Fig.1.8, showing spectrum modification for 
mefenamic acid94 and a plot of p-cyclodextrin-tenoxicam complex in solution, 
showing a type AL solubility curve. The plots obtained may be used to calculate 
equilibrium constants for the reaction, using the Benesi-Hildebrand equation95 . 
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Fig. 1.8: UV spectrophotometry. (a) Spectral changes with 13-cyclodextrin 
concentration94 and (b) a plot of solubility change with increased cyclodextrin 
concentration 96 . 
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Induced circular dichroism is observed with achiral guests in the presence of 
cyclodextrin and is sensitive to the orientation of the chromophore in the 
cavity97•98•99 . Other techniques measure changes in characteristics such as 
fluorescence and luminescence, as well as chemical shifts in proton NMR 
spectroscopy93•100•101 . 
Most of these techniques are applied to solutions of cyclodextrin and guest, though 
solid-state characterisation is possible using thermal analysis and X-ray diffraction 
where the complex formed is crystalline. The basis of the present study is the 
characterisation of complexes using these techniques, and they will be discussed in 
more detail in the methodology (Section 2), though the thermal behaviour of 
cyclodextrins may be discussed here. 
1.4.6 Thermal properties 
The behaviour of the cyclodextrins with temperature may be analysed using a 
number of techniques 10•13•102•103. Those of interest in this study have been 
thermogravimetric analysis (TGA), measuring mass loss over a temperature range, 
and differential scanning calorimetry (DSC), which records heat flow through a 
sample and the energy that may be absorbed or released. Changes in the thermal 
characteristics of a guest molecule, such as absence of a melting point endotherm 
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or delayed onset of decomposition, by association with cyclodextrin, may be used 
as an indication of complex formation. 
1.4. 7 Crystal structure 
There are a number of basic modes of packing in those crystal structures that have 
been reported for cyclodextrins and their complexes. These may be grouped 
according to whether the host molecules crystallise as monomers or dimers, as 
shown schematically in Fig 1.9. A number of factors may account for the mode of 
packing, especially the intermolecular contacts, such as hydrogen bonding, that are 
possible between host and guest and solvent water molecules, such that all 
possible contacts are satisfied. 
1.4.7.1 Monomeric complexes 
Herringbone - this is the arrangement adopted by the hydrates of a-, f3- and 
y-cyclodextrin31 ·32·39 and is confined mainly to complexes with very small guests that 
can be completely enclosed within the cavity, such as that of a.-cyclodextrin with 
iodine 104 and n-propano1105 and f3-cyclodextrin with methanol29 and ethanol106 though 
larger guest molecules, such as benzyl alcohol 107 and nicotinamide 108, may also 
complex in this manner where they can fully insert into the cavity. Both ends of the 
cavity are blocked by adjacent rings and the guest is completely isolated and 
trapped. Adjacent cyclodextrins are related by a crystallographic two-fold screw 
axis. 
Brick - an arrangement of layers parallel to the plane of the macrocycle, adjacent 
layers being displaced approximately by the radius of a cyclodextrin molecule. Both 
ends of the cavity are open, and the guest, either too large or too long to be fully 
accommodated within the cavity, is able to penetrate into the intermolecular space 
created between neighbouring cyclodextrins in the adjacent layer. This 
arrangement has so far been observed primarily in a.-cyclodextrin complexes with 
aromatic monocyclic compounds such as pyrrolidone109 and p-nitrophenoi1 10 , and 
also in the f3-cyclodextrin complex with triethylenediamine 111_ 
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Fig. 1.9: Scheme showing basic packing arrangements of cyclodextrin 
complexes. (a) Head-to-head channel structures, (b) head-to-tail channel 
structures, (c) cage (herringbone) and (d) layer (brick) structures. 
(Reproduced from 112). 
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1.4.7.2 Dimeric complexes 
Even where the guest molecule may be small enough to be fully enclosed within the 
cavity, p-cyclodextrin will preferentially crystallise as a dimer, such as in the complex 
with n-propanol113'114. The formation of head-to-head dimers is favoured by the 
establishment of 0(3)···0(3') hydrogen bonds between adjacent cyclodextrins, 
which confer further stability to an already relatively rigid molecule. Furthermore, 
the cavity volume of the dimer is approximately 2.5 times that of the monomer, and 
thus able to accommodate larger guest molecules. These molecules are not 
isolated within individual cavities, and the possibility exists for interactions between 
them that may stabilise the complex further. The cyclodextrin molecules are also 
less distorted from the plane of the macrocycle than in monomeric complexes, 
which may further contribute to complex stability 115 . 
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A characteristic of dimer complexes, observed with the increasing number of 
structures reported, is the formation of invariant layers (Fig.1.1 O) 115·116, differing in 
the relative displacement of adjacent layers: 
Channel - dimers are aligned along the axis, such that endless channels are formed 
into which the guest is inserted. These head-to-head channels are most commonly 
found with p-cyclodextrin complexes26 '117, though a number of head-to-tail 
complexes have been reported with a.-cyclodextrin and compounds such as 
m-nitroaniline118 and benzenesulphonate119 , with hydrogen bonding between 
primary and secondary OH groups. 
Chessboard - a lateral displacement of dimers in adjacent layers related by a two-
fold screw axis, such that each dimer is located above a space filled with solvent 
e.g. p-cyclodextrin with benzil and phenylethylmalonic acid. This is a similar 
arrangement to that of the brick-type cage structure observed with monomeric 
complexes. 
Intermediate - an arrangement between channel and chessboard, where the dimer 
cavity is partially closed on either end. The shift of dimers is almost equal to the 
inner diameter of the p-cyclodextrin cavity such that the axis of a dimer is located 
near the rim of the dimer below, creating a brick-like pattern similar to that found in 
monomeric complexes, e.g. 1-adamantane carboxylic acid complex 120 . 
Screw - a distorted channel arrangement where dimers are not aligned along the 
channel axis but displaced at an angle and related via a two-fold screw axis, 
forming distorted channels 115, e.g. p-cyclodextrin with racemic fenoprofen82 . 
The establishment of a further hydrogen bonding network has been proposed as 
the reason for the arrangement of dimers in layers116 . A primary network of 
intermolecular hydrogen bonds between the secondary faces of the individual 
monomers that make up the dimer, and a secondary network between these OH 
groups and solvent molecules, acting as a bridge to adjacent cyclodextrins in the 
same layers, act to stabilise the dimer within the layer. This arrangement has been 
found in the two-dimensional arrangement of all cyclodextrin dimers characterised 
to date. 
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Fig. 1.10: Packing arrangement for dimeric complexes (Reproduced from 115). 
(a) 
(c) 
Each ~-cyclodextrin molecule is represented by the 0(4) heptagon. 




The type of packing that is adopted appears to depend in large part on the nature of 
the guest included. Factors such as size, the character of functional groups that 
may interact through hydrogen bonding or hydrophobic interactions, and ionisation 
of the guest are all important. The crystalline complexes of a-cyclodextrin with 
small chain carboxylic acids, such as acetic, propionic and butyric acid, adopt the 
cage structure, whereas higher-chain acids will form channels 121 . Furthermore, 
ionisation may cause a change in arrangement e.g. molecular iodine converting 
from a cage-type structure in complexes with (3-cyclodextrin to channels on 
formation of the iodide, due to a polyiodide chain positioned inside the channel 104. 
The few reported structures of y-cyclodextrin show that the nature of the guest may 
have very little influence on the packing arrangement. The hydrates and deuterate 
of y-cyclodextrin crystallise in a cage structure very similar to that of 
(3-cyclodextrin37 '38·122 , but on complex formation a channel is assumed that is linear, 
even where the guest, such as n-propanol, is small 123 '124 . Furthermore, the 
cyclodextrin rings are stacked in an alternating head-to-head and head-to-tail 
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arrangement that is unique and would appear to be characteristic more of 
y-cyclodextrin than the nature of the guest molecule. Each cyclodextrin is 
positioned on a four-fold axis, and all structures of complexes recorded to date 







The hydrated form of o-cyclodextrin has been characterised and this is the only 
structure of this nine-glucose cyclodextrin to be published to date 125, and the 
structure of E-cyclodextrin has recently been elucidated126 . 
1.4.7.3 Substituted cyclodextrins 
The substituted cyclodextrins, specifically DIMEB and TRIMEB, have a more 
flexible macrocyclic structure, though a degree of rigidity is maintained in DIMEB by 
the formation of intramolecular 0(2)··· H-0(3) hydrogen bonds 127. A comparison 
between the geometrical parameters of selected complexes of j3-cyclodextrin, 
DIMEB and TRIMEB is given in Table 1.2. 
Whereas j3-cyclodextrin and DIMEB are similar in conformation, the macrocycle of 
TRIMEB deviates more significantly from planarity, due mainly to the greater 
inclination of the glucose moieties toward the centre of the cavity, as seen by the 
0(2)· · ·0(3) distance and the tilt angle. This may be due in part to the steric effects 
of substitution on the 0(2),0(3) rim. 
The crystal structures of DIMEB pentadecahydrate and TRIMEB monohydrate have 
been reported127·128 . TRIMEB is more distorted in the uncomplexed than complexed 
state, with six methylglucose moieties adopting the 4C1 conformation and one 
adopting the 1C4 conformation, and undergoes significant conformational changes to 
accommodate the guest molecule 128. 
There is less difference in the hydrophilic character of the intra- and intermolecular 
spaces of DIMEB, due to the presence of methyl groups, and guests can be found 
inside and outside the cavity131 ·129·130 , though interaction between guests usually 
does not occur. The 0(6) rim of TRIMEB is almost completely closed off by 
0(6)-methyl groups, giving the molecule a cup-shape into which the hydrophobic 
part of a guest molecule can insert only partially. The hydrophilic moiety protrudes 
and is able to interact with other TRIMEB molecules in the crystal. Unlike 
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Table 1.2: Geometrical parameters for p-cyclodextrin and methylated 
derivatives(reproduced from 112). 
J3-cyclodextrin3 D1MEB0 TRIMEBC 
0(4) hexagon radius (A)* 5.02 5.06 
0(4) .. ·0(4') distance (A)* 4.36 4.38 
0(2) .. ·0(3) distance (A)* 2.86 2.91 
Planarity of 0(4) hexagon° (0 ) 0.16 0.09 
Glycosidic 0(4) angle (0 ) 117 117 
Tilt-angle (0 )e 14 14 
* The average value for all residues 
a) triethylenediamine complex111 b) p-nitrophenol complex131 c) p-iodophenol complex132 







p-cyclodextrin, each guest molecule is usually isolated within each host molecule 
and channel structures are not formed 131 ·133·134. 
The complexes formed are often anhydrous, due to the hydrophobic environment of 
the crystal, though a few water molecules may be present to form hydrogen bonds 
with the host and guest molecule 131 ·133 . 
1.5 CYCLODEXTRINS AND NON-STEROIDAL ANTI-INFLAMMATORY 
DRUGS (NSAIDs) 
1.5.1 NSAIDs 
This is a group of chemically unrelated drugs, classified by structure, that share a 
common mechanism of action and therapeutic effect. They are anti-inflammatory, 
analgesic and anti-pyretic, with differences in the respective potencies of these 
effects between different structural classes and their analogues. The prototype for 
the group is aspirin (acetylsalicylic acid), originally synthesised by Hoffman in the 
previous century and released by Bayer in 1899, and the NSAIDs are often referred 
to as the aspirin-like drugs. They have been successfully employed in a number of 
acute and chronic conditions, primarily rheumatoid arthritis and acute gout135 . 
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The NSAIDs, with paracetamol as an exception, may be broadly defined as a group 
of heteroalkyl and -aryl alkanoic and enolic acids, possessing a common structural 
feature in an acid group with a large hydrophobic substituent. This appears to be 
important in determining the interaction with receptors in target tissues and evincing 
the anti-inflammatory effect. Paracetamol, a non-acidic p-aminophenol derivative, is 
primarily anti-pyretic, with a weak anti-inflammatory effect. The molecular structures 
of the most commonly used classes of NSAIDs are given in Table 1.3, and IUPAC 
nomenclature for those with which this study is concerned are given in Table 1.4. 
1.5.1.1 Mechanism of action 
Though the precise mechanism of action is still under investigation, a common 
interaction with specific enzyme receptor sites is observed with the NSAIDs. They 
inhibit the production of prostaglandins, a series of eicosanoids which mediate in 
inflammatory pathogenesis and are produced at the site of trauma, by blockade of 
the enzyme cyclooxygenase. This action, combined with other possible interactions 
still to be elucidated, determines the pharmacological and side-effect profiles of this 
group of drugs. 
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Table 1.4: Nomenclature for NSAIDs used in this study 136 
DRUG NOMENCLATURE 
diflunisal 2' ,4 '-difluoro-4-hydroxy-3-biphenylcarboxylic acid 
flufenamic acid 2-[[3-(trifluoromethyl)phenyl]-amino]benzoic acid 
tolfenamic acid 2-[(3-chloro-2-methylphenyl)-amino]benzoic acid 
niflumic acid 2-[[3-(trifluoromethyl)phenyl]-amino]-3-pyridine-
carboxylic acid 
mefenamic acid 2-[(2,3-dimethylphenyl)amino]-benzoic acid 
ibuprofen 2-(4-isobutylphenyl)propionic acid 
ketoprofen 2-(3-benzoylphenyl)propionic acid 
tenoxicam 4-hydroxy-2-methyl-N-2-pyridinyl-2H-thieno[2,3-e]-1,2-thiazine-3-
carboxamide 1, 1-dioxide 
piroxicam 4-hyd roxy-2-methyl-N-2-pyrid i nyl-2H-1 ,2-benzoth iazi ne-3-
carboxamide 1, 1-dioxide 
indomethacin 1-(4-chlorobenzoyl)-5-methoxy-2-methyl-1 H-indole-3-acetic acid 
sulindac (Z)-5-fluoro-2-methyl-1-[[4-(methylsulphinyl)-phenyl]methylene ]-1 H-
indene-3-acetic acid 
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Related to this mode of action is an important limiting factor to the use of the 
NSAIDs, especially in the long-term treatment of chronic osteo- and rheumatoid 
arthritis. Apart from their role in inflammation, the prostaglandins, specifically PGE2 
and PGb, inhibit acid secretion in the stomach and promote mucous secretion that 
protects the cell lining of the gastric mucosa. Depletion of prostaglandins thus robs 
the stomach of this protection, and ulceration and bleeding may result if NSAID use 
is prolonged, with debilitating and potentially fatal results 135·137·138·139·140. 
1.5.2 CYCLODEXTRIN INCLUSION OF NSAIDs 
The NSAIDs are small molecular weight compounds possessing a hydrophobic 
group that may comfortably insert into the cyclodextrin cavity, and a number of 
complexes have been prepared and become commercially available, with notable 
improvements in drug behaviour. 
The hydrophobic and acidic properties of the NSAIDs confer a poor aqueous 
solubility, especially in the acid environment of the stomach where the drug is 
present mainly in its unionised form. This is responsible in part for a direct irritant 
effect on the gastric lining with oral administration that can result in nausea, 
vomiting and gastric discomfort caused by hyperacidity, which, in combination with 
prostaglandin E2 inhibition, may ultimately progress to ulcer formation. 
By encapsulation in a soluble host molecule, it becomes easier to disperse the drug 
in an aqueous medium. This has a number of potential advantages: 
1. Enhanced absorption of the drug from the intestine, by delivering more to the 
absorbing surface. The intestinal mucosa preferentially absorbs hydrophobic 
molecules, and will readily dissociate the cyclodextrin-drug complex. This 
has a dual beneficial effect, by improving the rate of absorption and the onset 
of action, and by increasing the amount of drug that is potentially available 
for therapeutic effect141 '142 '143'144'145'146'147 . A scheme showing the process of 
dissolution and absorption is given in Fig.1.11. The complex will dissolve and 
dissociate rapidly in the gastrointestinal tract and be absorbed. Drug that has 
dissolved in excess of the saturation concentration will then recrystallise and 
be dissolved as more drug is absorbed. Further studies have suggested that 
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cyclodextrins may also improve absorption by interaction with and 
modification of the mucosal membrane148·149. 
2. Reduction of gastric side effects, which are the main limiting factor in the use 
of NSAIDs on a long-term basis 147,150.151.152,153,154,155_ 
3. Dosage form modification, for example the formulation of parenterals and 




Scheme showing dissolution and absorption of complexes in 
the gastrointestinal tract (G.I.T.}(adapted from 87). 
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Cyclodextrin toxicity 
An important limitation to the use of cyclodextrins is their potential toxicity, though in 
general they are considered to be safe, with high LD50 values being reported in test 
animals. Absorption of the whole molecule from the gut is minimal, and it is 
degraded by intestinal flora in the colon after the complex has dissociated and the 
drug has been absorbed. The relative amounts of unmetabolised cyclodextrin that 
are absorbed are less than 2% for u-cyclodextrin and from 1-6% for p-cyclodextrin 
with y-cyclodextrin being degraded higher up in the gastrointestinal tract so that less 
than 0.1% of the whole molecule is absorbed160 . The breakdown products - glucose 
and short-chain oligosaccharides - are non-toxic and readily assimilated. The 
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potential toxicity of methylglucose, and other derivatives, may limit the use of 
substituted cyclodextrins. 
A well-documented haemolytic effect, due to a high surface activity, with depletion 
of cholesterol from cell membranes, could limit parenteral administration. This is 
most pronounced with DIMEB and may lead to toxic effects. Furthermore, the 
relatively poor solubility of p-cyclodextrin, most commonly used because of its cavity 
size and cost-effectiveness, and its higher affinity for cholesterol than other native 
cyclodextrins, can lead to crystallisation and accumulation of the p-cyclodextrin-
cholesterol complex in the kidneys 13. 
The hydroxypropyl derivative of p-cyclodextrin has been extensively studied for use 
as an excipient in oral and parenteral drug formulation, for two main reasons. The 
derivatised molecule is more resistant to enzymatic breakdown in the 
gastrointestinal tract and the haemolytic effect occurs at considerably higher doses 
than with the unsubstituted p-cyclodextrin, being comparable to y-cyclodextrin, 
which is the safest of the native cyclodextrins for parenteral use, though its wider 
application is inhibited by cost13'157·161 ·162 . 
The sulphoalkylether cyclodextrins have also been studied, for use as drug carriers 
in formulations with a number of different routes of administration. Their safety 
profile is comparable to hydroxypropyl-f3-cyclodextrin, and they can favourably 
improve bioavailability 163'164 . 
1.6 AIMS OF THIS STUDY 
This introduction has given an overview of the structure and potential uses of the 
cyclodextrins as carrier molecules for a number of compounds. This study has 
concentrated specifically on the non-steroidal anti-inflammatory drugs as guest 
molecules for inclusion into cyclodextrins and their derivatives, and the application 
of physicochemical methods to establish that complexation has occurred. 
Complexes have been prepared by a number of methods, and characterised using 
techniques such as thermal analysis and X-ray diffraction studies, which are 
outlined in the methodology in Section 2. 
Results for a number of complexes are given in Section 3. With a knowledge of the 
physicochemical characteristics of the non-steroidal anti-inflammatory in question, it 
becomes possible to establish that complexation has occurred. The main aim of the 
study was to cultivate crystals of sufficient size for single crystal X-ray analysis. 
Where this was successful, unit cell data have been listed. In sections 4 and 5, the 
results of crystal structure solution for two complexes, both with the arylpropionic 
acid ibuprofen, are described in detail, with discussions on the implications of 
complexation and racemic resolution of chiral guests. 
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2. METHODOLOGY AND MATERIALS 
A number of methods were used to obtain solid-state complexes, both as powders 
and as crystals suitable for single-crystal X-ray studies. All complexes were 
prepared by bringing insoluble NSAIDs into a saturated aqueous solution of 
cyclodextrin, with slight variations in method being attempted according to the 
physicochemical and other properties of the host and drug being reacted. 
2.1 COMPLEXES WITH f3- AND y-CYCLODEXTRIN 
The methods used to obtain complexes are summarised in Fig. 2.1 and may be 
explained as follows: 
1. The main approach with all crystallisations with f3- and y-cyclodextrin was to 
slowly add an equimolar quantity, or other molar ratio, of drug to a hot, 
saturated solution of cyclodextrin, with prolonged stirring until a solution was 
obtained. This can be seen as an indication that the solubility of the poorly-
soluble drug had been enhanced by the presence of cyclodextrin, and some 
interaction was occurring between the two reactants. In some cases, an 
excess of either drug or cyclodextrin was used in an attempt to drive the 
equilibrium of the reaction toward complexation. Any excess drug that did 
not react was then filtered off and the resultant clear solution left to 
crystallise. 
Complete uptake of drug from stirring alone was often not successful, and a 
method of partial neutralisation was then employed. The dropwise addition 
of 0.01 M NaOH ionised the drug and brought it into solution. The pH was 
then adjusted down with 0.01 M HCI until a turbidity was observed in the 
solution, indicating precipitation of the poorly soluble drug in its unionised 
state. Minor adjustments in pH would then produce a solution either just 
above or at the precipitation point, giving a clear or slightly turbid solution. 
Turbidity would usually disappear with further stirring and so the guest was 
slowly brought into solution. 
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2. Cosolvents, such as acetone and ethanol, were used reluctantly as 
cyclodextrins form complexes with many organic solvents, possibly more 
readily than with the guest. Ternary complexes may also be formed. 
3. An interface was created between an aqueous solution of cyclodextrin and 
a non-miscible organic phase containing dissolved drug, with the aim of 
promoting crystallisation at the interface. A number of powder complexes 
could be obtained in this manner. 




Hot, saturated, solution of 
13- or y-cyclodextrin 
(50-60°C) 
Stirring for 30min-2hrs 
Coprecipitation 
Extraction of single 
crystals or filtration to 
obtain microcrystalline 
powder 
Equimolar amount of drug 
Partial neutralisation 
by addition of excess 
NaOH and then 
adjusting pH down with 
HCI 
stirring 
Clear or slightly 
turbid solution 
Crystallisation 
Solutions were filtered using Millex-LCR 0.5µm nylon microfilters and left to stand in 
specially prepared crystallisation vials. Solutions were left to incubate at 
temperatures ranging from 4-60°C, with slow evaporation being used to 
supersaturate the solution and precipitate a complex. 
2.2 COMPLEXES WITH DIMES AND TRIMES 
Due to their unique solubility characteristics, the preparation of complexes with the 
methylated cyclodextrins required a slightly different method, shown in Fig. 2.2, 
where all reactions were performed at room temperature and the resultant solution 
incubated at elevated temperature (45-55°C). 
Fig 2.2: Method of preparation of complexes with DIMES and TRIMES 
Saturated, stirring solution of 
DIMES or TRIM EB 
(room temp.) 
Equimolar amount of drug 




Extraction of single crystals or 
filtration to obtain microcrystalline 
powder 
Care was taken that the complex formed at high temperature did not dissolve back 
into solution once the sample vial was removed from the incubation oven. In cases 
where this occurred, and where the complex was unstable in air through loss of 
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water from the crystal, swift action was required to extract the crystal, remove 
solvent traces from the crystal faces and seal the crystal against water loss. It was 
necessary to remove all solvent from the surface of the crystal to prevent reaction 
with cyanoacrylate, which was used as a sealant and opacities on contact with 
water. 
2.3 THERMAL ANALYSIS 
2.3.1 Hot stage microscopy 
Visual characterisation of crystals was performed on a Nikon SMZ-10 stereoscopic 
microscope, using a Linkam TH600 hot stage with a silver heating/freezing block 
covering a range of -200 to 600°C. A Linkam C0600 temperature controller was 
used to incrementally increase the temperature over the range chosen. The 
temperature was raised at a rate of 5-10°C/min, and events such as opacity of the 
crystal, fusion and the onset of degradation were recorded for compa1·ison with data 
obtained for crystals of native cyclodextrin. Inspection of the morphology of the 
crystal under investigation also provided comparisons with uncomplexed 
cyclodextrin that could be used as an indication of complex formation. 
Photographic records were obtained with a Nikon FX-35 camera, using a Nikon 
Microflex AFX-11 Photomicrographic Attachment. Photographs were taken with 
400ASA film, and magnifications are given. 
2.3.2 Thermogravimetry (TGA) and differential scanning calorimetry (DSC) 
Thermal analysis was used in conjunction with hot stage microscopy to determine 
the behaviour of complexes with increase in temperature, and to provide 
comparison with native cyclodextrin and other complexes. Thermogravimetric 
analysis (TGA) measures mass loss over a temperature range, and was used to 
determine the number of water molecules of crystallisation per host molecule for 
each complex. DSC determines heat flow through the sample as measured against 
a reference, and can be used to accurately establish the melting point and the 
onset of other thermal events 1. 
TGA and DSC were performed on a Perkin-Elmer PC-7 series thermal analysis 
system. Scans were performed at 5 or 10°C/min under N2 gas at a flow rate of 
50ml/min. The temperature range over which analyses were performed was from 
30-330°C for p- and y-cyclodextrin and DIMES complexes, and from 30-220°C for 
TRIMEB complexes. Samples for DSC were placed in vented aluminium pans 
against an empty reference pan. Calibration for TGA was performed against the 
Curie points of alumel (163°C) and perkalloy (596°C), and for DSC using the 
temperature of melting of indium (156.6°C) and zinc (419.5°C), and the enthalpy of 
fusion of indium (28.62J/g). 
The temperature range over which experiments were conducted was dependent on 
the cyclodextrin involved. The onset of decomposition of P- and y-cyclodextrin, and 
of DIMES, occurs from 200°C, with complete degradation at 310-330°C, while 
TRIMEB has a melting point of approximately 160°C and degrades from 220°c 
upwards. 
2.4 ULTRAVIOLET SPECTROPHOTOMETRY AND ELEMENTAL ANALYSIS 
The cyclodextrins do not absorb in the ultraviolet wavelength range, and this 
property may be useful in determining the effect of cyclodextrin on the absorbance 
of chromophores on the guest molecule. A measure of the absorbance may also 
be used to establish the amount of guest present in a specific mass of sample to 
obtain complex stoichiometry though in general this method may not be sensitive. 
Spectrophotometry was performed on a Philips PU8720 UVNIS Scanning 
Spectrophotometer in the range of 200-600nm. Silica cuvettes were used. The 
apparatus was calibrated using a sample of solvent (water), and scans were run at 
a rate of 200nm/min. A standard calibration curve could be obtained for a guest 
compound using a range of known concentrations and Beer's Law was used to 
calculate the absorbance, against which a comparison could be made with the 
absorbance of the guest in a complex. Measurement of the decrease in absorption 
maxima for a guest in the presence of increasing concentration of cyclodextrin may 
also be used to quantify the dynamics of complexation and obtain a stability 
constant for a complex in solution, as described in Section 1.4.5. 
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Microanalysis was performed using a Fisons EA-1108 elemental analyser to 
determine the percentage of C, H, N and Sin a sample of each complex. 
2.5 X-RAY POWDER DIFFRACTION (XRD) 
Comparison was made between the XRD traces for complexes and physical 
mixtures of cyclodextrin and drug. The composition of mixtures was based on the 
molar ratios used in the preparation of the complex. 
2.5.1 Preparation of samples 
Physical mixtures were prepared by shaking equimolar amounts of cyclodextrin and 
drug on a Wig-L-Bug Amalgamator Model 3110-3A for three minutes without 
ballbearings to prevent the crystallinity of the complex from being destroyed. 
Complexes were isolated from the mother liquor by filtration under vacuum and then 
finely ground using a pestle and mortar. 
2.5.2 Recording of XRD patterns 
XRD traces were recorded in a 28 range of 6-40° on a Philips PW1050/80 vertical 
goniometer with Ni-filtered CuKa radiation ( )..=1.541 SA ) generated by a Philips PW 
1130/90 generator operating at 20mA and 40kV. Samples were mounted in 
aluminium holders and step scans (0.1° 28, 1s counting times) were carried out with 
1° divergence and 1° receiving slits. 
2.6 X-RAY PHOTOGRAPHY 
2.6.1 Crystal preparation 
Single crystals of suitable size, chosen for their ability to uniformly extinguish 
polarised light, were mounted for photography according to their stability in air. 
Stable crystals were mounted directly onto a glass fibre, either fully exposed or 
encased in cyanoacrylate to prevent any decay through slow diffusion of water from 
the crystal lattice. Unstable crystals were mounted naked in 0.3 or 0.5mm 
Lindemann capillary tubes, near a small volume of mother liquor which provided a 
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vapour pressure able to maintain the crystal. The glass fibre or capillary was then 
fixed in plasticine and mounted on a Stoe goniometer head. 
2.6.2 Photography 
Oscillation, Weissenberg and Buerger precession photographs were taken and, by 
inspection of Laue symmetries and systematic absences, it was possible to 
determine lattice and space group information. All photography was performed on 
Stoe Weissenberg and precession goniometers using Ni-filtered CuKa radiation 
(A=1.5418A) generated by a Philips PW 1120/00 generator operating at 20mA and 
40kV. 
2. 7 X-RAY STRUCTURE ANALYSIS 
2. 7.1 Data collection 
Where a suitable specimen was available, and the cell dimensions obtained from 
photography were not considered too large (<60A), crystal structure determination 
was attempted using intensity data collected from a single crystal. All attempted 
data collections were carried out on an Enraf-Nonius CAD4 diffractometer using 
graphite-monochromated MoKa radiation (A=0.71069A). Intensity data were 
collected at lowered temperatures. The specific conditions under which data were 
collected for the two structure solutions that were attempted are given in detail in 
sections 4 and 5. 
2. 7.2 Crystal structure solution 
Solution of crystal structures was attempted by isomorphous replacement, using the 
atomic coordinates for the non-hydrogen atoms from cyclodextrin structures with 
similar cell parameters as found in the Cambridge Structural Database. Once the 
atoms of the host and guest had been located after successive Fourier difference 
syntheses and examination of difference electron-density maps, the structure was 
refined by full-matrix least-squares analyses of the positions of all atoms using the 
programs SHELX-76 and SHELX-93 (minimisation of Iw( I F0 1-1 kFc I )2 and of 
Iw( I Fo2 I- I kF/ I )2 respectively) 2'3, until all atoms had been placed with 
acceptable temperature factors and site occupancy factors. Molecular parameters 
ti_· 
with esj{mated standard deviations were calculated using program PARST4, and 
molecular diagrams were drawn using program PLUT05. The details of structure 
solution and refinement for th0se complexes which were characterised are given in 
Sections 4 and 5. 
2.8 MATERIALS 
p-cyclodextrin and y-cyclodextrin were obtained from Sigma Chemicals, Missouri, 
USA and were recrystallised from water before use. 
TRIMEB and DIMES were obtained from Cyclolab, Budapest, Hungary and 
recrystallised from water before use. 
Diflunisal, flufenamic acid, tolfenamic acid, niflumic acid, mefenamic acid, 
indomethacin and sulindac were obtained from Sigma Chemicals, Missouri, USA 
and used as received. 
Racemic ketoprofen and piroxicam were obtained from Lennon Ltd., Port Elizabeth, 
South Africa and used as received. 
Racemic and (S)-ibuprofen were obtained from Boots Chemicals, Nottingham, 
England and used as received. 
Tenoxicam was obtained from Labochim, Milan, Italy and used as received. 
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3. COMPLEX CHARACTERISATION 
A summary of the methods used to prepare complexes, with the results obtained, is 
given in Table 3.1. Similar methods were followed with most crystallisations, 
depending on the host and drug being reacted, and a number of microcrystalline 
powder and single crystal complexes were obtained. More success was had with 
certain drugs than with others, most notably the fenamates and the profens, 
specifically ibuprofen, though some hosts did show an affinity for particular drugs 
where others did not. In some cases, no complexation or crystallisation of complex 
occurred at all, despite repeated efforts to idealise conditions. 
In general, complexes were more readily prepared with 13- and y-cyclodextrin than 
with the methylated derivatives. A number of reasons may account for this, and 
these are discussed in greater detail in Chapter 6. Crystals would usually appear 
within one or two days, depending on the final concentration of the reacting 
solution, though in some cases a powder complex would precipitate almost 
immediately, indicating the formation of an insoluble complex. In other cases, a 
complex formed in solution but would not readily crystallise. 
Initial characterisation, involving hot stage microscopy, thermal analysis and XRD, 
as well as UV spectrophotometry and elemental analysis when used to determine 
stoichiometry, confirmed whether a complex had been formed. Complexes for 
which X-ray intensity data were successfully collected and full or partial crystal 
structure solution was performed, namely those of ibuprofen with j3-cyclodextrin and 
TRIMEB, are detailed separately in Chapters 4 and 5. 
3.1 OXICAMS 
Numerous attempts were made to crystallise complexes with those oxicam 
NSAIDs that were available, using a wide pH range and other variations in vial 
conditions. Complexation with tenoxicam was effected in solution, though the 
cyclodextrin and drug tended to crystallise separately as their own hydrates. This 
would indicate the formation of a soluble complex that would not precipitate above 
the saturation concentrations of j3-cyclodextrin and drug, as suggested by 
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Table 3.1 Summary of prepared complexes 
DRUG CD METHOD RESULT 
A 
1 Separate crystallisation of 
p 1:1 mixturet CD and drug 
stirring at so-70°C 
2 Crystals - monoclinic yellow 
partial neutralisation 
prisms (1: 1 )+t 
(turbidity) 
tenoxicam 1 
(pH range) tt 
y standing (temp rangel 
1
·
2 Crystals - tetragonal yellow 
piroxicam2 prisms ( 11: 1 ) 
B 
1 :1 mixture 
DIMES 
stirring at room temp. 1
·




standing at 50°C 
1
·
3 Powder complex (1 :1) 
2 Crystals - monoclinic 
p A parallelepipeds (1 :1) 
mefenamic acid 1 4 Crystals - fine needles (1 :1) 
tolfenamic acid2 
flufenamic acid3 
niflumic acid4 y 
1
-




4 No complexation or 
TRIMES glass state 
continued .... 
t A molar excess of drug or cyclodextrin was also used. 
tt A pH range of 5-12 was used. A more acidic medium would accelerate hydrolysis of the CD ring. 
The oxicams are zwitterionic and pH may be important in inducing a polarity that may be 
favourable to complexation. 
; Crystallisation temperatures were (i) room temperature, (ii) 35°C, (iii) 55-60°C and 
(iv) 4-6°C. 
tt Denotes the host:guest stoichiometry of the complex. 
* Complexes obtained but not fully characterised. 
Table 3.1 continued 
DRUG CD METHOD RESULT 
13 1 :1 mixture 
1
·
2 Crystals - monoclinic 
stirring at 60-70°C parallelepipeds (1 :1) 
standing at room temp 
ibuprofen 1 and 60°Ct 
y (ibuprofen and 
1
·
2 Crystals - tetragonal prisms (1 :1) 
ketoprofen2* ketoprofen melt) 
8 
DIMES (ibuprofen is taken up 
TRIMES by DIMES without pH 
1
·
2 Crystals - orthorhombic 
adjustment) prisms (1: 1) 
1 Precipitation of powder 
indomethacin 1 13 A complex* 
y 




2 No complexation 
TRIMES 
13 
Crystals - irregular hexagons (1 :1) 
A 
diflunisal y Microcrystalline powder* 
DIMES 
B No complexation 
TRIMES 
t Incubation at a higher temperature allowed crystallisation to occur at a slower rate and 
crystals of a size suitable for single crystal analysis to be obtained. Bringing the guest into solution 
without pH adjustment was considered desirable as ionised molecules are less readily taken up 
into cyclodextrin cavities than unionised molecules. 
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Senel et af who show that an increase in cyclodextrin concentration will increase 
the amount of tenoxicam taken into solution, expressing an AL-type solubility curve, 
as described originally by Higuchi and Connors3. 
A UV profile obtained for tenoxicam with varying concentrations of f3-cyclodextrin is 
shown in Fig. 3.1. A decrease in the absorbance maximum at 373nm with 
increased cyclodextrin concentration is an indication that the absorbing 
chromophore is being shielded by the cyclodextrin, and thus that an interaction is 
occurring in solution, even though no solid-state complex may result. 
Fig.3.1 UV absorption spectrum for tenoxicam. The x axis gives wavelength in 
nm and they axis gives absorbance values. The absorption maximum at 
373nm decreases with increased cyclodextrin concentration. 
. . 
Thermal analysis confirmed the presence of two species in the reaction vial 
(Fig.3.2). The fusion point of tenoxicam is at 230°C, and a characteristic exotherm 
is seen at that temperature (peak 2), indicating that the drug is not included in the 
cavity but is rather present in its free or hydrated form. 
2 
3 
Ref. Chapter 1 /ER' 9b 
Ref. Chapter 1 /JH 31 











30 110 190 
Temperature ( °C ) 
270 
Mass of sample= 2.534mg. Onset of peak 1 = 105.4°C, of peak 2 =227.2°C. 
3.1.1 Piroxicam with p-cyclodextrin 
350 
A crystalline complex of p-cyclodextrin with piroxicam was obtained from a solution 
with pH 7, after prolonged standing at room temperature. The crystals obtained 
were monoclinic flat prisms with a pale yellow hue, ranging in length from 0.1 to 
1.5mm, with a thickness of 0.1 to 0.6mm. 
Hot stage microscopy and thermal analysis characterised the behaviour of the 
complex under a temperature regimen in comparison with ~-cyclodextrin, and a 
photographic record is given in Fig. 3.4a and b, showing opacification on loss of 
water molecules and decompostion at higher temperatures. Results obtained for 
DSC and TGA (Fig. 3.3a and b) show a mass loss from 40-130°C, indicated by a 
broad two-stage endotherm in DSC and gradual opacification of the crystal under 
the microscope. This mass loss is attributed to waters of crystallisation being lost 
by diffusion through the crystal lattice. A mass loss of 23.8% was observed, which 
is equal to 26 waters of crystallisation per cyclodextrin-guest unit, based on 
microanalysis results that indicated a 1: 1 stoichiometry of host and guest. 
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In Fig. 3.3b, a DSC profile for the complex is given. Water loss is indicated by the 
two-stage endothermic peak at 60-130°C. Suppression of the melting endotherm of 
piroxicam at 198-200°C (Fig. 3.3c) indicates the formation of a complex, and the 
onset of degradation of the complex occurs from approximately 240-250°C. These 
results are visualised in photographs in Fig. 3.4, showing the effect of temperature 
on the gross morphology and colouration of the crystals. Comparison is given with 
p-cyclodextrin hydrate, showing differences in crystal habit and in thermal 
behaviour. Whereas both crystals begin to splinter and opacity soon after removal 
from mother liquor, due to water loss as shown in TGA, the behaviour at higher 
temperatures differs. The native j3-cyclodextrin crystal undergoes a characterisitc 
phase change at 225°C and thereafter begins to degrade. The complex with 















Thermal analysis for j3-cyclodextrin - piroxicam complex. 
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CHNS microanalysis indicated the formation of a 1:1 complex in the crystal, based 
on the presence of sulphur. The calculated sulphur value was 2.2%, with the 
experimentally obtained amount being 2.3%t. 
t Microanalysis results, with calculated values for a 1: 1 complex in parentheses, are C: 45.94% 
(46.67%), H: 5.54% (5.66%), N: 3.32% (2.87%) and S: 2.36% (2.24%) 
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Fig. 3.4 Crystal morphology and hot stage microscopy for 
p-cyclodextrin hydrate and complex with piroxicam. 
a . Hot stage microscopy for p-cyclodextrin hydrate. Magnification x33 . 
(i) 30°c (ii) 1s0c (iii) 130°c 
(iv) 225°C (v) 310°C (vi) 350°C 
L 
b. Hot stage microscopy for p-cyclodextrin - piroxicam complex. Magnification x33. 
(iii) 150°C 
(iv) 240°C (v) 310°C (vi) 350°C 
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Unit cell data were obtained for a single crystal of p-cyclodextrin - piroxicam 
complex, and are given in Table 3.2. The complex crystallises in the monoclinic 
C-centred space group C2, based on the observation of Laue 2/m symmetry and 
systematic absences hkl: h+k=2n+1 ; hOI: (h=2n+1) ; OkO: (k=2n+1) in oscillation 
and Weissenberg photographs. The cell dimensions obtained are unique for 
p-cyclodextrin in this space group and have not been reported previously. The unit 
cell volume and Z value calculated from these data imply the presence of one 
cyclodextrin and one piroxicam molecule per asymmetric unit. Though a full 
intensity data collection at room temperature was successfully carried out, the 
applications of direct methods techniques in attempts to solve the molecular 
structure did not yield the positions of atoms of either the host or guest. The 
programs SHELX861 and S1R922 were both employed, and attempts were primarily 
made to locate the position of the sulphur atom of piroxicam, but these were 
unsuccessful. The Patterson strategy in SHELX86 was also attempted, though an 
acceptable model for the cyclodextrin and piroxicam molecule was not obtained. 
Table 3.2 Unit cell data for p-cyclodextrin - piroxicam complex 
Crystal system monoclinic 
Space group C2 
a (A) 27.2 
b (A) 12.4 
C (A) 24.8 
~ (0) 104.1 
Vol (A") 8110 
z 4 
3.1.2 Oxicams with y-cyclodextrin 
The complexation of y-cyclodextrin with oxicams was more successful, though the 
crystals obtained were small and yields were low. Only in the case of the complex 
with piroxicam was it possible to obtain enough sample for characterisation. In the 
complexes formed with tenoxicam and piroxicam the crystals obtained were 
tetragonal prisms, with a yellow colour visually related to the intensity of colour of 
the drug. The size was less than 0.1 mm in all dimensions, even with very slow 
crystallisation. The crystals were stable, and showed no signs of cracking when 
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exposed to air. The final volume of mother liquor from which crystals were obtained 
was low, related to the solubility of the host, and it was noted that a layer of 
amorphous y-cyclodextrin formed as a coat around the crystal on drying, possibly 
sealing it against water loss. 
Thermal analysis and hot stage microscopy confirmed the presence of water in the 
crystal. The thermal analysis result for y-cyclodextrin - piroxicam complex is given in 
Fig. 3.5, with the characteristic TGA profile of y-cyclodextrin hydrate given for 
comparison. From the TGA result, it was possible to obtain the number of waters of 
crystallisation present in the complex. Compared to a value of 8.3 waters for 
y-cyclodextrin hydrate, the complex was calculated to contain 19.2 waters of 
crystallisation per cyclodextrin unit based on microanalysis results that indicated the 
formation of a possible 1: 1 solid-state complex between y-cyclodextrin and 
piroxicam, though the values obtained could also indicate the formation of a 3:2 
complext. Decomposition of the complex commenced at a lower temperature than 













Thermal analysis for y-cyclodextrin - piroxicam complex. 
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t Microanalysis results for y-cyclodextrin - piroxicam complex, with calculated values for a 1: 1 and 
3:2 complex in parentheses, are C: 45.84% (46.46% and 45.89%), H: 5.93% (5.72% and 5.84%), 
N: 1,98% (2,58% and 1.84%) and S: 1,84% (1,96% and 1.41%). 
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3.2 FENAMATES 
3.2.1 Fenamates with f3-cyclodextrin 
A number of complexes were successfully formed with the fenamates, all as 
microcrystalline powders or small crystals, with sizeable crystals being obtained with 
tolfenamic acid. Equimolar amounts of host and guest were used in each case, 
with ionisation being necessary to bring the fenamate into solution (Table 3.1). 
Thermal analysis showed conclusively that complexation had occurred, through 
suppression of the melting endotherms for each guest under examination. An 
estimate of the crystal water was obtained with TGA, and a comparison of results is 
given in Table 3.3. Thermal analysis results are shown in Fig. 3.6 for the four 
fenamate NSAIDs that were part of this investigation. All show similar TGA and 
DSC profiles, and onset of decomposition occurs from approximately the same 
tern peratu re. 
Where it was possible to obtain good yields of powder complexes, X-ray powder 
diffraction (XRD) was performed to further establish that a complex had been 
formed. The XRD traces for the complexes with mefenamic acid and flufenamic 
acid are shown in Fig.3.7, together with XRD traces for 1:1 physical mixtures of 
cyclodextrin and guest prepared as outlined in section 2.6, based on the 
stoichiometry of each complex as determined using microanalysis. A comparison of 
the two traces shows that intensity peaks characteristic of f3-cyclodextrin and the 
guest have been suppressed and that the complex has a crystal structure that 
differs from that of f3-cyclodextrin alone. 
Table 3.3 TGA for fenamate complexes with f3-cyclodextrin 
f3-cyclodextrin TG mass loss No. of waters 
complex (%) presentt 
mefenamic acid 13.1 11.5 
tolfenamic acid 15.4 14.2 
flufenamic acid 13.8 12.8 
niflumic acid 14.4 13.2 
t The number of water molecules per cyclodextnn molecule, based on host:guest 
stoichiometry calculated from microanalysis (Table 3.4). 
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Fig. 3.6 Thermal analysis for p-cyclodextrin complexes with fenamate 
NSAIDs 
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Fig. 3.6 continued 
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Table 3.4 Microanalysis results for 1 :1 p-cyclodextrin-fenamate complexest 
C H N 
Cale. Exp. Cale. Exp. Cale. Exp. 
mefenamic acid 49.74 47.86 6.29 6.15 1.02 0.61 
tolfenamic acid 48.14 47.54 5.87 5.79 1.01 0.66 
niflumic acid 46.61 45.24 3.60 3.19 1.98 1.24 
flufenamic acid 47.49 46.68 5.65 5.78 0.98 0.6 
t Agreement between the observed and calculated values for each complex is not good and a 
number of factors may account for this, most notably the degree of hydration of each sample. This 
is discussed in Section 3.5. 
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Fig. 3. 7 XRD for p-cyclodextrin complexes with fenamate NSAIDs. 
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Crystals of a suitable size for X-ray photography were obtained for the complex with 
tolfenamic acid. These crystallised as monoclinic parallelepipeds, with dimensions 
ranging from 0.1 to 0.5mm. They were labile to air and were required to be fully 
immersed in mother liquor in Lindemann capillaries for X-ray photography. Unit cell 
and space group data were obtained and are listed below in Table 3.5. The 
complex crystallises in the space group P21, based on the observation of Laue 2/m 
symmetry and the systematic absences hkl: none ; OkO: k=2n+1 in oscillation and 
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Weissenberg photographs. The cell dimensions that were calculated for the 
complex are unique and have not been reported for other complexes with 
cyclodextrins. A screw axis parallel to the b axis implies the presence of three 
cyclodextrin molecules in the asymmetric unit though the arrangement of these 
units relative to each other cannot be ascertained without full structural analysis. 
Table 3.5 Unit cell data for p-cyclodextrin - tolfenamic acid complex 
Crystal system monoclinic 
Space group P21 
a (A) 15.46 
b (A) 64.24 
C (A) 14.65 
p (0) 129 
V(A, 11329 
z 6 
The gross morphology of the p-cyclodextrin - tolfenamic acid is shown in Fig. 3.8a, 
and the behaviour of the complex with elevation of temperature is given in Fig. 3.8b. 
The crystals undergo similar visual changes to those observed with the 
p-cyclodextrin - piroxicam complex, with initial opacification due to loss of crystal 
water molecules, and then a discolouring and finally blackening of the complex that 
accompanies decomposition. The decomposed crystal does not melt until 
approximately 370°C. Crystals of the p-cyclodextrin - niflumic acid complex are 
shown in Fig 3.8d(ii). These crystals were too small and fragile for X-ray analysis. 
3.3 PROFENS 
The most successful solid state complexations were achieved with the profens, 
specifically ibuprofen. The complexes of ibuprofen with p-cyclodextrin and TRIMEB 
are detailed in chapters 4 and 5. Unit cell data for those with y-cyclodextrin and 
DIMEB are given in Table 3.6 below. 
For the complex with y-cyclodextrin, the observation of Laue 4/mmm symmetry, 
combined with systematic absences hkl: none ; hOO: h = 2n+ 1, and the chiral nature 
of cyclodextrin, identified the space group as P4212. The space group for the 
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Fig. 3.8 Crystal morphology and hot stage microscopy for cyclodextrin 
complexes. 
a. p-cyclodextrin - tolfenamic acid complex. (i) Crystal habit under polarised light, 
viewed parallel to the unique axis (clear and green crystals) . Comparison is given to 
p-cyclodextrin (purple and yellow crystals). Magnification x45. 
b. Behaviour of p-cyclodextrin - tolfenamic acid complex with temperature. 
Magnification x33. 




y-cyclodextrin ibuprofen complex. Crystals immersed in mother liquor. 
Magnification x45 . 
(i) p-cyclodextrin - diflunisal complex and (ii) p-cyclodextrin - niflumic acid complex. 
Crystals immersed in mother liquor as viewed under polarised light. 
Magnification x45. 
(ii) 
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DIMES-ibuprofen complex was identified, based on observation of Laue mmm 
symmetry and the systematic absences hOO: h=2n+1 ; OkO: k=2n+1 ; 00/: /=2n+1, as 
P212121. 
Table 3.6 Unit cell data for ibuprofen complexes with y-cyclodextrin 
and DIMES 
y-cyclodextrin DIMES 
Crystal system tetragonal orthorhombic 
Space group P4212 P212121 
a (A) 23.7 10.1 
b (A) 23.7 15.3 
C (A) 45.9 53.6 
V(A; 25780 8280 
z 12 4 
As outlined in section 1.5.2, the tetragonal arrangement of y-cyclodextrin has been 
observed in all complexes reported to date, though the cell dimensions calculated 
for the complex with ibuprofen are unique. The tetragonal arrangement implies that 
all eight residues of the cyclodextrin are present in an identical conformation and 
the molecule is positioned on a four-fold axis parallel to c. The large cell volume 
and a Z value of 12 imply that six cyclodextrin molecules are stacked along the c 
axis, which is double the length of that recorded for other y-cyclodextrin complexes. 
The asymmetric unit would contain six by one-eighth y-cyclodextrin molecules, 
unlike three fractions as seen with other y-cyclodextrin complexes characterised to 
date i.e. with n-propanol and the crown ether 12-crown-43 .4. The morphology of the 
crystals of the y-cyclodextrin - ibuprofen complex is shown in Fig. 3.8c. 
The cell data obtained for the complex with DIMES are also unique. A number of 
crystal structures for DIMEB complexes have been reported to date, all crystallising 
in the orthorhombic space group P21212, 5·6 ·7·8 ·9 . Thermal analysis results for the 
complex with ibuprofen are shown in Fig. 3.9. Initial mass loss in TGA, 
corresponding to loss of crystal water, gives a total of one water molecule per 
DIMEB molecule. A second mass loss event of 4. 75% from approximately 
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135-250°C is too small to reflect loss of guest, given a 1: 1 stoichiometry in the 
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Microanalysis results for the complexes of ibuprofen with y-cyclodextrin and DIMES 
indicated the possible formation of 1 :1 complexes in the solid state. For the DIMES 
complex, the obtained values for C and H were 54.36% and 7.67% respectively, as 
compared to calculated values of 53.87% and 7. 79% respectively. The complex 
with y-cyclodextrin gave values for C and H of 46.89% and 5.89% respectively, as 
compared to 48.70% and 6.52%. This latter result may not be conclusive of the 
formation of a 1: 1 complex, as observed in the complex with piroxicam (Section 
3.1.2), and this may be due to the alignment of the y-cyclodextrin in channels and 
the possibility of the guest being disordered over a number of positions within these 
cavities (Section 1.4.7.2). 
3.4 OTHER COMPLEXES 
3.4.1 Diflunisal with P-cyclodextrin 
A complex of p-cyclodextrin with diflunisal was prepared as outlined in Table 3.1. 
Irregular hexagon-shaped crystals were obtained after overnight incubation at room 
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temperature, with a size range of 0.2 to 1 mm and a thickness of 0.1 to 0.2mm. 
Most crystals appeared as thin plates fused together parallel to the thin axis and 
obtaining single crystals from the batches proved difficult. The morphology is 
shown in a photograph in Fig.3.8d(i). 
Thermal analysis confirmed that a complex had been formed (Fig. 3.10). The 
crystals were unstable in air, due to loss of crystal water, and this is reflected by 
mass loss in TGA (Fig. 3.10a). A total mass loss of 14.4% was recorded from 
30-190°C, corresponding to 13 waters of crystallisation per molecule of 
p-cyclodextrin, based on 1: 1 stoichiometry obtained from microanalysis. 
These results were confirmed by XRD, shown in Fig. 3.11, with a comparison made 
between the profile for p-cyclodextrin and that of the complex, showing suppression 
of the intensity peaks characteristic of p-cyclodextrin by complexation and the 















Thermal analysis for J3-cyclodextrin - diflunisal complex. 




Temperature ( °C) 
Sample mass for b = 13.411 mg. Onset of peak 1 = 92.3°C. 
300 
Microanalysis results for the complex indicated the possible formation of a 1: 1 
complex. The obtained values of C and H were 40.29% and 5.58% respectively. 
This compares to calculated values of 39. 7 4% and 5.63% for a 1: 1 complex. This is 
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consistent with results obtained for complexation of diflunisal by J3-cyclodextrin in 
solution10 
Unit cell data and space group information were obtained for the complex from 
inspection of oscillation, Weissenberg and Buerger precession photography, and 
are tabulated in Table 3.7. The complex crystallises in the orthorhombic space 
group P212121, as identified from Laue mmm symmetry and systematic absences as 
outlined for the DIMES-ibuprofen complex, and the calculated unit cell volume, 





XRD for J3-cyclodextrin - diflunisal complex. 
Trace for (a) f3-cyclodextrin and (b) for complex. 
a 
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Unit cell data for J3-cyclodextrin - diflunisal complex 
Crystal system orthorhombic 
Space group P21212, 
a (A) 15.4 
b (A) 29.0 
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3.5 DISCUSSION 
A number of complexes were successfully prepared using the methods outlined in 
Sections 2.1 and 2.2. It was not possible to predict whether a host was suitable for 
a particular guest compound, despite the application of varying changes to the 
reaction conditions that might enhance complex formation. 
The main aim of these experiments was to produce solid state complexes, 
preferably suitably-sized single crystals for X-ray structure analysis and a number of 
complexes were obtained during the course of experimental work that were not fully 
characterised as detailed characterisations have been reported in a number of 
instances e.g. p-cyclodextrin with indomethacin and with ketoprofen11 •12•13•14. In 
certain instances, insufficient sample could be obtained for thorough analysis such 
as the y-cyclodextrin complexes with the fenamates. 
As has been mentioned in Section 1, the precipitation of a solid-state complex is 
dependent in large part on the solubility of the complex in comparison to the 
saturation concentrations of host and guest. Most of the NSAIDs used are 
practically insoluble in water, and continual stirring of a hot cyclodextrin solution 
over a long period was often not sufficient to bring the guest into solution. 
Adjustment of pH was used in the majority of cases i.e. a more basic environment to 
ionise the acidic NSAID molecule. Ionisation of a guest can however impede 
complexation, due in part to an increase in the possibility of interactions between 
the polar moiety on the guest and water molecules, thus affecting the stability 
constant as well as the solubility of the complex in solution. 
The stability constant for complexation in solution, as well as the phase solubility 
profile for a particular cyclodextrin and drug interaction are important in determining 
the rate of complexation and dissociation of the complex in solution as well as 
whether the complex that has formed will crystallise. Values for these constants 
have been noted from previous studies 14 . 
The complexation of piroxicam in solution with p-cyclodextrin possesses a stability 
constant value (Kc) of 90M·1, while p-cyclodextrin - ibuprofen has a Kc value 14 of 
1030M"1. Difficulty was observed in achieving the effective uptake of piroxicam into 
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solutions of p-cyclodextrin. Crystals of the piroxicam complex were very slow to 
appear (over a month) while those of the ibuprofen complex appeared relatively 
soon after reaction (24-36 hours) as discussed in Section 4. The complex with 
piroxicam follows a A-type phase solubility profile, forming a soluble complex, while 
the complex with ibuprofen follows a B-type solubility profile and would thus 
precipitate at an established solubility limit (Section 1.4.4). Crystals of the complex 
of y-cyclodextrin with piroxicam have a slightly higher value for K: and more of the 
drug was brought into solution during reaction time. Crystals were obtained more 
easily than crystals of the p-cyclodextrin complex 14 . 
The size of the guest may also inhibit or promote complexation. Only P- and 
y-cyclodextrin, and derivatives of p-cyclodextrin, were used, due to the size of the 
NSAIDs under investigation. The cavity of a-cyclodextrin would be too small and 
complexes were not prepared using this cyclodextrin, and stability constants for 
complexes with NSAIDs are generally lower than for p-cyclodextrin. Complexation 
appeared to occur more readily with y-cyclodextrin, though yields were often too low 
and crystals too small for complete characterisation to be possible. This may be 
due to the much greater aqueous solubility of y-cyclodextrin and the complexes that 
were formed. Complexes were not isolated for any of the cyclodextrins with a large 
guest such as sulindac, but success was had with smaller molecules such as 
ibuprofen and the fenamates. 
Another observation was the relative difficulty in forming complexes with the 
methylated cyclodextrins. Complexes were prepared with all the fenamates under 
investigation and p-cyclodextrin though none could be isolated with DIMES and 
TRIMEB. This may be due to the incubation conditions for crystallisation. These 
derivatives crystallise within a narrow temperature range and the environment may 
have been imperfect for crystallisation to occur. Furthermore, the cavities of DIMEB 
and TRIMEB are deeper than that of p-cyclodextrin (11A and SA respectively), and 
the cavities are more distorted in the uncomplexed state, which may impede the 
insertion of the guest. 
Complex stoichiometries have been determined where possible using 
microanalysis. The results were fairly conclusive, though there is a margin for error 
based on the relatively large molecular mass of the host compounds as compared 
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to the guests. The hygroscopic properties of the complexes analysed also posed 
difficulties when attempting to obtain accurate results. Samples were used as 
extracted from crystallisation vials and TGA performed to establish the water 
content as a percentage of the sample mass. Stoichiometry was calculated from 
microanalysis results using the percentage of water in the sample and values for the 
content of C, H, N and S then calculated for each sample. In other cases the 
sample was first dehydrated using TGA before microanalysis was performed, with a 
second TGA result being used to measure any uptake of atmospheric water during 
the course of analysis. 
Using these results it was possible to calculate the number of waters of 
crystallisation for each complex based on mass loss as measured using TGA. All 
complexes except that of TRIMEB with ibuprofen contain water molecules in the 
interstices between cyclodextrins in the crystal lattice and interact through hydrogen 
bonding with the OH groups on the primary and secondary rims of the cyclodextrin 
molecule. The relatively hydrophobic environment of the methylated cyclodextrin 
crystal structures generally excludes water molecules. 
Unit cell data were obtained for a number of complexes. The cell dimensions 
recorded are unique for the complexes of p-cyclodextrin with piroxicam, tolfenamic 
acid and diflunisal, and for y-cyclodextrin and DIMES with ibuprofen. For these 
complexes, however, it was not possible to collect X-ray intensity data and attempt 
any solution of the crystal structure despite repeated efforts, due to a number of 
factors, such as inferior crystal quality and the sometimes large unit cell volumes 
that were calculated from X-ray photography. These dimensions do however 
suggest a possible extension to the number of different modes of crystal packing of 
cyclodextrin complexes in the solid state. 
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4. COMPLEX OF J3-CYCL0DEXTRIN WITH IBUPROFEN 
4.1 PREPARATION OF COMPLEX 
Crystalline complexes of p-cyclodextrin with racemic and (S)-ibuprofen were 
prepared using equimolar ratios in aqueous solution. Ibuprofen is insoluble in water 
but has a relatively low melting point of 75-77°C (50-54°C for the (R)- and 
(S)-isomers) and was more easily brought into solution than other NSAIDs by 
raising the temperature of the reacting solution to 75-80°C 1. The resulting solution 
was incubated at 50-65°C, with the incubation temperature being varied in an effort 
to control the standing time for crystallisation and produce crystals of adequate size 
for X-ray analysis. A temperature of 50-55°C was found to be optimal, with crystals 
ranging in size from 0.2 to 1 mm being obtained. Allowing the reaction solution to 
cool or evaporate more rapidly produced a microcrystalline powder complex that 
was used in X-ray powder diffraction. 
4.2 THERMAL ANALYSIS 
TGA and DSC profiles obtained for the complexes with racemic and (S)-ibuprofen 
are shown in Fig. 4.1. Crystals removed from the mother liquor exhibited rapid 
cracking of the crystal surface on the hot stage microscope as a result of the loss of 
loosely bound interstitial water, shown by a steep mass loss in the initial stages of 
TGA as compared to that seen with p-cyclodextrin. 
The overall percentage mass loss with temperature was 13.5% from 30-120°C. 
Microanalysis results for the complex indicated the presence of 48. 95% C in a 
dehydrated sample as compared to a calculated value of 49.21% for a 1:1 complex. 
The mass loss in TGA thus corresponded to 12 waters of crystallisation per 
cyclodextrin molecule. This is represented in the DSC trace as a broad two-stage 
endothermic peak over a temperature range of 60-120°C, suggesting the loss of 
more loosely bound water molecules in the first stage of dehydration. Suppression 
of the melting endotherms for racemic and (S)-ibuprofen [Fig. 4.1 (i)-a and -b 
respectively] gives proof of the formation of a complex. The onset of degradation of 
the complex is indicated at approximately 280°C. 
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Figure 4.1 Thermal analysis for p-cyclodextrin - ibuprofen complex. 
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The morphology of the crystal and the behaviour with temperature are shown in 
photographs obtained from the hot stage microscope in Fig. 4.2 below. The 
crystallographic b axis runs parallel to the long diagonal (Fig. 4.2a). The crystal 
begins to opacity almost immediately after removal from mother liquor, and this is 
related to the steep initial mass loss seen on TGA (Fig. 4.1 (ii)-b). The crystal begins 
to decompose at 280°C when the crystal begins to brown, and final melting and 
decomposition occur from 340°C onwards. 
4.3 X-RAY POWDER DIFFRACTION 
Powder samples of complexes containing p-cyclodextrin with either racemic or (S)-
ibuprofen were prepared as outlined above. XRD profiles were obtained and 
compared with those for native p-cyclodextrin in an effort to further demonstrate the 
formation of a complex and the suppression of peaks characteristic of ibuprofen 
and p-cyclodextrin, as seen in the trace obtained for the 1: 1 physical mixture of the 
two components (Fig. 4.3a and b). 
The physical mixture of host and guest was composed according to results obtained 
for microanalysis, which indicated the formation of a 1: 1 complex. The experimental 
values for C and H composition were 48.84 and 5.94% respectively, which 
compares reasonably with calculated values of 49.24% and 6.56%. This result is 
partially confirmed by crystal structure analysis. 
A comparison with the XRD traces for the complex with (S)-ibuprofen shows a 
similarity in profiles that indicates the formation of isomorphous complexes with the 
racemate and pure isomer. The crystals exhibited identical morphology, and 
thermal behaviour under the hot stage microscope and with TGA and DSC was 
similar. 
4.4 X-RAY ANALYSIS 
4.4.1 Data collection and refinement 
A crystal of suitable size was extracted from a batch of complex crystals prepared 
with p-cyclodextrin and racemic ibuprofen. The crystals formed were colourless 
prismatic parallelepipeds. A polarising microscope and oscillation photography 
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Fig. 4.2 Complex morphology and hot stage microscopy. 
a. Crystals of p-cyclodextrin - (RS)-ibuprofen complex immersed in mother liquor as seen 
under polarised light. The unique axis is parallel to the long diagonal. 
Magnification x45. 
b. Hot stage microscopy for complex. The crystal is photographed at 30°C, 50°C, 90°C, 
280°C and 340°C. Opacification begins almost immediately after removal from mother 
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Fig. 4 3 XRD for J3-cyclodextrin - ibuprofen complex 
(i) XRD for j3-cyclodextrin - (S)-ibuprofen. (a) 1 :1 physical mixture and (b) complex. 
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were used to determine and align the axis of symmetry. The crystals are highly 
unstable to air and were sealed in Lindemann capillaries, fully immersed in mother 
liquor. Oscillation and Weissenberg photographs showed Laue 2/m symmetry, and 
the systematic absences hkl: h+k=2n+1 ; hOI: (h=2n+1) ; OkO: (k=2n+1 ), together 
with the absence of possible mirror planes or centres of inversion, due to the chiral 
nature of the cyclodextrins, confirmed the space group to be monoclinic centred C2. 
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The cell dimensions obtained were a=19.41A, b=24.41A and c=15.92A (,8=108.9°). 
This is isomorphous with a number of other p-cyclodextrin complexes with small 
molecular weight compounds such as potassium heptaiodide2, benzophenone3, 
biphenyl3, 2,5-diiodobenzoic acid4 and 3,3-dimethylbutylamine5. 
A crystal of 0.5x0.4x0.4mm was extracted from a crystallisation vial containing 
complex prepared with racemic ibuprofen, dried and rapidly sealed in cyanoacrylate 
before cracking of the crystal surface and subsequent loss of crystal integrity was 
allowed to occur. The sealed crystal was then attached with glue to the end of a 
glass fibre, sealed in a Lindemann capillary and mounted on a goniometer head. 
The choice of cyanoacrylate seal above immersion in mother liquor in a capillary 
tube was determined by the desire to collect intensity data at temperatures below 
0°C, as well as the possibility of diffraction from the mother liquor which could 
interfere with that from the crystal. 
The crystal was mounted on an Enraf-Nonius CAD4 diffractometer and intensity 
data were collected at 248K, as detailed in Section 2.7. Accurate cell dimensions 
were obtained by least-squares analysis of the setting angles of 24 reflections lying 
in the range 16°<Ek17°. The w-scan technique was used and a pre-scan 
acceptance parameter of zero was chosen to force the final intensity scans up to a 
maximum of 1 OOs, to ensure accurate measurement of weak reflections. Data were 
collected to (sin00 .. )max=0.595A-1. Three standard reflections were monitored hourly 
in the range of 15°<0<16° (13 5 1;8 12 4;7 7 7) and showed a loss of intensity of 
0.8% over the period of the data collection. Orientation control was performed 
every 200 reflections. Data were corrected for Lorentz-polarisation effects. Data 
collection details are outlined in Table 4.1. 
4.4.2 Structure solution 
Coordinates for the non-hydrogen atoms of the cyclodextrin host in the 
isomorphous 3,3-dimethylbutylamine complex were used for structure solution5 . 
Refinement of these atoms with full-matrix least-squares techniques [minimisation 
of LW( IF/ 1-1 kF/ I )2] was performed using SHELX936 , with subsequent 
successive difference Fourier syntheses being applied to reveal the positions of the 
atoms of the guest molecule and the waters of crystallisation present in the lattice. 
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All atoms of the cyclodextrin molecule were located with a site occupancy factor of 
1.000, except 0(6G4) which occupies two positions with site occupancies of 0.65 
and 0.35, and 0(6G6), which displayed high thermal motion though it occupied only 
one site. All atoms were assigned anisotropic temperature factors after a number of 
cycles of refinement. Hydrogen atoms attached to the carbon atoms on the 
cyclodextrin were inserted at idealised positions (C-H=0.98A for methine groups 
and 0.97A for methylene groups) and assigned a common variable isotropic 
temperature factor, excepting for C(6G4) where the hydroxyl group is disordered 
over two sites. A total of 12 water molecules of crystallisation were located and 
refined, some with anisotropic temperature factors. The guest could not be located 
beyond a diffuse electron density cloud located within the cyclodextrin cavity and 
could not be modelled, due to abnormal distances and angles between electron 
density peaks. Details of the structure refinement are given in Table 4.1 below and 
supplementary data such as atomic coordinates, temperature factors, bond lengths 
and angles, and torsion angles are presented in Appendix A. A listing of observed 
and calculated structure factors for the complex, given as F o 2 and F c2, together with 
standard deviations for the observed structure factors, is given in Appendix C on 
disk, in ASCII format as filenames BET1BUP1 .ASC and BETIBUP2.ASC. 
4.4.3 Geometry and hydrogen bonding 
The structure of the cyclodextrin molecule and the numbering scheme adopted for 
the complex, with the conformation and numbering scheme for each glucose 
moiety, are given in Fig. 4.4. All the glucose subunits are present in the 
4C1-conformation. Except for unit G4, all C(6Gn)-0(6Gn) bonds lie gauche to bonds 
C(4Gn)-C(5Gn) and 0(5Gn)-C(5Gn), and are directed away from the cavity. The 0(6) 
atom of G4 occupies two positions, a minor position [0(64A)] that points away from 
the cavity and a major position [0(6G4)] that points inward. The C(6)-0(6) bond is 
gauche to 0(5)-C(S) and anti to C(4)-C(5). 
The macrocycle shows a seven-fold symmetry based on 0(4n)···0(4n+1) distances 
and 0(4n_1)···0(4n)···0(4n+1) angles. These are given in Table 4.2a below, together 
with values for the deviation of each 0(4) atom from the heptagon formed by all 
0(4) atoms. The similarity in 0(4) lengths and angles, and the relatively small 
deviations indicate that a highly rigid conformation is adopted by the p-cyclodextrin 
molecule. 
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Table 4.1: Data collection and refinement details for 
1: 1 p-cyclodextrin-(RS)-ibuprofen complex 
Molecular formula C42H7003s.C13H1s02.12H20 
Mr/ gmor1 1557 
Crystal system Monoclinic 
Space group C2 
z 4 
a (A) 19.41(1) 
b (A) 24.41 (2) 
C (A) 15.92(1) 
p (0) 108.89(6) 
V (A3) 7133(9) 
De (gcm-3/ 1.242 
Crystal dimensions (mm) 0.5x0.4x0.4 
T/K 248 
Range scanned 8 (0) 1 s; 8 s; 25 
Index range h:0,23; k:0,28; 1:-18, 17 
Scan width 0.8 + 0.35 tan e 
Aperture width (mm) 1.12 + 1.05 tan e 
No. reflections collected 6657 
No. unique reflections 6451 
No. reflections with I > 2cr(I) 4853 
No. L.S. parameters 768 
R1 (I > 2cr(I)) 0.111 
w [cr2(Fo)2+(0.2770P)2r1 where 
P = (F/+2F/)!3 
wR2 (F2) 0.275 
s 1.073 
Shift.e.s.d. max., ave. 1.342, 0.087 
(Lip)max final (e A-3> 1.31 
(Lip)min final (e A-3) -0.27 
t An experimental value for the crystal density was not obtained as a suitable solvent mixture could 
not be found. 
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Fig. 4.4 Structure of j3-cyclodextrin - ibuprofen complex. 
a. Macrocyclic structure and numbering system of glucose residues and water oxygen 
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b. Numbering scheme and configuration for glucose moiety. C atoms are represented 
by numbers only. 
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a. Conformation of 0(4) heptagon 
Glycosidic 0(4n)···0(4n+1) 0(4n-1)···0(4n)···O( 4n+1) Deviation° 
oxygen angle distance angle (A) 
(o)a (A) (0) 
118.3 4.37 130.Su -0.009(4) 
119.3 4.23 124.6 0.019(4) 
118.5 4.53 128.4 -0.024(4) 
117.4 4.34 132.2 0.012(4) 
120.0 4.34 125.9 0.007(4) 
116.5 4.34 127.1 -0.015(4) 
119.1 4.46c 130.8e -0.012(4) 
The angle subtended at the (0)4 atom 1.e. the angle between C(48n),0(48n) and C(18n+1). 
For 87, the angle is defined between C(487), 0(487) and C(4G1 ). 
C . 
d 
The deviation of the 0(4) atom from the least squares plane formed by all 0(4) atoms. 
The distance 0(487) .. ·0(4G1 ). 
The angle formed by 0( 487) .. ·O( 4G1 ) .. ·O( 482). 
The angle formed by 0(4G6) .. ·0(4G7) .. ·0(4G1 ). e 
Tilt angles and torsion angle indices for glucose subunits. 
Radius of Tilt angle Torsion angle 
heptagon (A)a (0) indexd 
G1 4.96 12.0° 80.4c 120.6 
G2 5.21 12.0 80.4 121.9 
G3 4.99 7.9 84.7 115.8 
G4 4.86 15.6 76.6 114.4 
GS 5.17 13.2 80.2 111.0 
G6 5.15 10.6 82.0 116.6 
G7 4.93 6.9 86.0 112.7 
a The average value of the distance of each 04 atom from the centre of gravity of 
all 0(4) atoms= 5.04A. 
b The dihedral angle between the 0(4) plane and the optimum plane 
through 0(4n-1), C(1n), C(4n) and 0(4n) 
c The dihedral angle between the 0(4) plane and the optimum plane 
through C(2n), C(3n), C(5n) and 0(5n). 
d As defined in section 1.5.2. 
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The shape of the macrocycle is defined by the tilt angles in Table 4.2b. The 
dihedral angles between the plane of the macrocycle and the optimum planes that 
define the relative position of each glucose subunit show that all have a positive tilt 
angle and lean toward the centre of the cavity. This gives the molecule the 
characteristic truncated cone appearance with the 0(2), 0(3) - rim being wider than 
the 0(6) rim. 
A number of intramolecular 0(3Gn) .. ·0(2Gn+1) hydrogen bonds stabilise the 
cyclodextrin, as has been reported with other p-cyclodextrin structures. The 
average hydrogen bonding distance is 2.84(1 )A, and the average of the angles 
C(3Gn)-0(3Gn)" ·0(2Gn+1) and C(2Gn+1)-0(2Gn+1} .. ·0(3Gn) are 116.4° and 118.6° 
respectively, which are within the range required for hydrogen bonding (Table 4.3). 
These hydrogen bonds contribute to the rigidity and highly symmetrical 
conformation of the cyclodextrin. 











a The distance between 0(3Gn) and 0(2Gn+1 ). 
b Angle as defined in the text above. 
c Angle as defined in the text above. 
C(3)-0(3)···0(2') C(2')-0(2')···0(3) 









The p-cyclodextrin molecule crystallises as a dimer in the crystal, as evidenced by 
the formation of hydrogen bonds between 0(3) atoms on adjacent cyclodextrins 
related by a two-fold rotation axis parallel to b. The lengths and angles for these 
bonds are given below in Table 4.4, and the arrangement is shown schematically in 
Figure 4.5. 
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The 0(2Gn)···0(3G8.n) distances average 3.11A, and the C(2Gn)-0(2Gn)···0(3Ga.n) 
angle has an average value of 112.6°, and this could signify the formation of weak 
Table 4.4 
Fig. 4.5 
lntradimer hydrogen bonds for p-cyclodextrin dimer. 
Bonding distance Angle (0 ) 0 
(A)a 
G1 2.83(1) 116.0 
G2 2.85(1) 116.7 
G3 2.72(1) 118.3 
G4 2.82(1) 115.8 
GS 2.72(1) 113.3 
G6 2.85(1) 116.7 
G7 2.82(1) 118.7 
Average 2.80(1) 116.5 
a The distance 0(3Gn)· .. 0(3Ga.n)', related by the symmetry operator -x, y, -z+1. 
b 
The angle C(3Gn)-0(3Gn)···0(3Ga.n)'. 
Arrangement of p-cyclodextrin dimer. The 0(2),0(3) face is 
designated by larger circles. Water molecules and hydrogen atoms are 
shown. View is down (01 OJ, showing generation of the dimer by the two-fold 





I crystallographic two-fold axis 
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Fig. 4.6 Hydrogen bonding between adjacent dimers parallel to c axis. 
Head-to-head cyclodextrin molecules are related by a two-fold axis parallel 
to b along a channel axis parallel to c. The symmetry operation for 0(64A)' 




hydrogen bonds. The angle C(3G8.n)-0(3G8.n)· · ·0(2Gn), however, has an average 
value of 159.7°, and though this is large it cannot be said that no hydrogen bonding 
occurs between these two OH groups in the dimer. No 0(2Gn)·· ·0(2Ga-n) hydrogen 
bonds are found in the complex either, despite some favourable distances. 
The dimers are arranged in C-centred layers and these layers are held together via 
a hydrogen bonding network through water molecules that link dimers within a layer 
and dimers of one layer to those of adjacent layers. The dimers are stacked upon 
each other parallel to the c axis to form channels. Direct hydrogen bonding between 
adjacent 0(6) layers along the channel is found only with the minor position of 
0(6G4), which is bonded to a symmetry-related 0(64A) atom (Fig. 4.6). The length 
of the bond is 2.95(5)A, with an angle C(6G4)-0(64A) .. ·0(64A)' of 105.7°. 
Other interdimer hydrogen bonds are directed towards dimers positioned in the 
same layer. The hydrogen bonding distance 0(2G5) .. ·0(2G7)' is 2.73(1)A. with an 
angle C(2G5)-0(2G5) .. ·0(2G7)' of 111.1 °t. Two hydrogen bonds between the 0(6) 
rims of neighbouring cyclodextrin molecules lying parallel to the xy-plane are bonds 
The symmetry operation is -x+1/2, y-1/2, 1-z. 
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Fig. 4. 7. Channel packing arrangement of complex. 
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extending from (i) 0(6G1 )···0(6G3)" and (ii) 0(6G3)···0(6G7)'"tt . The angle for (ii) 
may be too large but could satisfy the conditions for hydrogen bonding. 
A scheme showing the packing of p-cyclodextrin dimers in channels and the 
C-centering condition is given in Figures 4.7a and 4.7b respectively. Adjacent 
dimers that are projected along the xy-plane are displaced by 3.03A relative to the 
axis of the channel which is almost exactly parallel to c. These dimers form infinite 
planes (Fig.4.8), with the channels and layers being connected to each other by a 
hydrogen bonding network through water molecules. 
Fig. 4.8 Formation of layers by cyclodextrin channels parallel to the 
xy-plane. 
Two networks of water molecules form hydrogen bonds to primary and secondary 
hydroxyl groups (Table 4.5). One water molecule, O(W11 ), does not bond directly 
to a cyclodextrin molecule but is connected to other water molecules. The water 
molecules that interact with the 0(6) rim of the cyclodextrin - O(W1),0(W2), O(W4), 
O(W7), O(W8) and O(W12) - form bridges between adjacent dimers in the same 
layer, while those that interact with the 0(2),0(3) rim - O(W3), O(W5), O(W6), 
O(W9), O(W10) and O(W11) indirectly - form part of an infinite sublayer of water 
molecules that runs between the cyclodextrin channels. There are no water 
molecules positioned inside the cyclodextrin cavity. 
tt (i) Bond length of 2.74(1 )0 and angle C(6G1 )-0(6G1) · 0(6G3)" of 118.9° The symmetry 
operation is -x-1/2, y+1/2, -z. 
(ii) Bond length of 2.89(1 )A and angle C(6G3)-0(6G3) 0(6G7)" of 131. ?°. The symmetry 
operation is x-1/2, y-1/2, z. 
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Table 4.5 Hydrogen bonding distances and angles to water molecules 
Hydrogen Angle (0 ) 0 
bond length 
(A)a 
0(6G1)· .. 0(W4) 2.76(1) C(6G1)-0(6G1 ···O(W4) 131.6 
0(6G2)·· ·O(W1) 2.80(1) C(6G2)-0(6G2) · · ·O(W1) 131.2 
···O(W12) 2.83(1) C(6G2)-0(6G2) · · ·O(W12) 125.1 
0(6G3)···0(W2) 2.76(1) C(6G3)-0(6G3) · · ·O(W2) 105.3 
0(6G4)···0(W4) 2.78(1) C(6G4)-0(6G4)···0(W4) 106.6 
0(64A) · · ·O(W4) 3.04(1) C(6G4)-0(64A)···O(W4) 113.0 
0(6G5)···0(W7) 2.76(1) C(6G5)-0(6G5)···0(W7) 122.2 
0(6G6)· · ·O(W8) 2.79(1) C(6G6)-0(6G6) · · ·O(W8) 125.8 
0(6G7)· · ·O(W2) 2.78(1) C(6G7)-0(6G7)···0(W2) 123.3 
0(2G1)···0(W6) 2.71(1) C(2G1 )-0(2G1 )···O(W6) 110.5 
0(2G2)· .. 0(W10) 2.66(1) C(2G2)-0(2G2) · · ·O(W10) 98.4 
0(3G2)···0(W9) 3.03(1) C(3G2)-0(3G2)···0(W9) 141.5 
0(2G3)·· ·O(W3) 2.68(1) C(2G3)-0(2G3)· · ·O(W3) 101.6 
0(2G4)···0(W5) 2.74(1) C(2G4)-0(2G4)···0(W5) 98.1 
0(3G4)···0(W10) 2.91(1) C(3G4)-0(3G4)···0(W10) 106.9 
0(3G5)···0(W6) 2.82(1) C(3G5)-0(3G5)···0(W6) 118.5 
0(3G6)···0(W5) 2.96(1) C(3G6)-0(3G6) · · ·O(W8) 108.3 
a 
b 
A range of 2.5-3.1A is considered to be acceptable for cyclodextrin hydrogen bonds, due to the 
disorder of water molecules and the inability to locate hydrogen atoms 
Angles within a range of 90-140° are considered as possible hydrogen bonding angles. 
The guest molecule is located inside the cavity, but is greatly disordered and could 
not be visualised beyond a diffuse electron density cloud. A number of electron 
density peaks were located, having values of 0.5-0.7eA·3 , as compared to 1.3eA·3 
and higher for water oxygen molecules, and it was not possible to model a guest 
molecule due to abnormal bond angles and lengths, and the mode of complexation 
could not be established. The positioning of this electron density cloud is shown in 
Fig. 4.9 by the positions of peaks that were identified, indicating the placement of 
the cloud in relation to the p-cyclodextrin dimer. A group of six peaks arranged in a 
rough hexagon could be discerned, though attempts to include these in the model 
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Fig. 4.9 Guest positioning inside f3-cyclodextrin cavity 
a. Stereoview down c axis. Guest molecules are shown as larger circles positioned 
inside the cavity. 
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as a phenyl group were not successful. Subsequent difference electron density 
maps did not elucidate the presence of guest substituent groups. This disorder is 
not uncommon and can be compared to a number of examples of guest disorder in 
the channel arrangement that have been reported for f3-cyclodextrin complexes2•3·5. 
Microanalysis results for a dehydrated sample of the complex revealed a carbon 
content of 48.84% C and 5.94% H. The calculated values for a 1: 1 complex are 
49.24% and 6.56%, and these values correspond reasonably despite a discrepancy 
in values for H due possibly to the presence of water in the sample. This result 
compares with other f3-cyclodextrin complexes with profens, where a 2:2 dimer 
complex is formed in each case7'8 . This disorder is inherent to cyclodextrin 
complexes of this type, and few structures have been reported where the guest is 
SECTION 4 4-18 ==-=-=~...:...:....-'--------------------------
revealed and placed. It is not possible to ascertain whether the disorder is statistical 
or whether the guest molecule is undergoing a high degree of thermal motion or is 
actually migrating though the channels, despite collecting intensity data at reduced 
temperatures and being able to position water molecules with site occupancy 
factors of 1.0. The channels formed by the cyclodextrin molecule are almost exactly 
linear and the guest appears to be positioned near the centre of the cavity as a long 
chain of overlapping peaks generated by symmetry, suggesting a number of 
possible position in gs for the guest and possible interactions with the host. 
4.5 DISCUSSION 
A complex of p-cyclodextrin and racemic ibuprofen has been crystallised and the 
crystal structure has been elucidated. The cyclodextrin molecules crystallise as 
dimers and these pack in infinite head-to-head channels into which the guest 
molecule is inserted. Water molecules fill the interstices between these channels. 
The guest molecule is disordered within the channels and cannot be located from 
examination of electron density maps, and it is not possible to identify which 
enantiomers are included in the complex. A complex hydrogen bonding network 
between cyclodextrin hydroxyl groups and water molecules maintains the structure 
of the complex, and crystallinity is lost on dehydration. A series of intramolecular, 
intradimer and interdimer hydrogen bonds between hydroxyl groups maintain the 
conformation of the p-cyclodextrin molecule. 
All atoms of the cyclodextrin molecule, and all water molecules, were located and 
were not disordered. All atoms have site occupancy factors of 1, except the 0(6) 
group of G4, which occupies two positions with occupancy factors of 0.65 and 0.35. 
This disorder is important as the minor position of 0(6G4) forms a hydrogen bond to 
its symmetry related hydroxyl group on an adjacent dimer in the next layer of the 
channel. This is the only direct hydrogen bond linking the dimers in the channel. 
The relative weakness of this bond, due to the low site occupancy, may explain in 
part the instability of the crystal structure. 
The two-dimensional network of water molecules that maintains the structure is 
constructed in a similar fashion to that proposed by Le Bas and Tsoucaris9, with the 
intramolecular and intradimer network of hydrogen bonds extending into the 
interstices. Their findings show that nine possible hydrogen bonds are formed with 
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water molecules by 0(2) and 0(3) hydroxyl groups ( the secondary network of 
hydrogen bonds), though only eight could be located for this structure. They 
furthermore state that two hydrogen bonds are directed towards dimers located in 
the same layer, though only one of these could be identified for the secondary 
hydroxyl rim. Two hydrogen bonds were located from the 0(6) rim (the primary 
network) to 0(6) groups on neighbouring dimers in the same layer, and one to the 
adjacent layer. These differ from the number identified by Le Bas and Tsoucaris. 
The geometrical parameters that define the conformation of the cyclodextrin ring in 
the complex are comparable to those of other cyclodextrin complexes that 
crystallise in the channel arrangement. In a study of conformational parameters by 
Lipkowitz et at1°, distributions of a number of parameters were plotted, and values 
for tilt angles, distance of 0(4) groups from the centre of the cavity and deviations 
of 0(4) groups from planarity for this complex lie within the ranges observed for 
p-cyclodextrin complexes. 
Due to the disorder of the guest, it was not possible to establish which enantiomer 
was included in the complex. Complexes with both racemic and pure (S)-ibuprofen 
were prepared though only the complex with the racemate was characterised. XRD 
showed that similar complexes are formed and they showed identical behaviour with 
thermal analysis. The possibility of racemic resolution of ibuprofen and other profen 
anti-inflammatories using the cyclodextrins is discussed in section 5.5. 
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5. COMPLEX OF TRIMEB WITH IBUPROFEN1'2 
5.1 PREPARATION OF COMPLEX 
Preparation of the crystalline complex is outlined briefly in Table 3.1. Equimolar 
amounts of TRIMEB and racemic ibuprofen were dissolved in distilled water at room 
temperature and the resulting solution incubated at 50°C for 48h to obtain crystals. 
Microcrystalline complexes of TRIMEB with racemic and (S)-ibuprofen were 
prepared by stirring equimolar amounts of host and drug in aqueous solution for 
24hrs at room temperature and filtering the insoluble powders that formed. 
5.2 THERMAL ANALYSIS 
Initial investigations using hot stage microscopy showed that melting of the complex 
occurred at approximately 185°C. This was confirmed by DSC, with a melting 
endotherm present at 186.3°C, as compared to fusion of TRIMEB at 159.1°C 
[Fig.5.1a and b respectively]. TGA showed negligible mass loss over the 
temperature range [Fig.5.1 c]. This was attributed to loss of surface water, and it 
was concluded that no water molecules of crystallisation were present in the 
complex. This conclusion was supported by no evidence of crystal cracking under 
the hot stage microscope, and confirmed by X-ray analysis. 
5.3 CRYSTAL STRUCTURE SOLUTION 
5.3.1 Photography 
A crystal was removed from a batch of complex obtained with racemic ibuprofen 
and attached unsealed to a glass fibre, then mounted on a goniometer as outlined 
in Section 2.7. Oscillation and Weissenberg photography revealed Laue mmm 
symmetry, corresponding to the orthorhombic system. The systematic absences 
hOO: h=2n+1 ; OkO: k=2n+1 ; 00/: /=2n+1 confirmed the space group as P212121. 
5.3.2 Data collection and refinement 
A single crystal was removed from a batch prepared from racemic ibuprofen and 
TRIMEB, and mounted on a diffractometer as outlined in Section 2.7. Intensity data 
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Fig. 5.1. Thermal analysis for TRIMEB - (RS)-ibuprofen complex. 






Sample mass for a= 13.313mg, for b = 14. 706mg 














were collected at 253K. Accurate cell dimensions were obtained by least squares 
analysis of the setting angles of 24 reflections in the range 16°<8<17°C. Thew-scan 
technique was used and, to ensure accurate measurement of weak reflections, a 
pre-scan acceptance parameter of zero was chosen to force the final intensity 
scans up to a maximum of 1 OOs per reflection. Data were collected to 
(sin80,)max=0.595A·1. Three reflections (3 15 8; 3 2 21; 5 15 6) were used as 
standards and were monitored hourly, showing only a 2.5% intensity decrease over 
the data collection period. Orientation control was performed every 200 reflections 
and data were corrected for Lorentz-polarisation effects. Crystal data collection and 
refinement details are given in Table 5.1. 
5.3.3 Structure solution 
The structure was solved using coordinates for the non-hydrogen atoms - excluding 
0(6), C(?), C(8) and C(9) for each methylglucose residue - of the isomorphous 
TRIMEB - (S)-naproxen complex3. After refinement of these atoms by full-matrix 
least-squares techniques [minimisation of Lw( I F0 1-1 kFc I )2 using SHELX-764], 
successive difference Fourier syntheses revealed all remaining non-hydrogen 
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Table 5.1 Crystal data, experimental and refinement parameters for 
TRIMEB - ($)-ibuprofen complex. 
Molecular formula Cs3H11203s.C13H1s02 
Mr/ gmor1 1635.8 
Crystal system Orthorhombic 
Space group P212121 
z 4 
a (A) 15.232(7) 
b (A) 21.327(7) 
C (A) 27.597(7) 
V (A3) 8965(5) 
De (g cm-3)t 1.211 
Crystal dimensions (mm) 0.3 X 0.4 X 0.5 
T/K 253 
Range scanned e (0 ) 1 s; e s; 25 
Index range h:0, 18; k:0,25; 1:0,32 
Scan width 0.8 + 0.35 tan e 
Aperture width (mm) 1.12 + 1.05 tan e 
No. reflections collected 8619 
No. unique reflections 7473 
No. reflections with I > 2cr(I) 4888 
No. L.S. parameters 1112 




Shift.e.s.d. max., ave. 0.921, 0.04 
(~P)max final (e A-3) 0.15 
(~P)min final (e A-3) -0.11 
atoms. One molecule of ibuprofen, in the (S)-configuration, was located in the 
cavity of TRIMEB. All atoms were assigned anisotropic temperature factors. 
Hydrogen atoms attached to carbon atoms on both the host and guest were 
inserted at idealised positions (C-H=1.00A), with methyl hydrogen atoms on the 
host and guest being assigned a variable isotropic temperature factor. Other 
t The density of the complex could not be obtained experimentally. A suitable solvent mixture could 
not be identified as TRIMEB is freely soluble in a number of solvents. 
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hydrogen atoms on the cyclodextrin and ibuprofen molecule were assigned 
common variable isotropic temperature factors. Due to abnormally long bond 
lengths and large bond angles for atoms of the guest isobutyl group, the position of 
H(13) was not idealised, and was instead obtained from a difference Fourier 
synthesis and allowed to refine with distance constraints to C(12), C(13) and C(14). 
Final fractional coordinates for all atoms of the complex are given in Appendix B. A 
full listing of observed and calculated structure factors (Fo and Fe), is given in 
Appendix Con disk, in ASCII format, under the filename TRIBUP.ASC. 
5.3.4 Description of structure 
The structure of the complex and the numbering system used for TRIMEB and 




Structure of TRIMEB - (S)-ibuprofen complex. (a) Numbering system 
and conformation of ($)-ibuprofen, (b) numbering system of cyclodextrin 
trimethylglucose molecules ( C atoms are represented by numbers only) and 
(c) structure of complex showing numbering of glucose residues. 
continued .... 
Fig 5.2 continued 
C. 
into the cavity of TRIMEB, with the propionic acid group protruding from the 
0(2),0(3) rim. All methylglucose groups of TRIMEB are in the 4C1 conformation, 
with the 0(2)-C(?) bonds being directed away from the cavity and the 0(3)-C(S) 
bonds directed inward. The C(6)-0(6) bonds of residues G2, G4 and G7 are 
directed toward the cavity in the (+)-gauche conformation, and those of G1, G3, GS 
and G6 are directed away in the (-)-gauche conformation. All 0(6)-C(9) bonds are 
trans to the respective C(5)-C(6) bonds, except in G(6) where the bond lies gauche 
(Fig. 5.2). TRIMEB assumes a cup-shape into which the guest molecule is 
recessed, in contrast to structures with p-cyclodextrin where the cavity conforms to 
a more annular shape. The conformation and the extent of penetration of the guest 
into the cavity are shown in Fig. 5.3. There are no water molecules present in the 
complex. 
5.3.4.1 Geometry and hydrogen bonding 
The geometrical data for TRIMEB are given in Table 5.2, based on parameters as 
outlined in Section 1.3.2. All the calculated parameters show good agreement with 
those for the complex of TRIMEB with (S)-naproxen3 , and are comparable to those 
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Fig. 5.3 Stereodiagram of the TRIMEB - (S)-ibuprofen complex 
a. View into TRIMEB cavity parallel to b axis. 
b. View normal to b axis, showing extent of guest penetration into the cavity. 
for the complex formed with the (S)-isomer of flurbiprofen5·6 , both of which are 
analogues of ibuprofen and belong to the profen group of NSAIDs. 
The conformation of the isobutyl group of (S)-ibuprofen may be defined by torsion 
angles •1, •2 and ,3 , and that of the propionic acid group by ,4, • 5 and , 6, as defined 
in Table 5.3. Comparison can be made with the conformation of free ibuprofen as 
the racemate and the pure (S)-isomer. (S)-ibuprofen crystallises with two molecules 
in the asymmetric unit, and torsion angles are outlined for both molecules7•8. 
Whereas the torsion angle values for free ibuprofen are similar, the isobutyl group 
in the complexed molecule is brought nearly normal to the plane of the phenyl ring. 
The positions of the phenyl and propionic acid groups are similar to those in free 
ibuprofen, as well as to those found in the TRIMEB - (S)-naproxen complex. The 
angle that the phenyl group makes with the least-squares plane of the 0(4) atoms 
of the macrocycle is 20.9°, while that of TRIMEB - (S)-naproxen is 23.3°. 
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The carboxylic acid group interacts with an adjacent TRIMEB methoxy group to form 
a hydrogen bond. An 0-H· · ·O hydrogen bond is formed between 0(10) and 
0(3G2) on a symmetry-related cyclodextrin ( x+1/2, -y+1/2, -z+1) with a distance of 
2. 72(1 )A (Fig. 5.4). This is the only intermolecular hydrogen bond present in the 
crystal structure. This interaction is also observed in other TRIMEB-profen 
structures. 
Table 5.2 Geometrical data for TRIM EB 
Residue Tilt angle Deviation° Torsion angle Glycosidic Radius of 
(o)a (A) indexc oxygen angled heptagon• 
(0) 
G1 28.3 0.446(6) 116.0 128.7 
G2 18.7 0.208(6) 139.8 124.8 
G3 -11.3 -0.511 (6) 116.3 124.0 
G4 41.9 -0.013(6) 139.7 137.3 
GS 33.3 0.566(6) 118.4 120.4 
G6 -14.1 -0.312(6) 128.6 126.5 
G7 36.3 -0.383(6) 138.1 130.2 
Average 127.4 
a As defined in Table 1.3.2. 
b The deviation of 0(4) atoms from the least-squares plane through all 0(4) atoms. 
c As defined in section 1.3.2. 










e The radius of heptagon (A) is the average value of the distance of each 0(4) atom from the centre 
of gravity of seven 0(4) atoms. 
Table 5.3 Torsion angles. (a) Racemic ibuprofen, (b) (S)-ibuprofen and 
(c) TRIMEB - (S)-ibuprofen complex. Values in degrees. 
Atoms aT b(i) b(ii) C 
.1 C(2)-C(1 )-C(7)-C(11) 42(1) 40(1) 28(1) 48(2) 
.2 C(2)-C(1 )-C(7)-C(8) -81 (1) -85(1) -95(1) -78(1) 
.3 C(1 )-C(7)-C(8)-0(9) -88(1) -81 (1) 83(1) -83(1) 
.4 C(3)-C(4)-C(12)-C(13) -102(1) -92(1) -79(1) -59(2) 
.s C(4)-C(12)-C(13)-C(14) -170(1) -170(1) 171 (1) -37(3) 
.6 C(4)-C(12)-C(13)-C(15) 67(1) 66(1) -64(1) 173(1) 
t The values for i:1, i:2 and ,3 will have opposite signs for each isomer. The values given here are 
for the (S)-isomer. 
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A series of intramolecular C-H· .. Q hydrogen bonds maintain the conformation of the 
macrocycle (Table 5.4). Five C6(Gn)-H···OS(Gn-1) bonds stabilise the residues G1, 
G2, G4, GS and G7, while the negative tilt angles of G3 and G6 are maintained by 
bonds C(1G3)-H···0{3G4) and C(1G5)-H···0(6G6) (Fig. 5.5). The existence of 
these bonds has been confirmed by previous reports in other TRIMEB complexes 
and in uncomplexed TRIMEB9•10·11 . 
The packing arrangement of the complex in the crystal is shown in Fig. 5.6. 
Complex units are packed head-to-tail in a screw channel mode with axes almost 
parallel to the b axis. 
Fig. 5.4 Intermolecular hydrogen bond between 0(10) and 0(3G2)1. 
I=x+1/2, -y+1/2, -z+1 
Table 5.4 lntramolecular C-H···O hydrogen bonds in TRIMEB. 
Distance (A) Angle (0 ) 
C H 0 C···O C-H* H···O C-H···O 
C(6G1) -H(611) 0(5G7) 3.23(1) 1.00 2.56 123.8 
C(6G2) -H(622) O(SG1) 3.39(1) 1.00 2.47 153.0 
C(1G3) -H(1 G3) 0(3G4) 3.09(1) 1.00 2.43 123.2 
C(6G3) -H(631) O(SG2) 3.17(1) 1.00 2.38 135.7 
C(1GS) -H(1G5) 0(6G6) 3.24(1) 1.00 2.44 136.6 
C(6GS) -H(651) O(SG4) 3.12(1) 1.00 2.42 126.4 
C(6G6) ·H(661) O(SGS) 3.20(1) 1.00 2.37 139.5 
* 1deal1sed hydrogen pos1t1ons inserted during refinement of crystal structure 
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Fig. 5.5 View of TRIMEB showing hydrogen atoms and intramolecular 
C-H···O hydrogen bonds. 
Hydrogen atoms are shown. Hydrogen bonds are represented by dotted 
lines. 
Fig. 5.6 Stereoview of packing arrangement of complex in the crystal. 
View down a axis towards the origin. The intermolecular hydrogen bond is 
indicated by the arrow. 
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5.4 X-RAY POWDER DIFFRACTION (XRD) 
A representative XRD pattern for the complex was generated using the program 
LAZY PULVERIX12 , which utilises unit cell data, atomic coordinates and thermal 
parameters (Fig. 5. ?a). Comparison was made with experimental XRD patterns 
obtained as described in Section 2.7 (Fig. 5.7b and c). 
5.5 RACEMIC RESOLUTION 
In preparing crystals for structure solution, racemic ibuprofen was used. The crystal 
drawn for X-ray analysis revealed only the (S)-isomer in the complex, and it was 
decided to investigate the possibility that TRIMEB exhibits selectivity toward 
ibuprofen as studies have shown that only the (S)-isomer of the profen 
anti-inflammatories is active against cyclooxygenase, the enzyme responsible for 
the onset of the inflammation cascade 13 . 
Powder complexes with both racemic and (S)-ibuprofen were prepared (Section 5.1) 
and thermal analysis, XRD and polarimetry were applied to establish the 
composition of the complexes. Thermal analysis results were comparable for both 
complexes. In the prepared complexes, traces of free ibuprofen were present in the 
samples used for DSC and these presented as small endothermic peaks 
corresponding to the melting points. In the complex prepared from racemic 
ibuprofen, a peak was seen at 75°C only, which is the melting point of the 
racemate, as compared to an endotherm at 54°C for the complex with 
(S)-ibuprofen, corresponding to the melting point for that isomer. From this result it 
was possible to state that a complex is formed equally with both isomers. XRD 
patterns obtained for both complexes also showed a similarity that suggested the 
complexes formed are isomorphous (Fig. 5.8). 
Measurements of optical rotation were used as confirmation of these results. 
Crystals isolated from the complex prepared using racemic ibuprofen were 
dissolved in a 40:60 ethanol:water mixture ( the complex is sparingly soluble in 
water). This gave [a.]0 =132±3°. The mother liquor was diluted with ethanol to give 
the same solvent composition and the rotation measured was [a.]0=130±3°. An 
ethanolic solution of mother liquor from a crystallisation using (S)-ibuprofen gave a 
measurement of [a.]o=118°. It could thus be concluded from the similar results 
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obtained for the crystals and mother liquor of the racemate complex, and the 
difference with that for the pure isomer complex, that the (S)-isomer is not 

















XRD results for complex. (a) Calculated pattern based on single 
crystal data, (b) experimental pattern from powder complex and (c) pattern 
from recrystallised TRIMEB alone. 
10 15 20 25 30 35 40 
28 ( 0 ) 
Comparison of XRD patterns for complexes prepared with 
racemic and ($)-ibuprofen. (a) TRIMEB - (RS)-ibuprofen powder and 
(b) TRIMEB - (S)-ibuprofen. 
10 15 20 25 30 35 40 
28 ( 0 ) 
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5.6 DISCUSSION 
The studies cited in this report using other profen anti-inflammatories as guests 
have made use of one or both isomers in the preparation of complexes with 
TRIMEB and with p-cyclodextrin. The TRIMEB-flurbiprofen complex was prepared 
with the drug (R)- and (S)-isomers and the racemate6, and the results showed that 
isomorphous complexes are formed with each isomer, with some notable structural 
differences. The biphenyl group of flurbiprofen is inserted into the cavity with the 
propionic acid moiety protruding, and the (S)-isomer is hydrogen bonded to an 
adjacent cyclodextrin molecule as found here for (S)-ibuprofen in its complex. The 
biphenyl group is disordered within the cavity, adopting an (R) and (S) configuration. 
The (R)-isomer crystallises with one water molecule in the complex which forms a 
hydrogen bonding bridge from the carboxylic acid to a neighbouring TRIMEB 
molecule. The configuration of the biphenyl group is similar to that of free 
flurbiprofen, indicating weak binding by the cavity and the authors suggest this may 
be due to steric effects. The packing pattern of TRIMEB is isomorphous for both 
isomers. From these results, it is not, however, possible to predict in detail the 
mode of complexation of (R)-ibuprofen with TRIMEB. 
In the complex of flurbiprofen with p-cyclodextrin, reaction with the racemate leads 
to a 2:2 complex being formed, with one (R)- and one (S)-isomer being enclosed in 
a cyclodextrin dimer14. Reaction with the (R)-isomer alone gives an isomorphous 
complex with the (S)-isomer being replaced by one (R)-isomer15 . In a similar study 
concerning the complexation of fenoprofen by p-cyclodextrin 16·17 , it was found that 
the cyclodextrin includes both the (R)- and (S)-isomer, though the modes differ 
significantly. The (S)-isomer is more tightly bound to the host than the (R)-isomer, 
due to a more favourable conformation for the carboxylic acid substituent which 
results in the formation of a number of hydrogen bonds to the primary and 
secondary hydroxyl groups of the cyclodextrin. Where the racemate was 
complexed, disorder of the guests was noted and the authors concluded that a 3: 1 
occupancy ratio of (S)- and (R)- isomers was responsible. 
This suggests that the cyclodextrins may exhibit chiral selectivity toward the profen 
anti-inflammatories. However, these complexes are not isomorphous with the 
complex obtained for p-cyclodextrin and ibuprofen outlined in Section 4, and it 
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would not be possible to predict the mode of inclusion of the guest and its isomers 
from these models. 
Chromatographic studies using a number of cyclodextrins and their derivatives as 
stationary phases have concluded that some of them, especially j3-cyclodextrin and 
derivatives, are selective towards certain of the profens under certain 
conditions 18'19'20. A 13-cyclodextrin column showed chiral selectivity toward racemic 
ibuprofen at low pH i.e. below the pKA value. A column containing y-cyclodextrin 
showed no selectivity, suggesting that the size of the cavity is not optimal. Chiral 
separation would be based on the number and strength of favourable intermolecular 
contacts between host and guest, and a tight fit in the cavity would be required for 
these contacts to occur. Furthermore, a notable difference would need to be 
observed between the mode of interaction of each isomer, such that one isomer 
would preferentially interact with the host molecule, for separation to be possible. 
The elucidation of the crystal structures of native j3-cyclodextrin and TRIMEB with 
the same guest molecule - ibuprofen - allow for comparisons between the two 
modes of crystallisation. The structure of TRIMEB - (S)-ibuprofen is isomorphous 
with previously reported structures of TRIMEB complexes using analogues of 
ibuprofen as guest molecules. The complex with j3-cyclodextrin is not isomorphous 
with other 13-cyclodextrin - profen complexes despite packing in a channel 
arrangement similar to those complexes. The channels formed in the complex with 
ibuprofen are more linear and the guest is disordered within these channels and 
cannot be modelled, as has been observed with a number of complexes in the 
channel packing arrangement of j3-cyclodextrin. 
The geometrical parameters that define the conformation of the macrocycle, as 
shown in Tables 4.2 and 5.2 show that the ring of j3-cyclodextrin adopts a more rigid 
relative positioning of the glucose residues, as illustrated by the radius of the 
heptagon, deviation of 0(4) atoms from the plane of the macrocycle and glycosidic 
oxygen angles. This is maintained by a complex network of intramolecular and 
intermolecular hydrogen bonds. The macrocycle of TRIMEB is maintained by a 
series of C-H···O hydrogen bonds, and distortion may be due to a number of 
factors, such as the steric effects of the methyl substituents on each residue. 
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The tilt angles observed for each residue of the host molecule are a measure of the 
macrocyclic shape. In the TRIMEB complex, the 0(6) rim of the host molecule is 
narrowed and the molecule assumes a cup-shaped appearance. The guest 
molecule is inserted into the cavity and isolated from other ibuprofen molecules in 
the complex. The channel packing of the p-cyclodextrin complex , with both ends of 
the cavity being open, suggests however that interaction is possible between guest 
molecules even though this could not be ascertained. 
The water molecules present in the interstitial spaces are vital in maintaining the 
crystal structure and crystallinity is lost upon their removal. No water molecules are 
present in the TRIMEB complex, due to the hydrophobic environment, and the 
crystals are thus more stable to air and heat. 
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6. CONCLUSION 
Inclusion of NSAIDs by the cyclodextrins can improve a number of their 
physicochemical properties and thereby improve the bioavailability, side effect 
profile and other characteristics when administered orally or by other routes. A 
number of review articles have been devoted to studies of cyclodextrin complexes 
,,z.,3 
with NSAIDs and other drugs~ and the main objective of this study has been the 
preparation of solid state complexes and their characterisation where possible using 
a range of physicochemical methods. 
A number of complexes have been prepared and properties such as host:guest 
stoichiometry, water content, thermal behaviour and X-ray diffraction characteristics 
have been recorded. Where crystals of suitable size have been cultivated, single 
crystal X-ray photography and X-ray intensity data collection have been performed. 
A list of all complexes for which a thorough investigation was carried out is given in 
Table 6.1 below. For each complex, the host:guest:water stoichiometry is given 
together with space group information and unit cell dimensions where these have 
been obtained. 
Complexes were generally more easily prepared with native 13- and y-cyclodextrins 
than with DIMES and TRIMES, and a number of reasons may account for this. The 
conformation of DIMES is similar to that of p-cyclodextrin, due to the formation of a 
network of (0)2···H-0(3) hydrogen bonds, though the cavity is deeper and the 0(6) 
rim narrower than in p-cyclodextrin and steric effects may be important in inhibiting 
complex formation. The conformation of the TRIMES molecule in the uncomplexed 
state tends to be more distorted and the macrocycle is more collapsed than that of 
either P- or y-cyclodextrin4·5 . It would thus be possible to state that the insertion of 
the guest into the cavity of DIMES or TRIMES, according to the established mode of 
complexation whereby the conformation of the ring is altered to accommodate the 
guest, could require greater energy than would be needed for complexation with 
native cyclodextrin. Simple heating of the reaction solution would not be possible 
due to the unusual solubility profiles of the methylated cyclodextrins whereby 
solubility decreases with temperature, and other factors would need to play a role in 
promoting complex formation. 
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Table 6.1 Summary of characterised complexes 
HOST-GUEST COMPOSITION SPACE UNIT CELL 
(host:guest:water) GROUP DATA* 
p-cyclodextrin - piroxicam a=27.197(5)A 
1 :1 :25.8 C2 b=12.43(1)A 
c=24.815(5)A 
P=104.19(2)0 
y-cyclodextrin - piroxicam 1:1:19.2 
p-cyclodextrin - mefenamic acid 1:1:11.5 
p-cyclodextrin - flufenamic acid 1 :1 :12.8 
p-cyclodextrin - niflumic acid 1:1:13.2 
a=15.5A 




p-cyclodextrin - ibuprofen** 1 :1 :12.0 C2 b=24.41 (2)A 
c=15.92(1)A 
p=108.9(6)0 
y-cyclodextrin - ibuprofen 1:1:18.3 P4212 a=b=23.7A 
c=45.9A 
a=10.1A 
DIMES - ibuprofen 1 :1: 1 P212121 b=15.3A 
c=53.6A 
a=15.232(7)A 
TRIMEB - ibuprofen** 1 :1 :0 P212121 b=21.327(7)A 
c=27.597(7)A 
a=15.4A 
p-cyclodextrin - diflunisal 1:1:13.0 P212121 b=29.oA 
c=29.7A 
* Unit cell data with standard deviations are given for those complexes where parameters were 
obtained diffractometrically. 
** Complexes for which complete structural analysis was successfully performed. 
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In cases where complexation did proceed with DIMEB and TRIMEB, specifically in 
the case of ibuprofen, the size of the guest molecule would appear to be of 
importance. Relatively larger molecules such as the oxicam and indene derivatives 
(indomethacin and sulindac) do not form complexes with cyclodextrins as readily as 
the smaller profens, fenamates and salicylates, and this has been shown in 
numerous literature studies and been the observation in this study. Other factors, 
such as ionisation of the guest and the phase solubilities of complexes that may 
form in solution but not precipitate as solid complexes, should also be noted. 
Numerous difficulties were encountered in the preparation of many complexes, and 
obtaining crystals of suitable quality for X-ray analysis was hampered by a number 
of factors such as crystal size and the inability to optimise conditions for 
crystallisation despite repeated efforts, and many attempts to characterise 
complexes failed. Where success was achieved, the unit cell dimensions and 
instability of the crystals outside of the mother liquor precluded intensity data 
collection and the solution of the structure, which was the true aim of this study. 
Certain hosts showed a greater affinity for a particular guest than others. With the 
DIMES-ibuprofen complex it was observed that pH adjustment or other manipulation 
of the reaction medium was unnecessary, and that the guest molecule was rapidly 
and completely taken into solution with simple stirring. This is related to the stability 
constant of the complex and suggests that the interaction between host and guest is 
enhanced by specific intermolecular interactions that would need to be elucidated. 
Reported stability constants for the complexes of DIMES and j3-cyclodextrin with 
ibuprofen give a value for the DIMES complex that is approximately four times 
greater, and the authors suggest that the deeper cavity and greater closeness of fit 
between host and guest may be responsible for these observations6 . The ability of 
the host and guest molecule to interact with each other through a number of 
intermolecular forces such as hydrogen bonding, van der Waals forces and 
hydrophobic interactions would need to be considered. 
The advantages of complexation are related to these properties and have been 
reviewed extensively. Dispersion of NSAIDs, which are usually insoluble, especially 
in the acidic environment of the stomach where they are present mainly in their 
unionised form, can allow for more rapid dissolution and absorption, thereby 
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decreasing the time to peak plasma concentration and increasing the maximum 
plasma concentration. The anti-inflammatory activity of piroxicam is improved 2.65 
times by inclusion into p-cyclodextrin7. The complex formed dissociates rapidly in 
the gastric environment and more free drug is delivered to the site of absorption. 
The only steady-state pharmacokinetic parameter that is modified is the T max value 
due to this effect8 . Gastric irritation is also considerably reduced9 . 
A similar modification is noted with the p-cyclodextrin - ibuprofen complex. The 
improvement in aqueous solubility of ibuprofen by complexation with 13-cyclodextrin 
is 2.1 times, and for TRIM EB it is 1.9 times 10, and the complexes formed are 
relatively insoluble compared to the cyclodextrin alone. This is not as great an 
enhancement as is observed with other compounds though it can be sufficient to 
significantly improve bioavailability. The amount of free drug that is absorbed is 
similar to that of the uncomplexed drug, but the rate of absorption is improved 2.5 
times in a similar manner to the piroxicam complex11 . Furthermore, the bitter taste 
and irritant effect of ibuprofen on the tongue are masked by complexation which 
may improve formulation of the drug 12. 
In conclusion, the NSAIDs are favourable candidates for inclusion by cyclodextrins, 
with the aim of improving their therapeutic behaviour, and much work has been 
devoted to ascertaining the mode of inclusion and properties of the complexes in 
the solid state. Physicochemical characterisation of solid state complexes is 
possible using a wide range of techniques, and a number of complexes have been 
prepared and characterised to provide evidence for inclusion. The results of X-ray 
analysis for a number of complexes, and the unique cell data that were obtained, 
indicate that the mode of packing of cyclodextrin complexes in the solid state may 
be more varied than has been reported until now. The elucidation of the crystal 
structures of these complexes would improve the understanding of these modes 
and thereby enhance knowledge of the inclusion capabilities of these important 
compounds. 
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Appendix A: SUPPLEMENTARY DATA FOR 
J3-CYCLODEXTRIN - (RS)-IBUPROFEN COMPLEX 
TABLE A1. Fractional atomic coordinates (x 10
4
) and thermal parameters 
(A 2 x 103> with estimated standard deviations in parentheses for 
~-cyclodextrin - (RS)-ibuprofen complex. 
Ueq = (1/3)IiiiUiia(a(ai.ai 
Atom x/a y/b zJc Ueq/Uiso * 
C(1 G1) -546(4) 2680(4) 2465(6) 36(2) 
C(2G1) -938(5) 2757(4) 3137(6) 37(2) 
0(2G1) -431(3) 2868(4) 3987(4) 46(2) 
C(3G1) -1384(4) 2247(4) 3167(5) 33(2) 
0(3G1) -1800(3) 2323(4) 3737(4) 43(1) 
C(4G1) -1684(4) 2135(4) 2229(5) 32(2) 
0(4G1) -2268(3) 1635(3) 2257(4) 35(1) 
C(5G1) -1444(5) 2072(4) 1601(6) 38(2) 
0(5G1) -1022(3) 2560(4) 1627(4) 41 (1) 
C(6G1) -1888(7) 1971 (5) 642(6) 57(3) 
0(6G1) -2344(5) 2395(5) 255(5) 78(3) 
C(1G2) -3026(5) 1637(4) 1905(5) 35(2) 
C(2G2) -3340(5) 1406(4) 2593(5) 37(2) 
0(2G2) -3115(4) 1737(4) 3364(4) 45(1) 
C(3G2) -3105(5) 817(4) 2795(5) 35(2) 
0(3G2) -3427(4) 589(4) 3402(4) 47(2) 
C(4G2) -3340(5) 490(4) 1933(5) 34(2) 
0(4G2) -3060(3) -051(4) 2126(4) 36(1) 
C(5G2) -3039(5) 751(5) 1253(6) 42(2) 
0(5G2) -3264(4) 1309(4) 1113(4) 42(1) 
C(6G2) -3275(7) 475(5) 364(6) 56(3) 
0(6G2) -4032(5) 444(5) 014(6) 74(2) 
C(1G3) -3541 (5) -500(4) 1891 (5) 35(2) 
C(2G3) -3370(5) -861(4) 2709(5) 38(2) 
0(2G3) -3509(4) -572(4) 3420(4) 47(2) 
C(3G3) -2620(5) -1059(4) 2966(5) 39(2) 
0(3G3) -2454(4) -1422(4) 3706(4) 45(2) 
C(4G3) -2490(5) -1354(4) 2193(5) 35(2) 
0(4G3) -1731 (3) -1458(4) 2431(4) 42(1) 
C(5G3) -2740(5) -1001(5) 1336(5) 39(2) 
0(5G3) -3443(3) -796(4) 1181(4) 38(1) 
C(6G3) -2754(5) -1321(5) 527(5) 47(2) 
0(6G3) -3287(4) -1753(4) 348(4) 52(2) 
C(1G4) -1499(5) -1991 (5) 2273(6) 45(2) 
C(2G4) -983(5) -2209(5) 3142(6) 43(2) 
0(2G4) -1346(4) -2220(4) 3792(4) 49(2) 
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C(3G4) -293(4) -1896(5) 3449(5) 36(2) 
0(3G4) 214(4) -2151 (4) 4232(4) 47(2) 
C(4G4) 050(5) -1889(5) 2721(5) 43(2) 
0(4G4) 710(3) -1578(4) 3017(4) 38(1) 
C(5G4) -494(6) -1626(6) 1890(6) 57(3) 
0(5G4) -1143(4) -1948(5) 1626(4) 57(2) 
C(6G4) -209(8) -1564(9) 1124(8) 91(5) 
0(6G4) -712(12) -1319(12) 469(11) 115(9) 0.57** 
0(64A)* 42(17) -2146(15) 942(23) 117(9) 0.43· •• 
C(1G5) 1351 (5) -1831(5) 2965(6) 41(2) 
C(2G5) 1935(5) -1760(4) 3836(6) 40(2) 
0(2G5) 1717(4) -1997(4) 4542(4) 50(2) 
C(3G5) 2112(5) -1162(5) 4006(5) 37(2) 
0(3G5) 2715(3) -1077(4) 4797(4) 46(2) 
C(4G5) 2308(5) -917(5) 3248(5) 39(2) 
0(4G5) 2386(3) -339(4) 3375(4) 42(2) 
C(5G5) 1742(5) -1042(5) 2360(6) 43(2) 
0(5G5) 1556(4) -1610(4) 2268(4) 51(2) 
C(6G5) 1972(7) -907(7) 1569(7) 68(3) 
0(6G5) 2543(6) -1228(7) 1527(7) 99(4) 
C(1G6) 3012(6) -081 (5) 3349(6) 47(2) 
C(2G6) 3307(5) 268(5) 4180(6) 45(2) 
0(2G6) 3445(4) -047(4) 4963(4) 47(2) 
C(3G6) 2754(5) 721(5) 4141(5) 36(2) 
0(3G6) 3040(4) 1078(4) 4885(4) 46(2) 
C(4G6) 2603(5) 1049(5) 3293(6) 41(2) 
0(4G6) 2037(3) 1421(3) 3246(4) 34(1) 
C(5G6) 2381(7) 664(6) 2488(6) 56(3) 
0(5G6) 2887(5) 234(4) 2586(5) 63(2) 
C(6G6) 2332(11) 937(8) 1635(10) 98(6) 
0(6G6)* 3036(11) 1050(9) 1614(13) 155(6) 
C(1G7) 2161(5) 1986(4) 3151(6) 37(2) 
C(2G7) 1976(5) 2281(4) 3898(6) 38(2) 
0(2G7) 2445(3) 2115(4) 4737(4) 41(2) 
C(3G7) 1193(4) 2208(4) 3792(5) 34(2) 
0(3G7) 1006(4) 2513(4) 4459(4) 47(2) 
C(4G7) 729(4) 2403(4) 2883(5) 33(2) 
0(4G7) -013(3) 2274(3) 2775(3) 34(1) 
C(5G7) 949(5) 2131(4) 2154(5) 38(2) 
0(5G7) 1719(3) 2183(4) 2322(4) 43(2) 
C(6G7) 586(6) 2369(5) 1243(6) 46(2) 
0(6G7) 690(4) 2953(4) 1245(4) 54(2) 
O(W1) 5000(0) -411(5) 0000(0) 59(3) 
O(W2) 4546(4) -1300(4) 800(4) 53(2) 
·** Site occupancy factors for 0(6G4) and 0(64A) 
APPENDIX A A-3 
O(W3) 5231(7) -1024(7) 3419(7) 116(5) 
O(W4)* 3504(7) 2860(7) 9362(9) 116(4) 
O(W5)* 4159(8) 1786(8) 4540(11) 128(5) 
O(W6) 4133(5) 8743(5) 4738(7) 76(2) 
O(W7) 3951(5) 9163(5) 1998(6) 76(2) 
O(W8)* 5863(8) 281 (7) 8215(10) 117(4) 
O(W9) 5112(9) 426(12) 3664(22) 234(15) 
O(W10)* 4382(11) 1796(10) 6327(13) 166(7) 
O(W11) 5000(0) -245(13) 5000(0) 153(9) 
O(W12)* 0000(0) 6314(13) 0000(0) 153(9) 
TABLE A2. Anisotropic atoms have thermal parameters (A2 x 103) of the form: 
exp[-21r2(U h2a*2 + U k2b*2 + U3312c*2 + 2U hka*b* + 
11 22 12 
2U hla*c*+ 2U klb*c*)] 
13 23 
Atom U11 U22 U33 U23 U13 U12 
C(1G1) 33(4) 31(4) 40(4) 16(3) 7(3) 2(3) 
C(2G1) 39(4) 23(4) 41(4) -3(3) 1(3) 1(3) 
0(2G1) 46(3) 45(3) 41(3) -13(3) 5(3) 5(3) 
C(3G1) 38(4) 31(4) 32(4) 5(3) 12(3) 5(3) 
0(3G1) 46(3) 55(4) 31(3) -6(3) 15(3) -2(3) 
C(4G1) 41 (4) 24(4) 29(4) 6(3) 8(3) -2(3) 
0(4G1) 44(3) 25(3) 33(3) 4(2) 7(2) -5(2) 
C(5G1) 42(4) 40(4) 31(4) 7(3) 9(3) -9(4) 
0(5G1) 48(3) 39(3) 32(3) 12(2) 9(2) -7(3) 
C(6G1) 81(7) 60(7) 31(5) 1(4) 20(5) -20(6) 
0(6G1) 73(5) 93(7) 52(5) 23(4) -2(4) -10(5) 
C(1G2) 45(4) 31(4) 25(4) 1(3) 6(3) -4(3) 
C(2G2) 43(4) 35(4) 31(4) -4(3) 9(3) -2(3) 
0(2G2) 59(4) 41(3) 42(3) -9(3) 25(3) -8(3) 
C(3G2) 46(4) 35(4) 23(4) 3(3) 10(3) -2(3) 
0(3G2) 73(4) 38(3) 38(3) -3(3) 32(3) -12(3) 
C(4G2) 46(5) 29(4) 29(4) 2(3) 18(3) -5(3) 
0(4G2) 42(3) 31(3) 34(3) 2(2) 9(2) -7(2) 
C(5G2) 53(5) 40(4) 36(4) 6(4) 17(4) -11(4) 
0(5G2) 53(3) 36(3) 30(3) -1(2) 2(2) -15(3) 
C(6G2) 76(7) 59(6) 32(5) 6(4) 18(5) -16(5) 
0(6G2) 94(6) 74(6) 49(4) -10(4) 17(4) -29(5) 
C(1G3) 45(4) 39(4) 22(4) -6(3) 11 (3) -9(4) 
C(2G3) 67(6) 28(4) 27(4) -5(3) 27(4) -13(4) 
0(2G3) 76(4) 44(3) 29(3) -9(3) 28(3) -12(3) 
C(3G3) 72(6) 26(4) 18(3) -1 (3) 14(4) -15(4) 
APPENDIX A A-4 !...!!.....!.....!:.!...:..=.!!:..:....!...!...--------------------------
0(3G3) 77(4) 33(3) 26(3) 3(2) 20(3) -3(3) 
C(4G3) 45(5) 37(4) 23(4) -6(3) 11 (3) -11 (3) 
0(4G3) 46(3) 42(3) 30(3) -8(2) 0(2) -4(3) 
C(5G3) 48(5) 46(5) 20(4) -7(3) 8(3) -15(4) 
0(5G3) 48(3) 42(3) 20(3) -8(2) 6(2) -6(3) 
C(6G3) 47(5) 68(6) 22(4) -6(4) 5(3) 1(4) 
0(6G3) 72(4) 50(4) 28(3) -13(3) 8(3) -1(3) 
C(1G4) 51(5) 49(5) 28(4) -11 (4) 3(4) -8(4) 
C(2G4) 51(5) 43(5) 34(4) -8(4) 11(4) 0(4) 
0(2G4) 54(4) 54(4) 41(3) 4(3) 18(3) 1(3) 
C(3G4) 43(4) 46(5) 18(3) 2(3) 10(3) 6(4) 
0(3G4) 51(3) 64(4) 23(3) 6(3) 8(2) 3(3) 
C(4G4) 47(5) 62(6) 19(4) -4(4) 9(3) -3(4) 
0(4G4) 47(3) 39(3) 28(3) -4(2) 11 (2) 4(3) 
C(5G4) 56(5) 85(8) 21(4) 3(4) 1(4) -6(5) 
0(5G4) 55(4) 91(6) 21(3) -18(3) 6(3) -6(4) 
C(6G4) 79(8) 154(16) 39(6) 16(8) 18(6) -18(9) 
0(6G4) 120(15) 159(23) 46(8) 11 (11) -1 (9) -53(15) 
C(1G5) 52(5) 47(5) 34(4) 1(4) 26(4) 1(4) 
C(2G5) 52(5) 44(5) 31(4) 3(4) 21(4) 15(4) 
0(2G5) 67(4) 52(4) 32(3) 6(3) 18(3) 8(3) 
C(3G5) 39(4) 53(5) 22(3) (3)13 0(3) 11(4) 
0(3G5) 49(3) 66(4) 18(3) 5(3) 10(2) 4(3) 
C(4G5) 53(5) 46(5) 24(4) -2(3) 21(4) 15(4) 
0(4G5) 47(3) 49(4) 37(3) 1(3) 24(3) 18(3) 
C(5G5) 49(5) 54(5) 29(4) 3(4) 19(4) 4(4) 
0(5G5) 65(4) 68(4) 25(3) -14(3) 22(3) -5(3) 
C(6G5) 79(7) 104(1) 23(4) -1 (5) 20(5) -24(7) 
0(6G5) 101(7) 144(11) 75(6) -37(7) 57(6) -30(7) 
C(1G6) 62(6) 50(5) 38(5) 9(4) 30(4) 23(5) 
C(2G6) 54(5) 40(5) 48(5) 7(4) 27(4) 12(4) 
0(2G6) 62(4) 37(3) 42(3) 8(3) 15(3) 8(3) 
C(3G6) 38(4) 43(4) 27(4) 0(3) 13(3) 7(4) 
0(3G6) 67(4) 36(3) 29(3) 0(2) 6(3) 13(3) 
C(4G6) 36(4) 52(5) 40(5) 9(4) 19(4) 4(4) 
0(4G6) 44(3) 28(3) 35(3) 6(2) 19(2) 2(2) 
C(5G6) 79(7) 66(6) 33(5) 3(5) 32(5) 23(6) 
0(5G6) 88(5) 71(5) 52(4) 9(4) 54(4) 24(4) 
C(6G6) 160(16) 91 (11) 51(7) 29(7) 46(9) 53(11) 
C(1G7) 44(5) 36(4) 3(4) 11(3) 1(3) -2(3) 
C(2G7) 52(5) 24(4) 37(4) 3(3) 13(4) -4(3) 
0(2G7) 47(3) 32(3) 35(3) 1(2) 0(3) 3(2) 
C(3G7) 44(4) 31(4) 27(4) -3(3) 1(3) -1(3) 
0(3G7) 56(4) 54(4) 27(3) -7(3) 7(3) 14(3) 
C(4G7) 45(4) 24(3) 26(4) 5(3) 9(3) -1(3) 
0(4G7) 46(3) 23(3) 31(3) 3(2) 12(2) -5(2) 
C(5G7) 55(5) 32(4) 28(4) 4(3) 16(4) 4(4) 
0(5G7) 48(3) 46(3) 37(3) 16(3) 15(3) -3(3) 
APPENDIX A A-5 
C(6G7) 54(5) 52(5) 28(4) 9(4) 9(4) 5(4) 
0(6G7) 7(4) 5(4) 44(4) 23(3) 18(3) 9(3) 
O(W1) 50(5) 58(6) 59(6) 0(0) 5(5) 0(0) 
Ory,J2) 63(4) 51(4) 42(3) 7(3) 11 (3) 7(3) 
O(W3) 118(9) 149(12) 67(6) 41(7) 10(6) -48(8) 
Ory,J6) 63(5) 73(6) 86(6) -25(5) 16(4) 5(4) 
Ory,J7) 80(5) 81(6) 75(6) 1(5) 37(5) 4(5) 
Ory,J9) 87(1) 241 (27) 381(38) -133(27) 84(16) -37(13) 
00f'J11) 82(11) 159(21) 211 (26) 0(0) 40(14) 0(0) 
TABLEA3. Bond lengths (A) with estimated standard deviations in 
parentheses for p-cyclodextrin - (RS)-ibuprofen complex. 
C(1 G1) - 0(5G1) 1.39(1) C(5G3) - C(6G3) 1.50(1) 
C(1 G1) - 0(4G7) 1.40(1) C(6G3) - 0(6G3) 1.44(1) 
C(1 G1) - C(2G1) 1.51 (1) C(1 G4) - 0(5G4) 1.42(1) 
C(2G1) - 0(2G1) 1.42(1) C(1 G4) - C(2G4) 1.52(1) 
C(2G1)-C(3G1) 1.53(1) C(2G4) - 0(2G4) 1.43(1) 
C(3G1)-0(3G1) 1.41(1) C(2G4) - C(3G4) 1.48(1) 
C(3G1)- C(4G1) 1.52(1) C(3G4) - 0(3G4) 1.45(1) 
C(4G1) - 0(4G1) 1.44(1) C(3G4) - C(4G4) 1.51 (1) 
C(4G1) - C(5G1) 1.52(1) C(4G4) - 0(4G4) 1.43(1) 
0(4G1)- C(1G2) 1.40(1) C(4G4) - C(5G4) 1.54(1) 
C(5G1) - 0(5G1) 1.44(1) 0(4G4)- C(1G5) 1.41 (1) 
C(5G1) - C(6G1) 1.51 (1) C(5G4) - 0(5G4) 1.43(1) 
C(6G1)- 0(6G1) 1.37(2) C(5G4) - C(6G4) 1.50(2) 
C(1 G2) - 0(5G2) 1.44(1) C(6G4) - 0(6G4) 1.32(3) 
C(1 G2) - C(2G2) 1.52(1) C(6G4) - 0(64A 1.56(4) 
C(2G2) - 0(2G2) 1.42(1) C(1 G5) - 0(5G5) 1.40(1) 
C(2G2) - C(3G2) 1.51 (1) C(1 G5) - C(2G5) 1.49(1) 
C(3G2) - 0(3G2) 1.42(1) C(2G5) - 0(2G5) 1.44(1) 
C(3G2) - C(4G2) 1.53(1) C(2G5) - C(3G5) 1.50(1) 
C(4G2) - 0(4G2) 1.42(1) C(3G5) - 0(3G5) 1.43(1) 
C(4G2) - C(5G2) 1.52(1) C(3G5) - C(4G5) 1.50(1) 
0(4G2) - C(1 G3) 1.41 (1) C(4G5) - 0(4G5) 1.42(1) 
C(5G2) - 0(5G2) 1.43(1) C(4G5) - C(5G5) 1.51(1) 
C(5G2) - C(6G2) 1.50(1) 0(4G5)- C(1G6) 1.38(1) 
C(6G2) - 0(6G2) 1.39(2) C(5G5) - 0(5G5) 1.43(1) 
C(1 G3) - 0(5G3) 1.40(1) C(5G5) - C(6G5) 1.50(1) 
C(1 G3) - C(2G3) 1.52(1) C(6G5) - 0(6G5) 1.38(2) 
C(2G3) - 0(2G3) 1.43(1) C(1 G6) - 0(5G6) 1.39(1) 
C(2G3) - C(3G3) 1.46(1) C(1 G6) - C(2G6) 1.52(1) 
C(3G3) - 0(3G3) 1.43(1) C(2G6) - 0(2G6) 1.41 (1) 
C(3G3) - C(4G3) 1.51(1) C(2G6) - C(3G6) 1.53(1) 
C(4G3) - 0(4G3) 1.42(1) C(3G6) - 0(3G6) 1.43(1) 
C(4G3) - C(5G3) 1.55(1) C(3G6) - C(4G6) 1.51 (1) 
0(4G3)- C(1G4) 1.42(1) C(4G6) - 0(4G6) 1.41 (1) 
C(5G3) - 0(5G3) 1.40(1) C(4G6)- C(5G6) 1.54(2) 
APPENDIX A A-6 
0(4G6) - C(1 G7) 1.42(1) C(3G7) - 0(3G7) 1.44(1) 
C(5G6) - 0(5G6) 1.41 (1) C(3G7) - C(4G7) 1 51 (1) 
C(5G6) - C(6G6) 1.49(2) C(4G7) - 0(4G7) 1.43(1) 
C(6G6) - 0(6G6) 1.40(3) C(4G7) - C(5G7) 1.51 (1) 
C(1 G7) - 0(5G7) 1.41 (1) C(5G7) - 0(5G7) 1.44(1) 
C(1 G7) - C(2G7) 1.53(1) C(5G7) - C(6G7) 1.51 (1) 
C(2G7) - 0(2G7) 1.41 (1) C(6G7) - 0(6G7) 1.44(1) 
C(2G7) - C(3G7) 1.49(1) 
TABLEA4. Bond angles (°) with estimated standard deviations in 
parentheses for ~-cyclodextrin - (RS)-ibuprofen complex. 
0(5G1) - C(1 G1) - 0(4G7) 112.0(7) 0(5G3) - C(1 G3) - 0(4G2) 111.2(6) 
0(5G1) - C(1 G1) - C(2G1) 112.1 (7) 0(5G3) - C(1 G3) - C(2G3) 110.1 (7) 
0(4G7)-C(1G1)- C(2G1) 108.9(6) 0(4G2) - C(1G3)- C(2G3) 106.3(6) 
0(2G1) - C(2G1) - C(1 G1) 110.2(7) 0(2G3) - C(2G3) - C(3G3) 111.6(7) 
0(2G1)-C(2G1)- C(3G1) 110.6(7) 0(2G3) - C(2G3) - C(1 G3) 110.3(7) 
C(1 G1) - C(2G1) - C(3G1) 109.9(7) C(3G3) - C(2G3) - C(1 G3) 110.7(7) 
0(3G1)- C(3G1)- C(4G1) 109.9(7) 0(3G3) - C(3G3) - C(2G3) 112.0(7) 
0(3G1)-C(3G1)- C(2G1) 111.2(7) 0(3G3) - C(3G3) - C(4G3) 108.9(7) 
C(4G1) - C(3G1) - C(2G1) 107.7(6) C(2G3) - C(3G3) - C(4G3) 110.1(7) 
0(4G1)- C(4G1) - C(5G1) 110.0(7) 0(4G3) - C(4G3) - C(3G3) 107.5(7) 
0(4G1) - C(4G1) - C(3G1) 107.1(6) 0(4G3) - C(4G3) - C(5G3) 109.7(7) 
C(5G1)- C(4G1)- C(3G1) 110.4(7) C(3G3) - C(4G3) - C(5G3) 111.4(7) 
C(1 G2) - 0(4G1) - C(4G1) 118.3(6) C(4G3) - 0(4G3) - C(1 G4) 118.5(6) 
0(5G1) - C(5G1) - C(6G1) 107.3(7) 0(5G3) - C(5G3) - C(6G3) 106.9(7) 
0(5G1) - C(5G1) - C(4G1) 109.5(7) 0(5G3) - C(5G3) - C(4G3) 111.3(7) 
C(6G1) - C(5G1) - C(4G1) 115.0(8) C(6G3) - C(5G3) - C(4G3) 112.4(8) 
C(1G1) - 0(5G1) - C(5G1) 113.4(6) C(5G3) - 0(5G3) - C(1 G3) 114.9(6) 
0(6G1) - C(6G1) - C(5G1) 113.9(9) 0(6G3) - C(6G3) - C(5G3) 111.2(7) 
0(4G1) - C(1 G2) - 0(5G2) 110.3(7) 0(5G4) - C(1G4) - 0(4G3) 108.5(8) 
0(4G1)- C(1G2)- C(2G2) 109.1 (6) 0(5G4) - C(1 G4) - C(2G4) 110.8(8) 
0(5G2) - C(1 G2) - C(2G2) 109.6(7) 0(4G3) - C(1 G4) - C(2G4) 108.2(7) 
0(2G2) - C(2G2) - C(3G2) 111.8(7) 0(2G4) - C(2G4) - C(3G4) 112.1(7) 
0(2G2) - C(2G2) - C(1 G2) 109.2(7) 0(2G4) - C(2G4) - C(1 G4) 109.4(8) 
C(3G2) - C(2G2) - C(1 G2) 109.9(7) C(3G4) - C(2G4) - C(1 G4) 112.3(8) 
0(3G2) - C(3G2) - C(2G2) 110.3(7) 0(3G4) - C(3G4) - C(2G4) 110.5(7) 
0(3G2) - C(3G2) - C(4G2) 109.7(7) 0(3G4) - C(3G4) - C(4G4) 108.6(7) 
C(2G2) - C(3G2) - C(4G2) 109.0(7) C(2G4) - C(3G4) - C(4G4) 109.1(7) 
0(4G2) - C(4G2) - C(5G2) 109.5(7) 0(4G4) - C(4G4) - C(3G4) 108.8(7) 
0(4G2) - C(4G2) - C(3G2) 108.0(6) 0(4G4) - C(4G4) - C(5G4) 110.7(8) 
C(5G2) - C(4G2) - C(3G2) 110.4(7) C(3G4) - C(4G4) - C(5G4) 108.3(8) 
C(1G3) - 0(4G2) - C(4G2) 119.3(6) C(1G5) - 0(4G4) - C(4G4) 117.4(7) 
0(5G2) - C(5G2) - C(6G2) 107.3(8) 0(5G4) - C(5G4) - C(6G4) 109.7(9) 
0(5G2) - C(5G2) - C(4G2) 110.0(7) 0(5G4) - C(5G4) - C(4G4) 108.5(9) 
C(6G2) - C(5G2) - C(4G2) 114.4(7) C(6G4) - C(5G4) - C(4G4) 114 (1) 
C(5G2) - 0(5G2) - C(1 G2) 113.6(6) C(1 G4) - 0(5G4) - C(5G4) 114.7(7) 
0(6G2) - C(6G2) - C(5G2) 111 (1) 0(6G4) - C(6G4) - C(5G4) 108 (2) 
APPENDIX A A-7 
0(6G4) - C(6G4) - 0(64A 118 (2) C(4G6) - C(3G6) - C(2G6) 110.4(7) 
C(5G4) - C(6G4) - 0(64A 106 (2) 0(4G6)- C(4G6) - C(3G6) 108.1(7) 
0(5G5)- C(1G5) - 0(4G4) 111.1(7) 0(4G6) - C(4G6) - C(5G6) 110.3(8) 
0(5G5) - C(1 GS) - C(2G5) 111.5(7) C(3G6) - C(4G6) - C(5G6) 109.9(8) 
0(4G4) - C(1 GS) - C(2G5) 108.3(7) C(4G6) - 0(4G6) - C(1 G7) 118.5(7) 
0(2G5) - C(2G5) - C(1 GS) 110.6(8) 0(5G6) - C(5G6) - C(6G6) 105.7(9) 
0(2G5) - C(2G5) - C(3G5) 110.8(7) 0(5G6) - C(5G6) - C(4G6) 111.5(9) 
C(1 GS) - C(2G5) - C(3G5) 109.8(7) C(6G6) - C(5G6) - C(4G6) 114 (1) 
0(3G5) - C(3G5) - C(4G5) 107.5(7) C(1 G6) - 0(5G6) - C(5G6) 115.1(7) 
0(3G5) - C(3G5) - C(2G5) 111.9(7) 0(6G6) - C(6G6) - C(5G6) 110 (2) 
C(4G5) - C(3G5) - C(2G5) 110.2(7) 0(5G7) - C(1 G7) - 0(4G6) 111.1 (7) 
0(4G5) - C(4G5) - C(3G5) 108.8(6) 0(5G7) - C(1 G7) - C(2G7) 110.1(7) 
0(4G5) - C(4G5) - C(5G5) 110.0(7) 0(4G6) - C(1 G7) - C(2G7) 106.6(6) 
C(3G5) - C(4G5) - C(5G5) 111.9(8) 0(2G7) - C(2G7) - C(3G7) 113.3(7) 
C(1G6) - 0(4G5) - C(4G5) 120.0(7) 0(2G7) - C(2G7) • C(1 G7) 111.0(7) 
0(5G5) - C(5G5) - C(6G5) 105.1(9) C(3G7) - C(2G7) - C(1 G7) 110.1(7) 
0(5G5) • C(5G5) - C(4G5) 112.0(8) 0(3G7) · C(3G7) · C(2G7) 110.5(7) 
C(6G5)- C(5G5) - C(4G5) 114.5(8) 0(3G7) · C(3G7) · C(4G7) 109.2(7) 
C(1 GS) - 0(5G5) - C(5G5) 114.7(7) C(2G7) - C(3G7) - C(4G7) 110.0(7) 
0(6G5) - C(6G5) - C(5G5) 112 (1) 0(4G7)- C(4G7) - C(3G7) 108.1(6) 
0(4G5) - C(1G6) - 0(5G6) 111.9(8) 0(4G7) - C(4G7) - C(5G7) 109.5(6) 
0(4G5) - C(1G6) · C(2G6) 108.5(7) C(3G7) · C(4G7) · C(5G7) 111.4(7) 
0(5G6) · C(1 G6) · C(2G6) 111.2(8) C(1G1)- 0(4G7)- C(4G7) 119.1(6) 
0(2G6) - C(2G6) - C(1 G6) 111.9(8) 0(5G7) • C(5G7) - C(6G7) 106.2(7) 
0(2G6) - C(2G6) - C(3G6) 111.1 (7) 0(5G7) - C(5G7) · C(4G7) 110.7(7) 
C(1 G6) - C(2G6) · C(3G6) 107.9(7) C(6G7) - C(5G7) - C(4G7) 114.1(7) 
0(3G6) • C(3G6) · C(4G6) 109.1(7) C(1 G7) - 0(5G7) · C(5G7) 115.3(6) 
0(3G6) - C(3G6) - C(2G6) 109.1(7) 0(6G7) - C(6G7) - C(5G7) 110.9(8) 
TABLE AS. Torsion angles (0 ) with estimated standard deviations 
in parentheses for ~-cyclodextrin - (RS)-ibuprofen complex. 
0(5G1) - C(1 G1) - C(2G1) - 0(2G1) 178.8(6) C(3G1)- C(4G1)- C(5G1)- 0(5G1) -57.9(8) 
0(4G7)- C(1G1)- C(2G1)- 0(2G1) 54.3(8) 0(4G1) · C(4G1) · C(5G1)- C(6G1) 63.3(9) 
0(5G1) • C(1G1) · C(2G1) · C(3G1) 56.7(8) C(3G1)- C(4G1)- C(5G1) · C(6G1) -178.8(8) 
0(4G7)- C(1G1)- C(2G1)- C(3G1) -67.8(8) 0(4G7) · C(1 G1) · 0(5G1) · C(5G1) 63.8(9) 
0(2G1) - C(2G1) - C(3G1) - 0(3G1) 62.7(8) C(2G1) - C(1 G1) - 0(5G1) - C(5G1) -58.9(9) 
C(1 G1) - C(2G1) - C(3G1) - 0(3G1) -175.5(6) C(6G1)-C(5G1)-0(5G1)- C(1G1) -175.6(8) 
0(2G1) - C(2G1) - C(3G1) - C(4G1) -176.9(7) C(4G1)-C(5G1)-0(5G1)- C(1G1) 58.9(9) 
C(1 G1) - C(2G1) - C(3G1) - C(4G1) -55.0(8) 0(5G1)- C(5G1) - C(6G1) - 0(6G1) -59 (1) 
0(3G1) · C(3G1) · C(4G1) · 0(4G1) -62.2(8) C(4G1) · C(5G1)- C(6G1) · 0(6G1) 63 (1) 
C(2G1)- C(3G1) - C(4G1) - 0(4G1) 176.5(6) C(4G1)- 0(4G1)- C(1G2) · 0(5G2) 111.5(7) 
0(3G1)- C(3G1)- C(4G1)- C(5G1) 178.0(6) C(4G1)- 0(4G1)- C(1G2) · C(2G2) -128.1(7) 
C(2G1) • C(3G1)- C(4G1)- C(5G1) 56.8(8) 0(4G1)- C(1G2) · C(2G2) · 0(2G2) 60.2(9) 
C(5G1) · C(4G1) · 0(4G1)- C(1G2) -112.8(8) 0(5G2) - C(1 G2) - C(2G2) · 0(2G2) -178.9(7) 
C(3G1)- C(4G1)- 0(4G1) · C(1G2) 127.3(7) 0(4G1) - C(1 G2) · C(2G2) - C(3G2) -62.8(8) 
0(4G1) - C(4G1) · C(5G1) - 0(5G1) -175.9(6) 0(5G2) · C(1 G2) - C(2G2) - C(3G2) 58.1(9) 
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0(2G2) - C(2G2) - C(3G2) - 0(3G2) 61.6(9) 0(5G4) - C(1 G4) - C(2G4) - 0(2G4) 176.9(8) 
C(1 G2) - C(2G2) - C(3G2) - 0(3G2) -177.0(6) 0(4G3) - C(1G4) - C(2G4) - 0(2G4) 58 (1) 
0(2G2) - C(2G2) - C(3G2) - C(4G2) -177.9(7) 0(5G4) - C(1 G4) - C(2G4) - C(3G4) 52 (1) 
C(1 G2) - C(2G2) - C(3G2) - C(4G2) -56.4(9) 0(4G3) - C(1 G4) - C(2G4) - C(3G4) -67 (1) 
0(3G2)- C(3G2) - C(4G2) - 0(4G2) -63.9(9) 0(2G4) - C(2G4) - C(3G4) - 0(3G4) 62 (1) 
C(2G2) - C(3G2) - C(4G2) - 0(4G2) 175.1 (7) C(1 G4) - C(2G4) - C(3G4) - 0(3G4) -174.2(7) 
0(3G2) - C(3G2) - C(4G2) - C(5G2) 176.3(7) 0(2G4) - C(2G4) - C(3G4) - C(4G4) -178.5(7) 
C(2G2) - C(3G2) - C(4G2) - C(5G2) 55.4(9) C(1 G4) - C(2G4) - C(3G4) - C(4G4) -55 (1) 
C(5G2)- C(4G2) - 0(4G2) - C(1G3) -114.8(8) 0(3G4) - C(3G4) - C(4G4) - 0(4G4) -60 (1) 
C(3G2) - C(4G2) - 0(4G2) - C(1 G3) 124.9(7) C(2G4) - C(3G4) - C(4G4) - 0(4G4) 179.1(7) 
0(4G2) - C(4G2) - C(5G2) - 0(5G2) -174.8(6) 0(3G4) - C(3G4) - C(4G4) - C(5G4) 179.2(8) 
C(3G2) - C(4G2) - C(5G2) - 0(5G2) -56.0(9) C(2G4) - C(3G4) - C(4G4) - C(5G4) 59 (1) 
0(4G2) - C(4G2) - C(5G2) - C(6G2) 64 (1) C(3G4) - C(4G4) - 0(4G4) - C(1 GS) 127.0(8) 
C(3G2) - C(4G2) - C(5G2) - C(6G2) -176.8(9) C(5G4) - C(4G4) - 0(4G4) - C(1 GS) -114.2(9) 
C(6G2) - C(5G2) - 0(5G2) - C(1 G2) -175.7(7) 0(4G4) - C(4G4) - C(5G4) - 0(5G4) -179.6(7) 
C(4G2) - C(5G2) - 0(5G2) - C(1 G2) 59.3(9) C(3G4) - C(4G4) - C(5G4) - 0(5G4) -60 (1) 
0(4G1) - C(1 G2) - 0(5G2) - C(5G2) 59.7(8) 0(4G4) - C(4G4) - C(5G4) - C(6G4) 58 (1) 
C(2G2) - C(1 G2) - 0(5G2) - C(5G2) -60.4(9) C(3G4) - C(4G4) - C(5G4) - C(6G4) 177 (1) 
0(5G2) - C(5G2) - C(6G2) - 0(6G2) -67 (1) 0(4G3) - C(1 G4) - 0(5G4) - C(SG4) 63 (1) 
C(4G2) - C(5G2) - C(6G2) - 0(6G2) 55 (1) C(2G4) - C(1 G4) - 0(5G4) - C(5G4) -55 (1) 
C(4G2) - 0(4G2) - C(1 G3) - 0(5G3) 109.2(8) C(6G4) - C(SG4) - 0(5G4) - C(1 G4) -174 (1) 
C(4G2) - 0(4G2) - C(1G3) - C(2G3) -131.0(7) C(4G4) - C(5G4) - 0(5G4) - C(1 G4) 60 (1) 
0(5G3) - C(1 G3) - C(2G3) - 0(2G3) -176.7(7) 0(5G4) - C(SG4) - C(6G4) - 0(6G4) 60 (1) 
0(4G2) - C(1G3) - C(2G3)- 0(2G3) 62.7(9) C(4G4) - C(SG4) - C(6G4) - 0(6G4) -178 (2) 
0(5G3) - C(1 G3) - C(2G3) - C(3G3) 59.3(8) 0(5G4) - C(SG4) - C(6G4) - 0(64A -67 (2) 
0(4G2) - C(1 G3) - C(2G3) - C(3G3) -61.3(8) C(4G4) - C(5G4) - C(6G4) - 0(64A 55 (2) 
0(2G3) - C(2G3) - C(3G3) - 0(3G3) 59.7(8) C(4G4) - 0(4G4) - C(1 GS) - O(SGS) 106.1(8) 
C(1 G3) - C(2G3) - C(3G3) - 0(3G3) -177.0(6) C(4G4) - 0(4G4) - C(1 GS) - C(2G5) -131.1(7) 
0(2G3) - C(2G3) - C(3G3) - C(4G3) -179.0(6) 0(5G5) - C(1 GS) - C(2G5) - 0(2G5) -179.2(7) 
C(1 G3) - C(2G3) - C(3G3) - C(4G3) -55.7(8) 0(4G4) - C(1G5) - C(2G5) - 0(2G5) 58.2(9) 
0(3G3) - C(3G3) - C(4G3) - 0(4G3) -66.0(9) O(SGS) - C(1 GS) - C(2G5) - C(3G5) 58.1(9) 
C(2G3) - C(3G3) - C(4G3)- 0(4G3) 170.9(6) 0(4G4) - C(1 GS) - C(2G5) - C(3G5) -64.4(9) 
0(3G3) - C(3G3) - C(4G3) - C(SG3) 173.9(7) 0(2G5) - C(2G5) - C(3G5) - 0(3G5) 62.7(9) 
C(2G3) - C(3G3) - C(4G3) - C(5G3) 50.7(9) C(1 GS) - C(2G5) - C(3G5) - 0(3G5) -174.8(6) 
C(3G3) - C(4G3) - 0(4G3) - C(1 G4) 133.7(7) 0(2G5) - C(2G5) - C(3G5) - C(4G5) -177.7(7) 
C(SG3)- C(4G3) - 0(4G3) - C(1G4) -105.1(8) C(1 GS) - C(2G5) - C(3G5) - C(4G5) -55.2(9) 
0(4G3) - C(4G3) - C(SG3) - 0(5G3) -167.8(6) 0(3G5) - C(3G5) - C(4G5) - 0(4G5) -64.8(9) 
C(3G3) - C(4G3) - C(5G3) - 0(5G3) -49.0(9) C(2G5) - C(3G5) - C(4G5) - 0(4G5) 173.0(7) 
0(4G3) - C(4G3) - C(5G3) - C(6G3) 72.3(9) 0(3G5) - C(3G5) - C(4G5) - C(SGS) 173.4(7) 
C(3G3) - C(4G3) - C(5G3) - C(6G3) -168.8(7) C(2G5) - C(3G5) - C(4G5) - C(5G5) 51.2(9) 
C(6G3) - C(5G3) - 0(5G3) - C(1 G3) 177.6(7) C(3G5) - C(4G5) - 0(4G5) - C(1 G6) 127.5(8) 
C(4G3) - C(5G3) - 0(5G3) - C(1 G3) 54.5(9) C(SGS) - C(4G5) - 0(4G5) - C(1G6) -109.6(8) 
0(4G2) - C(1 G3) - 0(5G3) - C(5G3) 58.2(9) 0(4G5) - C(4G5) - C(5G5) - 0(5G5) -170.1(7) 
C(2G3) - C(1 G3) - 0(5G3) - C(SG3) -59.4(9) C(3G5) - C(4G5) - C(5G5) - 0(5G5) -49.0(9) 
0(5G3) - C(5G3) - C(6G3) - 0(6G3) -57.8(9) 0(4G5) - C(4G5) - C(SGS) - C(6G5) 70 (1) 
C(4G3) - C(SG3) - C(6G3) - 0(6G3) 65 (1) C(3G5) - C(4G5) - C(5G5) - C(6G5) -168.5(9) 
C(4G3) - 0(4G3) - C(1 G4) - 0(5G4) 114.8(8) 0(4G4) - C(1G5) - O(SGS)- C(SGS) 63 (1) 
C(4G3) - 0(4G3) - C(1 G4) - C(2G4) -125.0(8) C(2G5) - C(1 GS) - 0(5G5) - C(SGS) -58 (1) 
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C(6G5) - C(5G5) - 0(5G5) - C(1 GS) 177.5(8) C(4G6) - C(5G6) - C(6G6) - 0(6G6) 73(2) 
C(4G5) - C(5G5) - 0(5G5) - C(1 GS) 53 (1) C(4G6)- 0(4G6) - C(1G7) - 0(5G7) 113.5(8) 
0(5G5) - C(SGS) - C(6G5) - 0(6G5) -58 (1) C(4G6)- 0(4G6)- C(1G7) - C(2G7) -126.6(8) 
C(4G5) - C(5G5) - C(6G5) - 0(6G5) 65 (1) 0(5G7) - C(1 G7) - C(2G7) - 0(2G7) -176.3(6) 
C(4G5)- 0(4G5)- C(1G6)- 0(5G6) 108.5(8) 0(4G6) - C(1 G7) - C(2G7) - 0(2G7) 63.1 (9) 
C(4G5)- 0(4G5) - C(1G6)- C(2G6) -128.5(8) 0(5G7) - C(1 G7) - C(2G7) - C(3G7) 57.4(9) 
0(4G5) - C(1 G6) - C(2G6) - 0(2G6) 57.3(9) 0(4G6) - C(1 G7) - C(2G7) - C(3G7) -63.2(8) 
0(5G6) - C(1 G6) - C(2G6) - 0(2G6) -179.3(7) 0(2G7) - C(2G7) - C(3G7) - 0(3G7) 58.6(9) 
0(4G5) - C(1G6)- C(2G6) - C(3G6) -65.2(9) C(1 G7) - C(2G7) - C(3G7) - 0(3G7) -176.4(6) 
0(5G6) - C(1 G6) - C(2G6) - C(3G6) 58 (1) 0(2G7) - C(2G7) - C(3G7) - C(4G7) 179.1 (6) 
0(2G6) - C(2G6) - C(3G6) - 0(3G6) 61 (1) C(1G7) - C(2G7)- C(3G7) - C(4G7) -55.8(8) 
C(1 G6) - C(2G6) - C(3G6) - 0(3G6) -176.1(7) 0(3G7) - C(3G7) - C(4G7) - 0(4G7) -64.6(8) 
0(2G6) - C(2G6) - C(3G6) - C(4G6) -179.1 (8) C(2G7) - C(3G7) - C(4G7) - 0(4G7) 174.1(6) 
C(1G6)- C(2G6) - C(3G6)- C(4G6) -56 (1) 0(3G7) - C(3G7) - C(4G7) - C(5G7) 175.0(7) 
0(3G6) - C(3G6) - C(4G6) - 0(4G6) -66.2(9) C(2G7) - C(3G7) - C(4G7) - C(5G7) 53.7(9) 
C(2G6) - C(3G6) - C(4G6) - 0(4G6) 173.8(7) 0(5G1)- C(1G1)- 0(4G7)- C(4G7) 112.6(7) 
0(3G6) - C(3G6) - C(4G6) - C(5G6) 173.4(7) C(2G1) - C(1 G1) - 0(4G7) - C(4G7) -122.9(7) 
C(2G6) - C(3G6) - C(4G6) - C(5G6) 53 (1) C(3G7) - C(4G7) - 0(4G7) - C(1 G1) 131.6(7) 
C(3G6) - C(4G6) - 0(4G6)- C(1G7) 124.4(8) C(5G7) - C(4G7) - 0(4G7) - C(1 G1) -106.8(8) 
C(5G6)- C(4G6) - 0(4G6) - C(1G7) -115.4(8) 0(4G7) - C(4G7) - C(5G7) - 0(5G7) -171.1(6) 
0(4G6) - C(4G6) - C(5G6) - 0(5G6) -170.7(8) C(3G7) - C(4G7) - C(5G7) - 0(5G7) -51.5(9) 
C(3G6) - C(4G6) - C(5G6) - 0(5G6) -52 (1) 0(4G7) - C(4G7) - C(5G7) - C(6G7) 69.1(9) 
0(4G6) - C(4G6) - C(5G6) - C(6G6) 70 (1) C(3G7) - C(4G7) - C(5G7) - C(6G7) -171.2(7) 
C(3G6) - C(4G6) - C(5G6) - C(6G6) -171 (1) 0(4G6) - C(1G7) - 0(5G7)- C(5G7) 60 (1) 
0(4G5) - C(1 G6) - 0(5G6) - C(5G6) 61 (1) C(2G7) - C(1 G7) - 0(5G7) - C(5G7) -57.8(9) 
C(2G6) - C(1 G6) - 0(5G6) - C(5G6) -60 (1) C(6G7) - C(5G7) - 0(5G7) - C(1 G7) 179.6(7) 
C(6G6) - C(5G6) - 0(5G6) - C(1 G6) -180 (1) C(4G7) - C(5G7) - 0(5G7) - C(1 G7) 55.2(9) 
C(4G6) - C(5G6) - 0(5G6) - C(1 G6) 56 (1) 0(5G7) - C(5G7) - C(6G7) - 0(6G7) -68.8(9) 
0(5G6) - C(5G6) - C(6G6) - 0(6G6) -50 (2) C(4G7) - C(5G7) - C(6G7) - 0(6G7) 53 (1) 
Table AS Fractional co-ordinates (x 104) of hydrogen atoms 
for ~-cyclodextrin - (RS)-ibuprofen complex. 
H x/a y/b zlc 
H(1G1) -298 3025 2426 
H(2G1) -1270 3070 2955 
H(3G1) -1056 1935 3374 
H(4G1) -2232 2437 2028 
H(5G1) -1107 1764 1808 
H(611) -1559 1905 306 
H(612) -2177 1642 608 
H(1G2) -3197 2014 1762 
H(2G2) -3873 1418 2348 
H(3G2) -2573 802 3057 
H(4G2) -3872 477 1694 
H(5G2) -2506 741 1490 
APPENDIX A A-10 --------'-----------------------------
H(621) -3089 677 -41 
H(622) -3073 108 424 
H(1G3) -4045 -370 1728 
H(2G3) -3695 -1179 2562 
H(3G3) -2291 -744 3126 
H(4G3) -2756 -1702 2088 
H(5G3) -2403 -693 1404 
H(631) -2866 -1077 19 
H(632) -2277 -1478 614 
H(1G4) -1922 -2234 2055 
H(2G4) -863 -2588 3040 
H(3G4) -393 -1520 3591 
H(4G4) 157 -2265 2585 
H(5G4) -618 -1260 2054 
H(1G5) 1257 -2223 2856 
H(2G5) 2373 -1951 3812 
H(3G5) 1684 -972 4061 
H(4G5) 2776 -1070 3251 
H(5G5) 1301 -832 2316 
H(651) 1561 -959 1032 
H(652) 2114 -525 1598 
H(1G6) 3374 -362 3355 
H(2G6) 3764 437 4178 
H(3G6) 2299 558 4163 
H(4G6) 3042 1252 3306 
H(5G6) 1905 505 2434 
H(661) 2080 700 1142 
H(662) 2057 1275 1577 
H(1G7) 2674 2046 3214 
H(2G7) 2058 2673 3838 
H(3G7) 1097 1818 3854 
H(4G7) 780 2801 2846 
H(5G7) 828 1741 2140 
H(671) 789 2200 823 
H(672) 69 2287 1054 
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Appendix B: SUPPLEMENTARY DATA FOR TRIMEB-(S}-IBUPROFEN 
COMPLEX. 
TABLE B1. Fractional atomic coordinates (x 10
4
) and thermal parameters (A2 x 103) with 
estimated standard deviations in parentheses for TRIMEB - (S)-ibuprofen 
complex. 
Ueq = (1/3) LiLi Uii at at ai.ai 
Atom x/a y/b zlc Ueq 
C(1 G1) 8631(6) 4637(5) 4754(4) 42(4) 
C(2G1) 7917(6) 4164(4) 4917(3) 38(4) 
C(3G1) 7372(6) 3943(4) 4486(3) 35(3) 
C(4G1) 6980(6) 4528(4) 4251(3) 36(4) 
C(5G1) 7712(6) 4970(4) 4093(3) 38(4) 
C(6G1) 7403(7) 5569(5) 3869(4) 51(4) 
C(7G1) 8547(7) 3736(5) 5633(4) 59(4) 
C(8G1) 6664(7) 2952(5) 4435(4) 70(5) 
C(9G1) 6354(9) 6358(5) 3941(4) 94(7) 
0(2G1) 8282(4) 3619(3) 5147(2) 45(3) 
0(3G1) 6696(5) 3547(3) 4660(2) 49(3) 
0(4G1) 6473(4) 4316(3) 3846(2) 39(2) 
0(5G1) 8220(4) 5141(3) 4516(2) 39(2) 
0(6G1) 6731(5) 5825(3) 4154(3) 63(3) 
C(1G2) 11802(6) 4178(5) 4041 (3) 47(4) 
C(2G2) 11517(6) 3738(5) 4457(4) 41(4) 
C(3G2) 10508(6) 3725(5) 4492(3) 37(4) 
C(4G2) 10141 (6) 4389(5) 4517(4) 43(4) 
C(5G2) 10530(6) 4805(5) 4123(4) 43(4) 
C(6G2) 10304(7) 5498(5) 4184(4) 60(5) 
C(7G2) 12676(8) 2992(6) 4478(5) 105(6) 
C(8G2) 9856(7) 2804(5) 4826(4) 61(5) 
C(9G2) 10303(11) 6451(6) 3786(6) 137(9) 
0(2G2) 11765(5) 3096(4) 4387(3) 63(3) 
0(3G2) 10273(4) 3389(3) 4913(2) 44(3) 
0(4G2) 9205(4) 4306(3) 4435(2) 40(3) 
0(5G2) 11468(5) 4765(3) 4141(2) 51(3) 
0(6G2) 10506(6) 5804(4) 3749(3) 89(4) 
C(1G3) 12454(7) 3908(5) 2177(3) 43(4) 
C(2G3) 12454(7) 3283(5) 2437(3) 46(4) 
C(3G3) 11917(7) 3332(5) 2904(4) 50(4) 
C(4G3) 12162(6) 3907(5) 3201(3) 43(4) 
C(5G3) 12126(6) 4495(5) 2891(3) 45(4) 
C(6G3) 12355(7) 5098(5) 3134(4) 53(4) 
C(7G3) 12527(15) 2280(7) 2137(6) 212(14) 
C(8G3) 11266(9) 2467(6) 3304(5) 96(7) 
C(9G3) 13455(8) 5616(6) 3562(5) 101(6) 
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0(2G3) 12162(6) 2812(4) 2134(3) 82(4) 
0(3G3) 12041 (5) 2768(3) 3172(3) 63(3) 
0(4G3) 11528(4) 3929(3) 3594(2) 41(2) 
0(5G3) 12702(4) 4402(3) 2488(2) 42(3) 
0(6G3) 13194(5) 5037(3) 3360(3) 61(3) 
C(1G4) 10512(6) 4540(5) 696(3) 48(4) 
C(2G4) 11366(6) 4166(6) 628(4) 60(5) 
C(3G4) 11644(6) 3877(5) 1102(3) 48(4) 
C(4G4) 11627(6) 4341(5) 1522(3) 39(4) 
C(5G4) 10813(6) 4733(5) 1537(3) 43(4) 
C(6G4) 10890(7) 5286(5) 1877(4) 57(5) 
C(7G4) 11272(10) 3863(7) -194(4) 122(8) 
C(8G4) 12646(9) 3037(5) 913(5) 83(6) 
C(9G4) 10153(9) 6043(6) 2336(5) 102(6) 
0(2G4) 11284(5) 3695(4) 289(3) 75(4) 
0(3G4) 12527(4) 3666(4) 1073(2) 56(3) 
0(4G4) 11628(4) 4013(3) 1972(2) 43(3) 
0(5G4) 10646(4) 5011 (3) 1061 (2) 49(2) 
0(6G4) 10085(5) 5557(4) 1972(3) 78(3) 
C(1G5) 7105(7) 4029(5) 610(4) 42(4) 
C(2G5) 7690(6) 3657(5) 268(4) 47(4) 
C(3G5) 8614(6) 3602(5) 454(4) 41(4) 
C(4G5) 8975(6) 4233(5) 591(4) 44(4) 
C(5G5) 8353(6) 4572(5) 928(3) 42(4) 
C(6G5) 8615(7) 5210(5) 1063(3) 47(4) 
C(7G5) 6600(8) 3043(6) -121(4) 82(6) 
C(8G5) 9436(9) 2731 (6) 166(5) 101(7) 
C(9G5) 9136(8) 6166(6) 732(4) 76(6) 
0(2G5) 7350(5) 3058(3) 179(3) 59(3) 
0(3G5) 9163(5) 3358(3) 81(3) 58(3) 
0(4G5) 9822(4) 4146(3) 818(2) 41(2) 
0(5G5) 7504(4) 4633(3) 710(2) 37(3) 
0(6G5) 8851(5) 5563(3) 638(2) 52(3) 
C(1G6) 5017(7) 3582(5) 2061(4) 44(4) 
C(2G6) 5333(7) 2975(5) 1840(4) 50(4) 
C(3G6) 6186(7) 3065(5) 1574(4) 50(5) 
C(4G6) 6125(6) 3592(5) 1222(4) 42(4) 
C(5G6) 5733(7) 4177(5) 1451(4) 43(4) 
C(6G6) 5536(7) 4703(5) 1108(4) 57(5) 
C(7G6) 5123(9) 1944(5) 2107(4) 92(6) 
C(8G6) 7293(8) 2325(5) 1341 (5) 91(6) 
C(9G6) 4195(7) 4436(7) 710(4) 84(6) 
0(2G6) 5426(5) 2529(3) 2227(3) 62(3) 
0(3G6) 6408(5) 2492(4) 1346(3) 62(3) 
0(4G6) 6998(4) 3707(3) 1055(2) 48(3) 
0(5G6) 4929(4) 4039(3) 1697(2) 47(3) 
0(6G6) 5109(5) 4541(4) 675(3) 64(3) 
C(1G7) 5654(6) 4630(5) 3765(4) 51(4) 
C(2G7) 4937(7) 4143(5) 3703(3) 43(4) 
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C(3G7) 5090(7) 3739(5) 3255(4) 47(4) 
C(4G7) 5222(7) 4147(5) 2819(3) 45(4) 
C(5G7) 5835(7) 4693(5) 2920(4) 51(5) 
C(6G7) 5778(9) 5187(6) 2525(4) 68(6) 
C(7G7) 4579(8) 4069(6) 4549(4) 70(6) 
C(8G7) 4423(7) 2731(6) 3335(4) 68(5) 
C(9G7) 6758(14) 5805(10) 2168(7) 243(15) 
0(2G7) 4838(4) 3731 (3) 4117(2) 52(3) 
0(3G7) 4347(4) 3344(3) 3166(2) 47(3) 
0(4G7) 5585(4) 3779(3) 2438(2) 45(3) 
0(5G7) 5662(5) 5012(3) 3361(2) 50(3) 
0(6G7) 6510(9) 5563(6) 2551(4) 148(6) 
C(1) 7340(7) 1749(6) 3431(4) 54(4) 
C(2) 6930(8) 2164(7) 3120(4) 74(5) 
C(3) 7311(10) 2750(7) 3014(5) 83(6) 
C(4) 8102(11) 2922(7) 3212(4) 81(7) 
C(5) 8526(8) 2491(7) 3501(4) 74(6) 
C(6) 8148(8) 1907(6) 3613(4) 70(5) 
C(7) 6896(8) 1097(6) 3553(4) 77(5) 
C(8) 6190(9) 1270(6) 3923(7) 93(7) 
0(9) 5435(7) 1339(5) 3782(4) 120(5) 
0(10) 6397(6) 1331(4) 4350(3) 98(4) 
C(11) 6564(9) 735(6) 3122(4) 85(6) 
C(12) 8551(10) 3550(6) 3102(5) 109(7) 
C(13) 8762(15) 3696(10) 2615(7) 208(15) 
C(14) 9040(12) 3328(9) 2267(5) 195(13) 
C(15) 9092(14) 4383(8) 2625(7) 265(15) 
TABLE 82. Anisotropic atoms have thermal parameters (A 2 x 103) of the form: 
exp[-2n2(U h2a*2 + U k2b*2 + U 12c*2 + 2U hka*b* 
11 22 33 12 
+ 2U hla*c*+ 2U klb*c*)] 
13 23 
Atom U11 U22 U33 U23 U13 U12 
C(1G1) 35(6) 51(7) 41(6) -18(6) 0(6) -1 (6) 
C(2G1) 42(7) 34(6) 38(6) 0(5) -1 (5) 10(6) 
C(3G1) 29(6) 43(7) 35(6) -6(5) 11(5) 1(6) 
C(4G1) 44(7) 29(6) 35(6) -1 (5) -9(5) 9(6) 
C(5G1) 44(7) 37(6) 33(6) -5(5) -1 (5) -6(6) 
C(6G1) 66(8) 35(7) 53(7) 19(6) -26(7) -5(7) 
C(7G1) 64(8) 64(8) 49(7) 7(6) -15(7) -3(7) 
C(8G1) 55(8) 68(9) 88(10) -5(8) 4(8) -25(7) 
C(9G1) 155(14) 51(8) 77(9) 13(8) -25(10) 42(10) 
0(2G1) 47(5) 43(4) 44(4) 0(4) -5(4) 2(4) 
0(3G1) 52(5) 46(5) 48(5) -3(4) 4(4) -6(4) 
0(4G1) 37(4) 41(4) 38(4) -9(4) -3(4) 1(4) 
0(5G1) 35(4) 40(4) 43(4) 8(4) -8(4) 6(4) 
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0(5G1) 35(4) 40(4) 43(4) 8(4) -8(4) 6(4) 
0(6G1) 78(6) 54(5) 58(5) -1 (5) -5(5) 24(5) 
C(1G2) 25(6) 68(9) 48(7) 18(7) -6(5) -2(6) 
C(2G2) 34(6) 48(7) 42(7) 0(6) -8(5) 7(6) 
C(3G2) 36(6) 49(7) 26(6) -2(6) 0(5) 4(6) 
C(4G2) 32(6) 47(7) 50(7) 2(6) 0(6) 0(6) 
C(5G2) 30(7) 46(7) 52(7) 14(6) 2(6) -1(6) 
C(6G2) 54(8) 50(8) 77(9) 1(7) 10(7) 0(7) 
C(7G2) 48(9) 114(12) 152(14) 47(11) 18(9) 42(9) 
C(8G2) 63(8) 47(7) 73(8) 12(7) 2(7) 16(7) 
C(9G2) 207(19) 48(10) 156(15) 42(10) 56(15) 28(12) 
0(2G2) 48(5) 75(6) 65(5) 19(5) 11(4) 19(5) 
0(3G2) 41(4) 47(5) 44(4) 1(4) -4(4) -2(4) 
0(4G2) 36(4) 44(4) 40(4) -4(4) -1(4) -4(4) 
0(5G2) 43(5) 50(5) 59(5) 1(4) 0(4) -1 (4) 
0(6G2) 117(8) 63(6) 87(7) 12(5) 19(6) -3(6) 
C(1G3) 47(7) 51(7) 33(6) -8(6) 9(6) 1(6) 
C(2G3) 36(6) 56(8) 47(7) 7(7) 8(6) 23(6) 
C(3G3) 31(6) 58(8) 62(8) 14(7) 5(6) 3(6) 
C(4G3) 27(6) 57(8) 45(7) 1(6) 7(5) 2(6) 
C(5G3) 28(6) 67(8) 41(6) 17(6) -6(5) 9(6) 
C(6G3) 52(8) 49(8) 58(7) 12(6) -9(7) -5(7) 
C(7G3) 415(38) 79(13) 141 (16) -48(13) 79(22) 8(20) 
C(8G3) 127(13) 62(9) 99(11) 36(8) 9(10) -15(10) 
C(9G3) 94(11) 73(10) 135(13) -34(10) -37(10) -1(9) 
0(2G3) 137(9) 49(5) 59(6) -23(5) 16(6) -1(6) 
0(3G3) 76(6) 46(5) 67(5) 16(4) 22(5) 5(5) 
0(4G3) 40(4) 51(4) 33(4) 2(3) -2(3) -1(4) 
0(5G3) 31(4) 55(5) 39(4) 17(4) 1(4) 0(4) 
0(6G3) 56(5) 53(5) 74(5) 0(4) -20(5) 8(4) 
C(1G4) 53(7) 66(8) 24(6) 20(6) -9(5) 0(7) 
C(2G4) 22(6) 99(10) 60(8) 31(8) 7(6) -7(7) 
C(3G4) 36(7) 64(8) 44(7) 7(6) -12(6) -5(6) 
C(4G4) 22(6) 55(7) 41(6) 16(6) -7(5) -5(5) 
C(5G4) 39(7) 38(6) 53(7) 7(6) -1 (6) -2(6) 
C(6G4) 53(8) 55(8) 63(8) 12(7) 0(7) 9(7) 
C(7G4) 132(14) 195(17) 39(8) -3(10) -1 (9) 19(14) 
C(8G4) 75(9) 65(9) 109(10) -24(9) -5(9) 13(9) 
C(9G4) 115(12) 79(10) 113(12) -7(10) -11 (11) 33(10) 
0(2G4) 72(6) 112(7) 41(5) -19(5) -6(4) 12(6) 
0(3G4) 37(4) 72(6) 59(5) -5(4) -2(4) 11(4) 
0(4G4) 28(4) 56(5) 46(4) 7(4) 2(4) -1 (4) 
0(5G4) 36(4) 57(5) 52(5) 26(4) -8(4) 0(4) 
0(6G4) 71(6) 90(6) 71(5) -23(5) -7(5) 17(6) 
C(1G5) 34(6) 40(7) 51(7) 2(6) -2(6) -3(6) 
C(2G5) 32(6) 71(9) 39(6) 13(6) -7(5) 6(7) 
C(3G5) 37(6) 43(7) 43(6) 6(6) 2(6) -3(6) 
C(4G5) 23(6) 72(9) 35(6) 21(6) 5(5) 16(6) 
C(5G5) 51(7) 45(7) 31(6) 14(6) -4(6) -11 (6) 
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C(6G5) 35(6) 76(9) 31(6) 11 (7) 5(5) 19(7) 
C(7G5) 60(9) 94(11) 93(10) -28(9) -7(8) -9(8) 
C(8G5) 104(12) 59(10) 138(13) -31 (9) 11 (11) 28(9) 
C(9G5) 79(10) 85(10) 63(8) -3(8) -18(8) -12(9) 
0(2G5) 53(5) 41(5) 84(6) -17(4) 5(5) -12(4) 
0(3G5) 51(5) 57(5) 65(5) -19(4) 3(4) 17(4) 
0(4G5) 32(4) 52(5) 40(4) 14(4) 0(4) -4(4) 
0(5G5) 29(4) 45(5) 35(4) 3(4) 0(3) 5(4) 
0(6G5) 66(5) 31(4) 59(5) -1(4) -17(4) -6(4) 
C(1G6) 36(7) 55(8) 41(7) 3(6) 2(6) -16(6) 
C(2G6) 56(8) 49(8) 45(7) 2(7) -7(6) -18(7) 
C(3G6) 42(7) 66(9) 42(7) 3(7) -8(6) -13(7) 
C(4G6) 28(6) 51(7) 46(7) -9(6) 1(5) -5(6) 
C(5G6) 33(7) 46(7) 50(7) 18(6) 0(6) -10(6) 
C(6G6) 47(8) 65(8) 58(8) 15(7) 25(7) 6(7) 
C(7G6) 129(13) 58(9) 90(10) 8(8) -8(10) -33(9) 
C(8G6) 77(11) 50(9) 145(13) 1(9) 23(10) 11 (8) 
C(9G6) 41(8) 146(13) 63(8) 29(9) 0(7) 2(8) 
0(2G6) 91(6) 42(5) 51(5) 3(4) -3(5) -27(5) 
0(3G6) 69(6) 43(5) 74(6) -8(5) 15(5) -4(5) 
0(4G6) 35(4) 57(5) 51(5) 14(4) -4(4) 3(4) 
0(5G6) 34(4) 63(5) 43(4) 17(4) 0(4) 3(4) 
0(6G6) 46(5) 96(7) 49(5) 19(5) 1(4) 11 (5) 
C(1G7) 35(7) 65(8) 54(7) -18(7) -5(6) 2(7) 
C(2G7) 28(6) 57(7) 44(7) 5(6) 2(5) 8(6) 
C(3G7) 37(7) 54(8) 50(7) 1(6) -9(6) 5(7) 
C(4G7) 38(7) 64(8) 34(6) 7(6) -4(6) -1(6) 
C(5G7) 48(8) 51(8) 54(8) 10(7) 1(6) 1(7) 
C(6G7) 89(10) 61(8) 54(8) 10(7) -12(8) -7(8) 
C(7G7) 74(9) 91(10) 45(8) -4(7) 16(7) -26(8) 
C(8G7) 52(8) 83(10) 69(8) 3(8) -2(7) -22(8) 
C(9G7) 294(33) 195(26) 240(29) -58(23) 115(27) 147(24) 
0(2G7) 49(5) 63(5) 43(4) -3(4) 0(4) -6(4) 
0(3G7) 47(5) 41(5) 52(5) 15(4) -5(4) -2(4) 
0(4G7) 42(4) 50(5) 41(4) 0(4) 6(4) 0(4) 
0(5G7) 68(5) 53(5) 31(4) 2(4) -5(4) -5(5) 
0(6G7) 184(13) 148(11) 110(9) 67(8) -17(9) -97(10) 
C(1) 40(7) 77(9) 46(7) -14(7) 20(6) 3(7) 
C(2) 50(8) 98(11) 73(9) -2(9) 8(7) -2(9) 
C(3) 81 (11) 98(12) 71(9) 10(9) 8(9) 2(10) 
C(4) 96(12) 104(13) 43(8) -4(8) 17(8) 5(11) 
C(5) 58(9) 97(11) 69(9) -19(9) 9(8) -29(9) 
C(6) 68(9) 94(11) 48(7) -13(8) 3(7) 4(9) 
C(7) 52(8) 80(10) 100(11) 18(9) 48(8) 21(8) 
C(8) 60(10) 60(9) 158(16) 29(11) -43(12) -19(8) 
0(9) 101(8) 147(9) 112(8) 16(7) 27(7) 6(8) 
0(10) 116(8) 127(8) 52(5) -9(6) -5(6) -22(7) 
C(11) 111 (11) 94(10) 50(8) -30(8) 1(8) -17(9) 






C(1 G1) - 0(5G1) 
C(1G1)- 0(4G2) 
C(2G1)- C(3G1) 
C(2G1) - 0(2G1) 




C(5G1) - C(6G1) 
C(5G1) - 0(5G1) 
C(6G1)- 0(6G1) 
C(7G1) - 0(2G1) 
C(8G1)- 0(3G1) 
C(9G1) - 0(6G1) 
0(4G1) - C(1G7) 
C(1 G2) - C(2G2) 
C(1 G2) - 0(5G2) 
C(1G2)- 0(4G3) 
C(2G2) - C(3G2) 
C(2G2) - 0(2G2) 
C(3G2) - C(4G2) 
C(3G2) - 0(3G2) 
C(4G2) - C(5G2) 
C(4G2) - 0(4G2) 
C(5G2) - C(6G2) 
C(5G2) - 0(5G2) 
C(6G2) - 0(6G2) 
C(7G2) - 0(2G2) 
C(8G2) - 0(3G2) 
C(9G2) - 0(6G2) 
C(1 G3) - C(2G3) 
C(1 G3) - 0(5G3) 
C(1G3) - 0(4G4) 
C(2G3) - C(3G3) 
C(2G3) - 0(2G3) 
C(3G3) - C(4G3) 
C(3G3) - 0(3G3) 
C(4G3) - C(SG3) 
C(4G3) - 0(4G3) 
C(5G3) - C(6G3) 













Bond lengths (A) with estimated standard deviations in parentheses 
for TRIMEB - (S)-ibuprofen complex. 
1.55(1) C(6G3) - 0(6G3) 1.43(1) 
1.41 (1) C(7G3) - 0(2G3) 1.26(1) 
1.43(1) C(8G3) - 0(3G3) 1.39(1) 
1.53(1) C(9G3) - 0(6G3) 1.41(1) 
1.44(1) C(1 G4) - C(2G4) 1.54(1) 
1.53(1) C(1 G4) - 0(5G4) 1.44(1) 
1.42(1) C(1G4) - 0(4G5) 1.39(1) 
1.52(1) C(2G4) - C(3G4) 1.51 (1) 
1.43(1) C(2G4) - 0(2G4) 1.38(1) 
1.50(1) C(3G4) - C(4G4) 1.52(1) 
1.45(1) C(3G4) - 0(3G4) 1.42(1) 
140(1) C(4G4) - C(5G4) 1.50(1) 
1.43(1) C(4G4) - 0(4G4) 1.43(1) 
1.41 (1) C(5G4) - C(6G4) 1.51 (1) 
1.40(1) C(5G4) - 0(5G4) 1.46(1) 
1.43(1) C(6G4) - 0(6G4) 1.38(1) 
1.54(1) C(7G4) - 0(2G4) 1.38(1) 
1.38(1) C(8G4) - 0(3G4) 1.42(1) 
1.41 (1) C(9G4) - 0(6G4) 1.45(1) 
1.54(1) C(1 GS) - C(2G5) 1.52(1) 
1.43(1) C(1 GS) - O(SGS) 1.45(1) 
1.52(1) C(1G5)- 0(4G6) 1.42(1) 
1.41(1) C(2G5) - C(3G5) 1.50(1) 
1.52(1) C(2G5) - 0(2G5) 1.40(1) 
1.45(1) C(3G5) - C(4G5) 1.50(1) 
1.53(1) C(3G5) - 0(3G5) 1.42(1) 
1.43(1) C(4G5) - C(SGS) 1.51 (1) 
1.40(1) C(4G5)- 0(4G5) 1.45(1) 
1.43(1) C(SGS) - C(6G5) 1.47(1) 
1.42(1) C(SGS) - O(SGS) 1.43(1) 
1.42(1) C(6G5) - 0(6G5) 1.44(1) 
1.51 (1) C(7G5) - 0(2G5) 1.41 (1) 
1.41 (1) C(8G5) - 0(3G5) 1.42(1) 
1.40(1) C(9G5) - 0(6G5) 1.38(1) 
1.53(1) C(1 G6) - C(2G6) 1.51(1) 
1.38(1) C(1 G6) - 0(5G6) 1.41(1) 
1.52(1) C(1 G6) - 0(4G7) 1.42(1) 
1.42(1) C(2G6) - C(3G6) 1.50(1) 
1.52(1) C(2G6) - 0(2G6) 1.44(1) 
1.45(1) C(3G6) - C(4G6) 1.49(1) 
1.49(1) C(3G6) - 0(3G6) 1.42(1) 
1.43(1) C(4G6) - C(5G6) 1.52(1) 
B-6 
APPENDIX B B-7 
C(3G6) - 0(3G6) 1.42(1) C(6G7) - 0(6G7) 1.38(1) 
C(4G6) - C(5G6) 1.52(1) C(7G7) - 0(2G7) 1.45(1) 
C(4G6) - 0(4G6) 1.43(1) C(8G7) - 0(3G7) 1.39(1) 
C(5G6) - C(6G6) 1.50(1) C(9G7) - 0(6G7) 1.24(2) 
C(5G6) - 0(5G6) 1.43(1) C(1)- C(2) 1.38(1) 
C(6G6) - 0(6G6) 1.40(1) C(1)- C(6) 1.37(1) 
C(7G6) - 0(2G6) 1.37(1) C(1) - C(7) 1.58(1) 
C(8G6) - 0(3G6) 1.39(1) C(2) - C(3) 1.41(2) 
C(9G6) - 0(6G6) 1.41 (1) C(3) - C(4) 1.37(2) 
C(1 G7) - C(2G7) 1.52(1) C(4) - C(5) 1.38(1) 
C(1 G7) - 0(5G7) 1.38(1) C(4) - C(12) 1.53(2) 
C(2G7) - C(3G7) 1.52(1) C(5) - C(6) 1.41(1) 
C(2G7) - 0(2G7) 1.45(1) C(7) - C(8) 1.53(2) 
C(3G7) - C(4G7) 1.50(1) C(7) - C(11) 1.51(1) 
C(3G7) - 0(3G7) 1.43(1) C(8)-0(9) 1.22(1) 
C(4G7) - C(5G7) 1.52(1) C(8) - 0(10) 1.23(2) 
C(4G7) - 0(4G7) 1.42(1) C(12) - C(13) 1.41(2) 
C(5G7) - C(6G7) 1.52(1) C(13) - C(14) 1.31(2) 
C(5G7) - 0(5G7) 1.42(1) C(13) - C(15) 1.55(2) 
TABLE B4. Bond angles (°) with estimated standard deviations 
in parentheses for TRIMEB - (S)-ibuprofen complex. 
0(5G1)- C(1G1)- 0(4G2) 111.3(8) C(3G2) - C(2G2) - 0(2G2) 104.7(8) 
C(2G1)- C(1G1)- 0(4G2) 106.7(8) C(2G2) - C(3G2) - 0(3G2) 108.3(8) 
C(2G1) - C(1 G1) - 0(5G1) 108.7(7) C(2G2) - C(3G2) - C(4G2) 110.6(8) 
C(1G1)- C(2G1)- 0(2G1) 112.5(7) C(4G2) - C(3G2) - 0(3G2) 109.9(8) 
C(1G1)- C(2G1)- C(3G1) 110.9(7) C(3G2) - C(4G2) - 0(4G2) 103.9(8) 
C(3G1) - C(2G1) - 0(2G1) 107.8(7) C(3G2) - C(4G2) - C(5G2) 111.5(8) 
C(2G1)- C(3G1) - 0(3G1) 108.4(7) C(5G2) - C(4G2) - 0(4G2) 110.0(8) 
C(2G1) - C(3G1) - C(4G1) 106.9(7) C(4G2) - C(5G2) - 0(5G2) 109.2(8) 
C(4G1) - C(3G1) - 0(3G1) 110.4(7) C(4G2) - C(5G2) - C(6G2) 113.4(9) 
C(3G1) - C(4G1) - 0(4G1) 106.5(7) C(6G2) - C(5G2) - 0(5G2) 106.2(8) 
C(3G1) - C(4G1) - C(5G1) 110.0(7) C(5G2) - C(6G2) - 0(6G2) 107.9(9) 
C(5G1) - C(4G1) - 0(4G1) 111.5(7) C(2G2) - 0(2G2) - C(7G2) 112.3(9) 
C(4G1) - C(5G1) - 0(5G1) 108.5(7) C(3G2) - 0(3G2) - C(8G2) 114.8(7) 
C(4G1)- C(5G1)- C(6G1) 114.7(8) C(1 G1) - 0(4G2) - C(4G2) 116.4(7) 
C(6G1) - C(5G1) - 0(5G1) 106.6(7) C(1 G2) - 0(5G2) - C(5G2) 114.5(7) 
C(5G1) - C(6G1) - 0(6G1) 109.3(8) C(6G2) - 0(6G2) - C(9G2) 110(1) 
C(2G1)- 0(2G1)- C(7G1) 112.6(7) 0(5G3) - C(1 G3) - 0(4G4) 111.6(8) 
C(3G1)- 0(3G1)- C(8G1) 114.3(7) C(2G3) - C(1G3) - 0(4G4) 109.5(8) 
C(4G1)- 0(4G1)- C(1G7) 116.4(7) C(2G3) - C(1 G3) - 0(5G3) 111.7(7) 
C(1 G1) - 0(5G1) - C(5G1) 114.8(7) C(1 G3) - C(2G3) - 0(2G3) 110.7(8) 
C(6G1)- 0(6G1)-C(9G1) 112.3(8) C(1 G3) - C(2G3) - C(3G3) 109.8(8) 
0(5G2) - C(1 G2) - 0(4G3) 114.0(8) C(3G3) - C(2G3) - 0(2G3) 112.8(8) 
C(2G2) - C(1 G2) - 0(4G3) 109.8(8) C(2G3) - C(3G3) - 0(3G3) 108.0(8) 
C(2G2) - C(1 G2) - 0(5G2) 107.5(7) C(2G3) - C(3G3) - C(4G3) 112.2(9) 
C(1 G2) - C(2G2) - 0(2G2) 114.0(8) C(4G3) - C(3G3) - 0(3G3) 111.6(9) 
C(1 G2) - C(2G2) - C(3G2) 109.8(8) C(3G3) - C(4G3) - 0(4G3) 105.4(8) 
APPENDIX 8 B-8 
C(3G3) - C(4G3) - C(5G3) 110.7(8) C(3G5)-0(3G5)-C(8G5) 113.4(9) 
C(5G3) - C(4G3) - 0(4G3) 111.7(8) C(1 G4)-0(4G5)-C(4G5) 119.5(7) 
C(4G3) - C(5G3) - 0(5G3) 107.5(8) C(1 G5)-0(5G5)-C(5G5) 112.2(7) 
C(4G3) - C(5G3) - C(6G3) 116.8(8) C(6G5)-0(6G5)-C(9G5) 114.2(7) 
C(6G3) - C(5G3) - 0(5G3) 109.0(8) 0(5G6)-C(1 G6)-0( 4G7) 112.2(8) 
C(5G3)-C(6G3)-0(6G3) 109.1(8) C(2G6)-C(1 G6)-0( 4G7) 110.9(9) 
C(2G3)-0(2G3)-C(7G3) 121 (1) C(2G6)-C(1 G6)-0(5G6) 109.6(9) 
C(3G3)-0(3G3)-C(8G3) 114.4(9) C(1 G6)-C(2G6)-0(2G6) 107.4(9) 
C(1 G2)-0(4G3)-C(4G3) 118.1 (7) C(1 G6)-C(2G6)-C(3G6) 111.3(9) 
C(1 G3)-0(5G3)-C(5G3) 114.4(7) C(3G6)-C(2G6)-0(2G6) 111.2(9) 
C(6G3)-0(6G3)-C(9G3) 110.2(8) C(2G6)-C(3G6)-0(3G6) 108.2(9) 
0(5G4)-C(1 G4)-0(4G5) 111.2(7) C(2G6)-C(3G6)-C( 4G6) 111.1 (9) 
C(2G4)-C(1 G4)-0(4G5) 110.9(8) C(4G6)-C(3G6)-0(3G6) 112.2(9) 
C(2G4)-C(1 G4)-0(5G4) 109.2(8) C(3G6)-C( 4G6)-0(4G6) 106.3(8) 
C(1 G4)-C(2G4)-0(2G4) 112.6(8) C(3G6)-C(4G6)-C(5G6) 111.9(9) 
C(1 G4)-C(2G4)-C(3G4) 110.1(8) C(5G6)-C(4G6)-0(4G6) 111.2(8) 
C(3G4)-C(2G4)-0(2G4) 108.5(9) C( 4G6)-C(5G6)-0(5G6) 111.4(8) 
C(2G4)-C(3G4)-0(3G4) 110.3(7) C( 4G6)-C(5G6)-C(6G6) 115.4(9) 
C(2G4)-C(3G4)-C(4G4) 112.9(9) C(6G6)-C(5G6)-0(5G6) 106.5(8) 
C( 4G4)-C(3G4)-0(3G4) 105.3(7) C(5G6)-C(6G6)-0(6G6) 116.5(9) 
C(3G4)-C( 4G4 )-0( 4G4) 110.1(8) C(2G6)-0(2G6)-C(7G6) 113.0(8) 
C(3G4)-C(4G4)-C(5G4) 113.5(7) C(3G6)-0(3G6)-C(8G6) 117.1(9) 
C(5G4)-C(4G4)-0(4G4) 104.5(7) C(1 G5)-0(4G6)-C(4G6) 117.9(7) 
C(4G4)-C(5G4)-0(5G4) 110.2(7) C(1 G6)-0(5G6)-C(5G6) 113.6(7) 
C( 4G4)-C(5G4)-C(6G4) 112.9(8) C(6G6)-0(6G6)-C(9G6) 116.0(9) 
C(6G4)-C(5G4)-0(5G4) 104.8(8) 0(4G1 )-C(1 G7)-0(5G7) 113.1 (7) 
C(5G4)-C(6G4)-0(6G4) 112.1(9) 0(4G1 )-C(1 G7)-C(2G7) 108.9(8) 
C(2G4)-0(2G4)-C(7G4) 118(1) C(2G7)-C(1 G7)-0(5G7) 108.7(8) 
C(3G4)-0(3G4)-C(8G4) 115.9(8) C(1 G7)-C(2G7)-0(2G7) 113.7(8) 
C(1 G3)-0(4G4)-C(4G4) 115.6(7) C(1 G7)-C(2G7)-C(3G7) 111.6(9) 
C(1 G4)-0(5G4)-C(5G4) 111.8(7) C(3G7)-C(2G7)-0(2G7) 108.2(8) 
C(6G4)-0(6G4)-C(9G4) 111.6(9) C(2G7)-C(3G7)-0(3G7) 110.5(8) 
0(5G5)-C(1 G5)-0( 4G6) 108.3(8) C(2G7)-C(3G7)-C( 4G7) 110.1(9) 
C(2G5)-C(1 G5)-0( 4G6) 110.6(8) C(4G7)-C(3G7)-0(3G7) 108.1(8) 
C(2G5)-C(1 G5)-0(5G5) 109.6(8) C(3G7)-C(4G7)-0(4G7) 109.0(8) 
C(1 G5)-C(2G5)-0(2G5) 111.6(8) C(3G7)-C( 4G7)-C(5G7) 112.4(8) 
C(1 G5)-C(2G5)-C(3G5) 112.2(9) C(5G7)-C(4G7)-0(4G7) 108.6(8) 
C(3G5)-C(2G5)-0(2G5) 109.5(8) C( 4G7)-C(5G7)-0(5G7) 114.3(8) 
C(2G5)-C(3G5)-0(3G5) 109.4(8) C( 4G7)-C(5G7)-C(6G7) 111.4(9) 
C(2G5)-C(3G5)-C( 4G5) 111.0(8) C(6G7)-C(5G7)-0(5G7) 105.8(9) 
C(4G5)-C(3G5)-0(3G5) 107.1(8) C(5G7)-C(6G7)-0(6G7) 109(1) 
C(3G5)-C( 4G5)-0( 4G5) 108.7(8) C(2G7)-0(2G7)-C(7G7) 112.1 (8) 
C(3G5)-C( 4G5)-C(5G5) 110.7(8) C(3G7)-0(3G7)-C(8G7) 115.4(8) 
C(5G5)-C( 4G5)-0( 4G5) 110.7(8) C(1G6)- 0(4G7) - C(4G7) 117.9(8) 
C(4G5)-C(5G5)-0(5G5) 110.5(7) C(1 G7) - 0(5G7) - C(5G7) 114.3(8) 
C(4G5)-C(5G5)-C(6G5) 115.4(8) C(6G7) - 0(6G7) - C(9G7) 117(1) 
C(6G5)-C(5G5)-0(5G5) 105.6(8) C(6) - C(1) - C(7) 121(1) 
C(5G5)-C(6G5)-0(6G5) 110.3(7) C(2) - C(1) - C(7) 120(1) 
C(2G5)-0(2G5)-C(7G5) 115.0(8) C(2) - C(1) - C(6) 118(1) 
APPENDIX 8 B-9 
C(1) - C(2) - C(3) 121 (1) C(8) - C(7) - C(11) 115(1) 
C(2) - C(3) - C(4) 121 (1) C(7) - C(8) - 0(10) 119(1) 
C(3) - C(4) - C(12) 123(1) C(7) - C(8) - 0(9) 117(2) 
C(3) - C(4) - C(5) 118(1) 0(9) - C(8) - 0(10) 122(1) 
C(5) - C(4) - C(12) 119(1) C(4)- C(12) - C(13) 119(1) 
C(4) - C(5) - C(6) 122(1) C(12)- C(13)- C(15) 106(2) 
C(1) - C(6) - C(5) 121 (1) C(12) - C(13) - C(14) 130(2) 
C(1) - C(7) - C(11) 115(1) C(14) - C(13) - C(15) 118(2) 
C(1) - C(7) - C(8) 103(1) 
TABLE 85. Torsion angles (°) with estimated standard deviations 
in parentheses for TRIMEB - (S)-ibuprofen complex. 
0(5G1) - C(1 G1) - 0(4G2) - C(4G2) 107.7(9) 0(4G3) - C(1 G2) - 0(5G2) - C(5G2) 55(1) 
C(2G1)- C(1G1) - 0(4G2) - C(4G2) -133.8(8) C(2G2) - C(1 G2) - 0(5G2) - C(5G2) -67(1) 
0(4G2) - C(1 G1) - 0(5G1) - C(5G1) 58(1) 0(5G2) - C(1 G2) - C(2G2) - 0(2G2) 175.8(8) 
C(2G1) - C(1 G1) - 0(5G1) - C(5G1) -59(1) 0(5G2) - C(1 G2) - C(2G2) - C(3G2) 59(1) 
0(5G1) - C(1 G1) - C(2G1) - 0(2G1) 177.7(7) 0(4G3) - C(1 G2) - C(2G2) - 0(2G2) 51 (1) 
0(5G1)- C(1G1)- C(2G1)- C(3G1) 57(1) 0(4G3) - C(1 G2) - C(2G2) - C(3G2) -66(1) 
0(4G2) - C(1 G1) - C(2G1) - 0(2G1) 57.6(9) C(1 G2) - C(2G2) - 0(2G2) - C(7G2) 76(1) 
0(4G2)-C(1G1)- C(2G1)- C(3G1) -63.3(9) C(1G2)- C(2G2)- C(3G2)- C(4G2) -52(1) 
C(1 G1) - C(2G1) - 0(2G1) - C(7G1) 77.4(9) C(1 G2) - C(2G2) - C(3G2) - 0(3G2) -172.1 (7) 
C(1G1)- C(2G1)- C(3G1)- C(4G1) -57.1(9) C(3G2) - C(2G2) - 0(2G2) - C(7G2) -164.0(9) 
C(1G1)- C(2G1)- C(3G1)- 0(3G1) -176.1 (7) 0(2G2) - C(2G2) - C(3G2) - 0(3G2) 65.2(9) 
C(3G1)- C(2G1)- 0(2G1)- C(7G1) -160.0(7) 0(2G2) - C(2G2) - C(3G2) - C(4G2) -174.4(8) 
0(2G1) - C(2G1) - C(3G1) - 0(3G1) 60.3(9) C(2G2) - C(3G2) - 0(3G2) - C(8G2) -111.7(9) 
0(2G1)- C(2G1) - C(3G1) - C(4G1) 179.3(7) C(2G2) - C(3G2) - C(4G2) - C(5G2) 49(1) 
C(2G1) - C(3G1) - 0(3G1) - C(8G1) -126.0(8) C(2G2) - C(3G2) - C(4G2) - 0(4G2) 167.3(7) 
C(2G1)-C(3G1)-C(4G1)- C(5G1) 58.8(9) C(4G2) - C(3G2) - 0(3G2) - C(8G2) 127.3(8) 
C(2G1)-C(3G1)- C(4G1)- 0(4G1) 179.8(7) 0(3G2) - C(3G2) - C(4G2) - 0(4G2) -73.2(9) 
C(4G1) - C(3G1) - 0(3G1) - C(8G1) 117.2(8) 0(3G2) - C(3G2) - C(4G2) - C(5G2) 168.5(8) 
0(3G1)- C(3G1) - C(4G1) - 0(4G1) -62.5(9) C(3G2)- C(4G2) -0(4G2)- C(1G1) 134.1(8) 
0(3G1)- C(3G1)- C(4G1)- C(5G1) 176.5(7) C(5G2) - C(4G2) - 0(4G2) - C(1 G1) -106.5(9) 
C(3G1)- C(4G1)- 0(4G1)- C(1G7) 140.3(8) C(3G2) - C(4G2) - C(5G2) - C(6G2) -170.3(8) 
C(3G1) - C(4G1) - C(5G1) - C(6G1) -178.5(8) C(3G2) - C(4G2) - C(5G2) - 0(5G2) -52(1) 
C(3G1)- C(4G1) - C(5G1) - 0(5G1) -59.5(9) 0(4G2) - C(4G2) - C(5G2) - 0(5G2) -166.7(7) 
C(5G1)- C(4G1) - 0(4G1) - C(1G7) -99.6(9) 0(4G2) - C(4G2) - C(5G2) - C(6G2) 75(1) 
0(4G1)- C(4G1) - C(5G1) - 0(5G1) -177.5(6) C(4G2) - C(5G2) - 0(5G2) - C(1 G2) 64(1) 
0(4G1) - C(4G1) - C(5G1) - C(6G1) 64(1) C(6G2) - C(5G2) - 0(5G2) - C(1 G2) -173.7(8) 
C(4G1) - C(5G1) - 0(5G1) - C(1 G1) 61.2(9) C(4G2) - C(5G2) - C(6G2) - 0(6G2) -165.9(9) 
C(6G1)- C(5G1)- 0(5G1)- C(1G1) -174.9(8) 0(5G2) - C(5G2) - C(6G2) - 0(6G2) 74(1) 
C(4G1)-C(5G1)- C(6G1)- 0(6G1) 46(1) C(5G2) - C(6G2) - 0(6G2) - C(9G2) 180(1) 
0(5G1) - C(5G1) - C(6G1) - 0(6G1) -73.6(9) 0(5G3) - C(1 G3) - 0(4G4) - C(4G4) 90.3(9) 
C(5G1) - C(6G1) - 0(6G1) - C(9G1) -174.5(8) C(2G3) - C(1 G3) - 0(4G4) - C(4G4) -145.6(8) 
C(4G1) - 0(4G1) - C(1 G7) - C(2G7) -130.4(8) 0(4G4) - C(1G3) - 0(5G3)- C(5G3) 61(1) 
C(4G1)- 0(4G1)- C(1G7)- 0(5G7) 108.7(9) C(2G3) - C(1 G3) - 0(5G3) - C(5G3) -62(1) 
0(5G2) - C(1 G2) - 0(4G3) - C(4G3) 106.7(9) 0(5G3) - C(1 G3) - C(2G3) - 0(2G3) 176.6(8) 
C(2G2)- C(1G2)- 0(4G3) - C(4G3) -132.6(8) 0(5G3) - C(1 G3) - C(2G3) - C(3G3) 51(1) 
APPENDIX B B-10 
0(4G4) - C(1G3) - C(2G3) - 0(2G3) 53(1) 0(4G4) - C(4G4) - C(5G4) - 0(5G4) -169.9(7) 
0(4G4) - C(1 G3) - C(2G3) - C(3G3) -73(1) 0(4G4) - C(4G4) - C(5G4) - C(6G4) 73(1) 
C(1 G3) - C(2G3) - 0(2G3) - C(7G3) 140(1) C(4G4) - C(5G4) - 0(5G4) - C(1 G4) 612(9) 
C(1G3) - C(2G3) - C(3G3) - C(4G3) -48(1) C(6G4) - C(5G4) - 0(5G4) - C(1 G4) -177.1(7) 
C(1 G3) - C(2G3) - C(3G3) - 0(3G3) -171.5(8) C(4G4) - C(5G4) - C(6G4) - 0(6G4) -166.2(8) 
C(3G3) - C(2G3) - 0(2G3) - C(7G3) -97(1) 0(5G4) - C(5G4) - C(6G4) - 0(6G4) 74(1) 
0(2G3) - C(2G3) - C(3G3) - 0(3G3) 65(1) C(5G4) - C(6G4) - 0(6G4) - C(9G4) 174.0(9) 
0(2G3) - C(2G3) - C(3G3) - C(4G3) -172.0(8) 0(5G5) - C(1 GS) - 0(4G6) - C(4G6) 113.4(9) 
C(2G3) - C(3G3) - 0(3G3) - C(8G3) -127(1) C(2G5)- C(1G5)- 0(4G6) - C(4G6) -126.5(9) 
C(2G3)- C(3G3) - C(4G3) - C(5G3) 52(1) 0(4G6) - C(1 GS) - 0(5G5) - C(5G5) 61 (1) 
C(2G3) - C(3G3) - C(4G3) - 0(4G3) 173.0(8) C(2G5) - C(1 GS) - 0(5G5) - C(5G5) -60(1) 
C(4G3) - C(3G3) - 0(3G3) - C(8G3) 110(1) O(SGS) - C(1 GS) - C(2G5) - 0(2G5) 177.2(8) 
0(3G3) - C(3G3) - C(4G3) - 0(4G3) -66(1) 0(5G5) - C(1 GS) - C(2G5) - C(3G5) 54(1) 
0(3G3) - C(3G3) - C(4G3) - C(5G3) 173.5(8) 0(4G6) - C(1 GS) - C(2G5) - 0(2G5) 58(1) 
C(3G3) - C(4G3) - 0(4G3) - C(1 G2) 148.4(8) 0(4G6) - C(1 GS) - C(2G5) - C(3G5) -66(1) 
C(5G3) - C(4G3) - 0(4G3) - C(1 G2) -91.4(9) C(1 GS) - C(2G5) - 0(2G5) - C(7G5) 72(1) 
C(3G3) - C(4G3) - C(SG3) - C(6G3) -179.8(9) C(1 GS) - C(2G5) - C(3G5) - C(4G5) -51 (1) 
C(3G3) - C(4G3) - C(SG3) - 0(5G3) -57(1) C(1 GS) - C(2G5) - C(3G5) - 0(3G5) -168.9(8) 
0(4G3) - C(4G3) - C(SG3) - 0(5G3) -174.0(7) C(3G5) - C(2G5) - 0(2G5) - C(7G5) -162.7(9) 
0(4G3) - C(4G3) - C(5G3) - C(6G3) 63(1) 0(2G5) - C(2G5) - C(3G5) - 0(3G5) 67(1) 
C(4G3) - C(5G3) - 0(5G3) - C(1 G3) 63.4(9) 0(2G5) - C(2G5) - C(3G5) - C(4G5) -175.5(8) 
C(6G3) - C(5G3) - 0(5G3) - C(1 G3) -169.1 (8) C(2G5) - C(3G5) - 0(3G5) - C(8G5) -109(1) 
C(4G3) - C(5G3) - C(6G3) - 0(6G3) 54(1) C(2G5) - C(3G5) - C(4G5) - C(5G5) 52(1) 
0(5G3) - C(5G3) - C(6G3) - 0(6G3) -68(1) C(2G5) - C(3G5) - C(4G5) - 0(4G5) 173.5(8) 
C(5G3) - C(6G3) - 0(6G3) - C(9G3) 175.7(9) C(4G5) - C(3G5) - 0(3G5) - C(8G5) 131.2(9) 
0(5G4) - C(1G4) - 0(4G5) - C(4G5) 101.6(9) 0(3G5) - C(3G5) - C(4G5) - 0(4G5) -67(1) 
C(2G4) - C(1G4) - 0(4G5) - C(4G5) -136.8(8) 0(3G5) - C(3G5) - C(4G5) - C(5G5) 171.0(8) 
0(4G5)- C(1G4)- 0(5G4)- C(5G4) 57.5(9) C(3G5) - C(4G5) - 0(4G5) - C(1 G4) 136.8(8) 
C(2G4) - C(1 G4) - 0(5G4) - C(5G4) -65.1 (9) C(SGS) - C(4G5) - 0(4G5) - C(1 G4) -101.3(9) 
0(5G4) - C(1 G4) - C(2G4) - 0(2G4) 178.8(8) C(3G5) - C(4G5) - C(5G5) - C(6G5) -176.5(8) 
0(5G4) - C(1 G4) - C(2G4) - C(3G4) 58(1) C(3G5) - C(4G5) - C(5G5) - 0(5G5) -57(1) 
0(4G5) - C(1 G4) - C(2G4) - 0(2G4) 56(1) 0(4G5) - C(4G5) - C(5G5) - 0(5G5) -177.5(7) 
0(4G5) - C(1 G4) - C(2G4) - C(3G4) -65(1) 0(4G5) - C(4G5) - C(5G5) - C(6G5) 63(1) 
C(1 G4) - C(2G4) - 0(2G4) - C(7G4) 75(1) C(4G5) - C(5G5) - O(SGS) - C(1 GS) 62(1) 
C(1G4) - C(2G4) - C(3G4) - C(4G4) -48(1) C(6G5) - C(5G5) - 0(5G5) - C(1 GS) -172.9(8) 
C(1 G4) - C(2G4) - C(3G4) - 0(3G4) -165.6(8) C(4G5)- C(5G5) - C(6G5) - 0(6G5) 49(1) 
C(3G4) - C(2G4) - 0(2G4) - C(7G4) -163(1) 0(5G5) - C(SGS) - C(6G5) - 0(6G5) -73.5(9) 
0(2G4) - C(2G4) - C(3G4) - 0(3G4) 71(1) C(SGS) - C(6G5) - 0(6G5) - C(9G5) -177.9(8) 
0(2G4) - C(2G4) - C(3G4) - C(4G4) -171.7(8) 0(5G6) - C(1G6) - 0(4G7) - C(4G7) 85(1) 
C(2G4) - C(3G4) - 0(3G4) - C(8G4) -90(1) C(2G6) - C(1 G6) - 0(4G7) - C(4G7) -151.9(8) 
C(2G4) - C(3G4) - C(4G4) - C(5G4) 46(1) 0(4G7) - C(1G6) - 0(5G6) - C(SG6) 63(1) 
C(2G4) - C(3G4) - C(4G4) - 0(4G4) 162.2(8) C(2G6) - C(1 G6) - 0(5G6) - C(SG6) -61 (1) 
C(4G4) - C(3G4) - 0(3G4) - C(8G4) 147.8(9) 0(5G6) - C(1 G6) - C(2G6) - 0(2G6) 179.0(8) 
0(3G4) - C(3G4) - C(4G4) - 0(4G4) -77.4(9) 0(5G6) - C(1 G6) - C(2G6) - C(3G6) 57(1) 
0(3G4) - C(3G4) - C(4G4) - C(SG4) 165.9(8) 0(4G7) - C(1 G6) - C(2G6) - 0(2G6) 55(1) 
C(3G4) - C(4G4) - 0(4G4) - C(1 G3) 92.7(9) 0(4G7) - C(1 G6) - C(2G6) - C(3G6) -67(1) 
C(5G4)- C(4G4) - 0(4G4)- C(1G3) -145.1(8) C(1 G6) - C(2G6) - 0(2G6) - C(7G6) 138.2(9) 
C(3G4) - C(4G4) - C(5G4) - C(6G4) -166.7(8) C(1 G6) - C(2G6) - C(3G6) - C(4G6) -52(1) 
C(3G4) - C(4G4) - C(5G4) - 0(5G4) -50(1) C(1 G6) - C(2G6) - C(3G6) - 0(3G6) -175.6(9) 
APPENDIX B 8-11 
C(3G6) - C(2G6) - 0(2G6) - C(7G6) -100(1) 0(3G7)-C(3G7)-C(4G7)-0(4G7) -74(1) 
0(2G6) - C(2G6) - C(3G6) - 0(3G6) 65(1) 0(3G7)-C(3G7)-C( 4G7)-C(5G7) 165.4(8) 
0(2G6) - C(2G6) - C(3G6) - C(4G6) -171.7(8) C(3G7)-C(4G7)-0(4G7)-C(1 G6) 102.7(9) 
C(2G6) - C(3G6) - 0(3G6) - C(8G6) -142(1) C(5G7)-C(4G7)-0(4G7)-C(1 G6) -134.6(9) 
C(2G6) - C(3G6) - C(4G6) - C(5G6) 49(1) C(3G7)-C(4G7)-C(5G7)-C(6G7) -165.3(9) 
C(2G6) - C(3G6) - C(4G6) - 0(4G6) 170.1(8) C(3G7)-C(4G7)-C(5G7)-0(5G7) -45(1) 
C(4G6) - C(3G6) - 0(3G6) - C(8G6) 95(1) 0( 4G7)-C( 4G7)-C(5G7)-0(5G7) -166.0(8) 
0(3G6) - C(3G6) - C(4G6) - 0(4G6) -69(1) 0( 4G7)-C( 4G7)-C(5G7)-C(6G7) 74(1) 
0(3G6) - C(3G6) - C(4G6) - C(5G6) 169.9(9) C(4G7)-C(5G7)-0(5G7)-C(1 G7) 55(1) 
C(3G6)- C(4G6) - 0(4G6) - C(1G5) 159.3(8) C(6G7)-C(5G7)-0(5G7)-C(1 G7) 177.7(8) 
C(5G6)- C(4G6) - 0(4G6) - C(1G5) -78(1) C( 4G7)-C(5G7)-C(6G7)-0(6G7) -162(1) 
C(3G6) - C(4G6) - C(5G6) - C(6G6) -172.2(9) 0(5G7)-C(5G7)-C(6G7)-0(6G7) 73(1) 
C(3G6) - C(4G6) - C(5G6) - 0(5G6) -51 (1) C(5G7)-C(6G7)-0(6G7)-C(9G7) 151(2) 
0(4G6) - C(4G6) - C(5G6) - 0(5G6) -169.3(8) C(6)-C(1 )-C(7)-C(8) 105(1) 
0(4G6) - C(4G6) - C(5G6) - C(6G6) 69(1) C(2)-C(1 )-C(7)-C(8) -78(1) 
C(4G6) - C(5G6) - 0(5G6) - C(1 G6) 58(1) C(6)-C(1 )-C(7)-C(11) -130(1) 
C(6G6) - C(5G6) - 0(5G6) - C(1 G6) -175.6(8) C(2)-C(1 )-C(7)-C(11) 48(2) 
C(4G6) - C(5G6) - C(6G6) - 0(6G6) 45(1) C(7)-C(1 )-C(6)-C(5) -180(1) 
0(5G6) - C(5G6) - C(6G6) - 0(6G6) -78(1) C(2)-C(1 )-C(6)-C(5) 3(2) 
C(5G6) - C(6G6) - 0(6G6) - C(9G6) 79(1) C(6)-C(1 )-C(2)-C(3) -4(2) 
0(4G1) - C(1 G7) - 0(5G7) - C(5G7) 61 (1) C(7)-C(1 )-C(2)-C(3) 179(1) 
0(4G1) - C(1 G7) - C(2G7) - C(3G7) -64(1) C(1 )-C(2)-C(3)-C(4) 1(2) 
0(4G1) - C(1 G7) - C(2G7) - 0(2G7) 59(1) C(2)-C(3)-C(4)-C(5) 3(2) 
C(2G7) - C(1 G7) - 0(5G7) - C(5G7) -61 (1) C(2)-C(3)-C(4)-C(12) 179(1) 
0(5G7) - C(1 G7) - C(2G7) - 0(2G7) -177.3(7) C(3)-C(4)-C(12)-C(13) -59(2) 
0(5G7) - C(1 G7) - C(2G7) - C(3G7) 60(1) C(3)-C( 4)-C(5)-C(6) -3(2) 
C(1 G7) - C(2G7) - 0(2G7) - C(7G7) 63(1) C(5)-C(4)-C(12)-C(13) 118(2) 
C(1 G7) - C(2G7) - C(3G7) - C(4G7) -53(1) C(12)-C(4)-C(5)-C(6) -180(1) 
C(1 G7) - C(2G7) - C(3G7) - 0(3G7) -171.9(8) C(4)-C(5)-C(6)-C(1) 1 (2) 
C(3G7)-C(2G7)-0(2G7)-C(7G7) -172.7(8) C(1 )-C(7)-C(8)-0(9) 98(2) 
0(2G7)-C(2G7)-C(3G7)-0(3G7) 63(1) C(1)-C(7)-C(8)-0(10) -83(2) 
0(2G7)-C(2G7)-C(3G7)-C( 4G7) -178.4(8) C(11)-C(7)-C(8)-0(10) 151(1) 
C(2G7)-C(3G7)-0(3G7)-C(8G7) -98(1) C(11 )-C(7)-C(8)-0(9) -28(2) 
C(2G7)-C(3G7)-C( 4G7)-C(5G7) 45(1) C(4)-C(12)-C(13)-C(14) -37(3) 
C(2G7)-C(3G7)-C(4G7)-0(4G7) 165.0(8) C(4)-C(12)-C(13)-C(15) 173(1) 
C( 4G7)-C(3G7)-0(3G7)-C(8G7) 141.3(9) 
Table 86 Fractional co-ordinates for hydrogen atoms 
of the TRIMEB-(S)-ibuprofen complex. 
H xla y/b z/c 
H(1G1) 8972 4810 5033 
H(2G1) 7543 4394 5156 
H(3G1) 7731 3705 4245 
H(4G1) 6602 4767 4482 
H(5G1) 8054 4737 3842 
H(611) 7176 5484 3536 
APPENDIX B B-12 
H(612) 7903 5872 3850 
H(711) 8795 3343 5776 
H(712) 8029 3874 5829 
H(713) 9005 4072 5637 
H(811) 6174 2702 4576 
H(812) 7233 2728 4490 
H(813) 6567 3006 4079 
H(911) 5880 6523 4157 
H(912) 6098 6244 3620 
H(913) 6814 6687 3897 
H(1G2) 12455 4215 4018 
H(2G2) 11813 3908 4752 
H(3G2) 10259 3516 4198 
H(4G2) 10282 4598 4832 
H(5G2) 10276 4652 3810 
H(621) 10657 5681 4455 
H(622) 9665 5546 4257 
H(721) 12818 2541 4425 
H(722) 12815 3110 4820 
H(723) 13033 3256 4252 
H(821) 9713 2600 5141 
H(822) 10260 2527 4637 
H(823) 9304 2873 4638 
H(921) 10450 6664 3474 
H(922) 10653 6642 4055 
H(923) 9663 6502 3855 
H(1G3) 12898 3893 1911 
H(2G3) 13069 3172 2531 
H(3G3) 11283 3385 2820 
H(4G3) 12776 3882 3328 
H(5G3) 11495 4547 2799 
H(631) 11902 5199 3385 
H(632) 12376 5442 2888 
H(731) 12232 2001 1897 
H(732) 12479 2092 2468 
H(733) 13160 2327 2049 
H(831) 11410 2078 3490 
H(832) 10927 2354 3007 
H(833) 10907 2753 3512 
H(931) 14042 5567 3719 
H(932) 13015 5751 3810 
H(933) 13493 5939 3300 
H(1G4) 10353 4749 383 
H(2G4) 11816 4472 511 
H(3G4) 11219 3527 1161 
H(4G4) 12155 4611 1471 
H(5G4) 10337 4443 1646 
H(641) 11281 5608 1726 
H(642) 11153 5140 2189 
APPENDIX B B-13 
H(741) 11210 3477 -398 
H(742) 11834 4081 -278 
H(743) 10767 4150 -257 
H(841) 13245 2903 1018 
H(842) 12586 2973 555 
H(843) 12194 2782 1086 
H(941) 9560 6228 2397 
H(942) 10561 6378 2220 
H(943) 10385 5858 2644 
H(1G5) 6518 4084 453 
H(2G5) 7701 3896 -44 
H(3G5) 8603 3322 745 
H(4G5) 9046 4497 294 
H(5G5) 8354 4305 1226 
H(651) 9130 5190 1288 
H(652) 8114 5423 1230 
H(751) 6404 2599 -164 
H(752) 6743 3228 -444 
H(753) 6118 3291 34 
H(851) 9817 2588 -107 
H(852) 8909 2453 189 
H(853) 9774 2711 476 
H(951) 9288 6381 423 
H(952) 9668 6147 945 
H(953) 8661 6405 902 
H(1G6) 4427 3516 2212 
H(2G6) 4900 2820 1595 
H(3G6) 6663 3182 1806 
H(4G6) 5723 3481 948 
H(5G6) 6206 4319 1676 
H(661) 6107 4907 1020 
H(662) 5157 5012 1282 
H(761) 5205 1654 2388 
H(762) 5460 1782 1822 
H(763) 4486 1969 2023 
H(861) 7365 1914 1172 
H(862) 7512 2288 1681 
H(863) 7638 2654 1166 
H(961) 3957 4323 384 
H(962) 3899 4825 829 
H(963) 4082 4084 941 
H(1G7) 5546 4903 4053 
H(2G7) 4385 4394 3669 
H(3G7) 5623 3476 3314 
H(4G7) 4637 4323 2727 
H(5G7) 6427 4491 2935 
H(671) 5238 5448 2575 
H(672) 5750 4980 2201 
H(771) 4318 3782 4796 
APPENDIX B B-14 
H(772) 4126 4377 4440 
H(773) 5087 4298 4695 
H(871) 3875 2494 3256 
H(872) 4512 2736 3694 
H(873) 4936 2524 3176 
H(971) 7292 6065 2230 
H(972) 6281 6077 2036 
H(973) 6901 5468 1928 
H 6357 2046 2967 
H 7000 3046 2791 
H 9119 2595 3634 
H 8469 1606 3827 
H 7329 789 3684 
H(111) 7105 706 2917 
H(112) 6078 925 2927 
H(113) 6389 307 3231 
H(121) 9112 3558 3290 
H(122) 8151 3888 3222 
H 8158 3801 2499 
H(141) 9652 3189 2339 
H(142) 9033 3563 1953 
H(143) 8648 2954 2242 
H(151) 9715 4392 2737 
H(152) 8720 4634 2852 
H(153) 9054 4565 2292 
